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ABSTRACT OF THE DISSERTATION 
THE ROLE OF ID3 AND PCB153 IN THE HYPERPROLIFERATION AND 
DYSREGULATION OF LUNG ENDOTHELIAL CELLS 
by 
Mayur Doke 
Florida International University, 2018 
Miami, Florida 
Professor Quentin Felty, Co-Major Professor  
  
 
Uncontrolled growth of vascular stem cells as a result of endothelial-mesenchymal 
transition is considered to cause hyper-proliferative vascular remodeling in severe 
pulmonary arterial hypertension (PAH) patients. Hyperplastic intimal growth is one of 
the causes of closure of the lumen of pulmonary arterioles. This abnormal vessel 
remodeling leads to the progressive increase in pressure of the pulmonary arterioles 
causing severe PAH. Environmental factors, including polychlorinated biphenyls (PCBs), 
are considered to be involved in hyper-proliferative vascular remodeling because genetic 
makeup can only explain about 10% of severe PAH cases. PCB involvement in lung 
toxicity has received attention because (i) they have been reported to accumulate in the 
lung; (ii) PCBs produce pathological vascular remodeling in the experimental model; 
high levels of PCBs are found in human lung tissue; and (iii) epidemiological studies 
show the association between lung toxicity and PCBs; and prevalence of hypertension 
and elevated concentrations of particularly PCB153. ID3 is an important determinant of 
mitogen and reactive oxygen species-induced G1→S phase cell cycle progression. 
Professor Deodutta Roy, Co-Major Professor
viii 
 
Although there is, still there is a critical gap in understanding the molecular 
mechanism(s) of pulmonary proliferative vascular remodeling associated with PCB 
exposure in humans and the role of the transcription regulator ID3. Our overall objective 
was to investigate ID3 mediated transcriptional reprogramming as a driver of PCB153-
induced pathological proliferative vascular remodeling. Stable ectopic expression of ID3 
in lung endothelial cells contributed to endothelial-mesenchymal transition (EndMT), cell 
proliferation, and cell migration. To determine the molecular mechanism by which ID3 
contributes to hyper-proliferative endothelial cells, we investigated ID3 transcriptional 
reprogramming using ChIP-Seq and RNA-Seq technology. We show here for the first 
time that ID3 is part of a more general mechanism of transcriptional regulation. We 
identified 19 genes whose RNA was differentially expressed in ID3 overexpressing cells. 
In summary, our data demonstrated that PCB153 and/or ID3 induces proliferation of lung 
endothelial cells via transcriptional reprogramming. Discoveries from these findings will 
lay the necessary groundbreaking work for testing the efficacy of ID3 antagonists for the 
prevention and treatment of pathological vascular remodeling as well as provide a new 
paradigm by which PCBs may contribute to lung vascular toxicity.  
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Introduction 
 
The overwhelming increase in the global incidence of pulmonary disease and its 
associated complications such as insulin resistance, atherosclerosis, obesity, and 
degenerative disorders including dementia constitutes a serious public health problem. 
Since some of the endocrine disruptors are lipophilic chemicals with long half-lives, they 
tend to bioaccumulate in the lipid rich tissue of exposed populations. Elevated exposure 
to these chemicals may predispose susceptible individuals to metabolic perturbative 
disorders by increasing the proliferation of the cells. The Inhibitor of DNA 
Binding/Differentiation-3, a member of the ID family of transcriptional regulators, has 
been shown to play a role in adipogenesis, angiogenesis and vasculogenesis. Therefore, 
ID3 may influence obesity and vascular dysfunction in response to environmental factors. 
This literature review will highlight the current understanding of how ID3 may contribute 
to complex chronic diseases like pulmonary artery hypertension via metabolic 
perturbations. Based on the increasing number of reports that suggest chronic exposure 
and accumulation of endocrine disrupting chemicals (EDCs) within the human body are 
associated with vascular disorders, we will also consider the impact of these chemicals on 
ID3. Improved understanding of the ID3 pathways by which exposure to EDCs can 
potentiate complex chronic diseases in populations with vascular disorders and metabolic 
disorders (obesity, metabolic syndrome, and glucose intolerance) will likely provide 
useful knowledge in the prevention and control of complex chronic diseases associated 
with exposure to environmental pollutants.  
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Toxic EEDs exposure to humans 
                     Estrogenic endocrine disruptors (EEDs) are compounds that alter hormone 
production or function including phytoestrogens, heavy metals, and anthropogenic 
chemicals. More specifically, EEDs include compounds such as genistein, arsenic, DES, 
PCBs, phthalates, and Bisphenol A (BPA). Polychlorinated biphenyls (PCBs) are man-
made aromatic chlorinated hydrocarbons. PCBs have been used commercially since 1930 
in various industrial applications like transformers, capacitors, plasticizers, paints, 
lubricants, and surface coatings because of their distinct physicochemical properties like 
low electrical conductance, fire resistance, and chemical inertness. PCBs consists of 209 
congeners (Ballschmiter & Zell, 1980; Rigaudy, Klesney, & International Union of Pure 
and Applied Chemistry, 1979), which have been manufactured as complex, and multiple 
mixtures of congeners by the progressive chlorination of batches of biphenyl until a 
particular PCB congener was achieved. As PCBs are lipophilic, they tend to 
bioaccumulate in nature. Moreover, the half-life of PCBs is about 2–6 years (Shiraia & 
Kissel, 1996). PCBs can able to accumulate in lipid-rich tissues of living organisms 
(ASTDR, 2000a; Matthews & Dedrick, 1984a). In humans, half of dry weight of the 
brain consist of lipids which make the brain lipid-rich organ after adipose tissue 
(Betsholtz, 2015). Moreover, lungs also harbor surfactant lipid composition, mainly di-
saturated phosphatidylcholine and cholesterol (Veldhuizen, Nag, Orgeig, & Possmayer, 
1998). PCBs being lipophilic in nature, conjugate with lipoproteins in plasma and cell 
membrane lipids and then eventually accumulate in the tissues of liver and lung (ASTDR, 
2000a; Elabbas et al., 2014; European Food Safety Authority, 2005). PCBs are lipophilic 
and chemically stable in nature so they can pass through any cell membranes and enter 
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into the nuclear compartment to bind estrogen receptors (Kimbrough & Krouskas, 2003; 
Safe, 1994). Although Stockholm Convention on Persistent Organic Pollutants has 
banned the production of PCBs in 2001, researchers have shown many evidences of 
bioaccumulation of PCBs in the ecosystem and food chain. Low chlorinated (1-4Cl) 
PCBs are volatilized into air, and highly chlorinated (5–9Cl) PCBs accumulate in food, 
soil, sediments, and humans (Dobson et al., 1993; Selene & Chou, 2003). Aquatic 
sediments are main reservoirs of high chlorinated PCBs and concentration of PCBs 
increases in the air due to evaporation from water to air which is always greater in 
summer than in winter, because these parameters increase with temperature (Per & 
Anderss, 1987). Lungs are a highly vascularized organ and receives chemicals from 
blood through food and air; hence, it is vulnerable to chemical toxicants. 
Bioaccumulation of PCBs can increase the inflammation in vascular injury which has 
been shown to promote crosstalk between different organ systems, leading to 
inflammatory disease pathologies (Achour et al., 2017; He et al., 2017; Lasserre et al., 
2009; Wahlang et al., 2017).  Moreover, several studies have shown higher levels of 
PCBs in breast, lung, and liver tissues (ASTDR, 2000a; Chao, Wang, Lin, & Chung, 
2006; Elabbas et al., 2014; European Food Safety Authority, 2005; Grimm et al., 2015; 
Polder et al., 2003). In addition to this, our secondary analysis of The National Health 
and Nutrition Examination Survey (NHANES) data from 1999-2004, we found that 
exposure to PCBs increases the risk of PAH in the U.S. population ≥ 20 years old. The 
concern over adverse health effects from human exposure to PCBs has led to 
investigations of non-dioxin-like polychlorinated biphenyls (NDL-PCBs), dioxin-like 
PCBs (DL-PCBs), together with polychlorinated dibenzo-p-dioxins (PCDDs) and 
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polychlorinated dibenzofurans (PCDFs) in foods and the effects of the consumption of 
these contaminated foods. The Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) committee has identified seven PCBs called as “indicator PCBs” (JECFA, 
2007). These PCBs are divided into two groups of NDL-PCBs and DL-PCBs depending 
on the site of chlorine substitution on the phenyl rings. Six out of these seven are NDL- 
PCBs (PCB 28, PCB 52, PCB 101, PCB 138, PCB153, and PCB 180), and one is a DL-
PCB (PCB 118). DL-PCBs bind strongly to the aryl hydrocarbon receptor (AhR) due to 
their planar structure (Bjermo et al., 2013). The higher chlorinated NDL-PCBs congeners 
are more stable and tend to bioaccumulate in greater concentration within the food- chain 
and particularly foods of animal origin like fish and fish products, milk, eggs, and meat 
products (Albro & Fishbein, 1972; ASTDR, 2000a; Elabbas et al., 2014; European Food 
Safety Authority, 2005; JECFA, 2007). Out of six NDL-PCBs, PCB153 showed higher 
half-life compared to other five PCBs which is about 14.4 years and has a very slow rate 
of biotransformation (Chen, Luo, Wong, & Chen, 1982; Matthews & Dedrick, 1984b; 
Ritter et al., 2011a). It has already been shown by epidemiological and experimental 
studies the association of PCB153 with metabolic disorders (Mullerova et al., 2008; 
Wahlang et al., 2013). We and others have shown that PCB153 increases oxidative stress 
or reactive oxygen species (ROS) that mediate hyper-proliferation of endothelial cells 
(Felty & Porther, 2008a; Mueller, Baudler, Welzel, Böhm, & Nickenig, 2002). However, 
ubiquitous exposure to weaker endocrine disruptors such as PCBs and BPA are more 
likely to occur in humans. NHANES data provide information about the U.S population 
in demographic, dietary, physical examination, laboratory, and questionnaire data ( 
Centers for Disease Control and Prevention, 2017). The analysis of NHANES survey data 
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showed that there is strong association between exposures to EDCs and risk of PAH. 
Moreover, meta-analysis of Gene Expression Omnibus (GEO) and NHANES data 
demonstrated PCB geometric mean concentrations found higher levels in people at risk of 
PAH than people not at risk of PAH (Assaggaf, 2017). Interestingly, the limits of 
detection (LODs) of PCB153 showed higher risk of PAH than other PCBs based on 
Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL 
Registry) scoring methods (Benza et al., 2012) (Assaggaf, 2017). 
EEDs signaling mechanism 
               Epidemiological studies have reported that women who received hormone 
replacement therapy (HRT) show higher risk to PAH when compared to women with no 
HRT (Irey, pathology, & 1973, ; Kleiger, Boxer, Ingham, Chest, & 1976, ; Morse, Horn, 
& Barst, 1999). Researchers have shown the involvement of estrogen in vascular and 
pulmonary disorders (Khalil, 2013). 17β-estradiol (E2) signaling occurs through both 
genomic (nuclear) and non-genomic (extra-nuclear) pathways (Heldring et al., 2007; 
Shanle & Xu, 2010). Nuclear estrogen receptors consist of ERα and ERβ while 
membrane estrogen receptors (mERs: GPER, GPR30, ER-X, and Gq-mER) are mostly G 
protein-coupled receptors (Bondar, Kuo, Hamid, & Micevych, 2009; Filardo, Quinn, 
Bland, & Frackelton, 2000; Gorosito, Lorenzo, & Cambiasso, 2008; Lagrange, 
Ronnekleiv, & Kelly, 1997; Qiu et al., 2003; Skipper et al., 1993; Toran-Allerand et al., 
2002). Relative binding affinities of ortho, para-DDE, hydroxylated PCB, BPA, and DES 
have been shown to be significantly weaker than E2 in binding to nuclear ERs and mERs 
like GPR30 (Bonefeld-Jorgensen, Andersen, Rasmussen, & Vinggaard, 2001; Korach, 
Sarver, Chae, McLachlan, & McKinney, 1988; Nadal et al., 2000; P. Thomas & Dong, 
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2006; Watson, Bulayeva, Wozniak, & Finnerty, 2005). Moreover, EEDs have been 
shown to mimic estrogenic activity and interfere with the endocrine system through these 
receptor signaling pathways (Diamanti-Kandarakis et al., 2009; Rasier, Parent, Gérard, 
Lebrethon, & Bourguignon, 2007; Zsarnovszky, Le, Wang, & Belcher, 2005). This has 
been suggested to be a result of the higher exposure to estrogen (Austin et al., 2009). 
Moreover, many idiopathic pulmonary arterial hypertension (IPAH) registries reported 
that females are more prone to PAH than men (Badesch et al., 2010b; Humbert et al., 
2006). Estrogen causes multiple effects through ERα and/or ERβ in PAH-associated 
pathways (Massaro, Clerch, & Massaro, 2007; Patrone et al., 2003). 
Pulmonary arterial hypertension 
 
Pulmonary artery hypertension  is complex and a multifactorial disease characterized by 
the multifactorial interaction of genetic, behavioral, and environmental factors. PAH is a 
progressive disease caused by narrowing or tightening of the pulmonary arteries. The 
right side of the heart becomes enlarged due to the increased strain of pumping blood 
through the lungs which leads to the common symptoms of PAH (breathlessness, fatigue, 
weakness, angina) (Genetic and Rare Diseases Information Center (GARD), 2009). In 
addition to this, hypertension and elevated triglyceride levels, obesity also constitute the 
metabolic and biochemical risk factors of vascular dysfunction (Kopeć et al., 2017). PAH 
is characterized by endothelial damage, increased pulmonary vascular resistance, and 
right heart failure. The estimated prevalence of PAH is 15–50 cases per million (Peacock, 
Murphy, McMurray, Caballero, & Stewart, 2007)  and has an annual incidence of 1–2 
cases per million people in the US and Europe (Gaine & Rubin, 1998). Interestingly, it is 
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2-4 times more prone in women than men (Badesch et al., 2010a). Researchers have 
shown molecular level interactions associated with PAH pathogenesis include: 
inflammation, uncontrolled vascular growth, and formation of obliterative vascular 
lesions (Irey & Norris, 1973). Epidemiological studies have shown that the incidence of 
PAH is more common in overweight and obese individuals with a BMI greater than 30 
kg/m2 (Badesch et al., 2010a). PAH mainly occurs in pulmonary artery which carries the 
blood from the right ventricle of the heart to the lungs for oxygenation. The pulmonary 
artery is divided into three layers- the outermost layer is known as the tunica externa, is 
mainly made of collagen fibers. Underneath that, the artery is lined by the tunica media, 
which is made up of smooth muscle cells. The innermost layer is called as the tunica 
intima. This layer is mainly made up of endothelial cells. These endothelial cells maintain 
a balance between vasodilation and vasoconstriction. The hollow internal cavity through 
which the blood flows is called the lumen. Increased proliferation and progressive 
migration of endothelial cells further results in intimal fibrosis. In the late stage of disease 
progression, the formation of plexiform lesions as shown in Figure 1. Progressive 
reduction of the blood flow leads to high pulmonary arterial pressure defined to be at 
least 25 mm Hg at rest or 30 mm Hg with exertion measured by right heart 
catheterization. According to the Dana Point classification system, PAH is classified into 
five groups. Group 1- Pulmonary arterial hypertension, Idiopathic (“primary pulmonary 
hypertension”) and secondary to systemic disorders. 
Group 2- Pulmonary hypertension due to left heart disease (pulmonary venous 
hypertension) 
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Group 3- Pulmonary hypertension associated with respiratory disease and/or hypoxia 
COPD, Interstitial lung disease, OSA 
Group 4- Chronic thromboembolic/embolic pulmonary hypertension 
Group 5- Pulmonary hypertension from unclear mechanisms. 
 The Mayo clinic in Florida did retrospective chart review study of patients from January 
1990 to October 2013 with PAH characterized by right heart catheterization (N = 640). 
The study revealed that 39% of PAH patients were associated with some form of 
metabolic risk factors like diabetes mellitus and obesity (Ussavarungsi, Thomas, & 
Burger, 2015). Researchers studied the PAH patients lung tissues sample and microarray 
data of those samples revealed decreased expression or mutation of bone morphogenetic 
protein receptor type II (BMPR2) (Du et al., 2003; Hamid et al., 2009; Machado et al., 
2001). BMPR2 is associated with TGF-beta superfamily of ligands which regulates 
signaling of downstream genes like the transcription factor peroxisome proliferator- 
activated receptor γ (PPARγ) and its downstream effectors, apolipoprotein E (ApoE) and 
adiponectin (Yang et al., 2002). PPARγ is best known for its role in glucose metabolism 
and adipogenesis (He et al., 2003; Hevener et al., 2003; Lehrke & Lazar, 2005). Earlier 
studies have also shown that patients with metabolic syndrome are associated with 
defective BMPR2 signaling. Together these studies help connect PAH with metabolic 
syndrome through dysregulated BMPR2 pathway. BMPR2 is known to regulate multiple 
important pathways like endothelin-1, MCP-1, and eNOS (Farber & Loscalzo, 2004; 
ITOH et al., 2006).  
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Figure 1. Pathological pulmonary arterial remodeling. (Revised from Gaine S. 
JAMA 2000;284:3160-3168). 
A mechanism of pulmonary arterial hypertension development. Sequence of events that 
leads from endothelial cell initial proliferation give rise to intimal and medial 
hypertrophy, neo vascularization of arterioles and complex vascular lesions. 
Transcription regulator ID3  
Transcriptional regulation by ID3 ultimately functions to increase cell 
proliferation and preserve multipotency. ID3 mediated gene regulation governing these 
processes in endothelial stem cells provide a possible explanation for how ID3 promotes 
vascular perturbations (Kaplan et al., 2015). ID3 protein-protein interactions occur via the 
helix loop helix (HLH)-motif. ID3 protein interactions block the DNA binding activity of 
basic HLH (bHLH) transcription factors encoded by the genes TCF3, TCF4, and TCF12. 
TCF3 gene encodes for E12, E47 proteins. TCF4 gene encodes for E2-2, and TCF12 
gene encodes for HEB proteins in humans (Murre, McCaw, & Baltimore, 1989). E12, 
E47, E2-2 and HEB proteins are class I bHLH proteins that possess the basic DNA 
binding domain. These E proteins specifically recognize and bind to Ephrussi-box (E-
box) sequences (CANNTG) on the DNA (Lazorchak, Jones, & Zhuang, 2005; Sun, 
2004). ID3 has been most often reported to interact with proteins encoded by the TCF3 
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gene (Benezra, Davis, Lockshon, Turner, & Weintraub, 1990). ID3 protein-protein 
interactions can regulate transcription by E-proteins preventing their binding and 
subsequent activation of target gene promoters (Benezra et al., 1990). ID3 has frequently 
been described throughout the literature as an inhibitor of gene expression. For example, 
ID3 promotes cells to pass through cell cycle checkpoints by inhibiting the expression of 
cell cycle inhibitor gene p21Cip1 as shown in Figure 2 (Taylor et al., 2006a). However, 
ID3 can also act as a positive transcriptional regulator depending on the cellular context. 
E-proteins suppress the expression of embryonic genes OCT4, SOX2, and NANOG 
leading to cell differentiation (Bensellam, Montgomery, Luzuriaga, Chan, & Laybutt, 
2015). As shown in Figure 2, ID3 can increase the expression of these embryonic genes 
by repressing TCF3. We have demonstrated that ectopic overexpression of ID3 in 
endothelial cells increased OCT4 and SOX2 expression and the acquisition of the 
vascular stem cell signature: CD133+ VEGFR3+ CD34+ (Das, Voelkel, & Felty, 2015). 
Based on these findings, ID3 can maintain undifferentiated cells by increasing the 
expression of embryonic pluripotency factors via repression of TCF3. Since ID3 is a 
transcription regulator of genes involved in both cell proliferation and stemness, EEDs 
may facilitate the uncontrolled proliferation of adipocytes through ID3 contributing to 
pulmonary or metabolic disorders. 
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ID3 and EEDs 
                     The molecular factors that contribute to endocrine disruption have yet to be 
fully elucidated. The ID (inhibitor of differentiation) family of small proteins consists of 
four proteins (ID1-ID4). ID1 and ID3 have been shown to regulate cell growth, self-
renewal, senescence, angiogenesis, and neurogenesis (Benezra et al., 1990; Lasorella, 
Benezra, & Iavarone, 2014; Zebedee & Hara, 2001) (Duncan, DiCicco-Bloom, Xiang, 
Benezra, & Chada, 1992; Ellmeier & Weith, 1995; Jen, Manova, & Benezra, 1997). 
Depending on the cellular context, ID1 and ID3 have been shown to exhibit overlapping 
functions as dual gene knockout combinations have demonstrated redundancy (Lyden et 
al., 1999a). ID1 and ID3 have been shown to be co-expressed in early development of 
cell cycle progression, angiogenesis, and neurogenesis in the mouse model (Duncan et 
Figure 2 - ID3 regulates a variety of cellular processes 
This includes cellular growth, senescence, apoptosis, differentiation, angiogenesis, 
and neoplastic transformation. This Figure illustrates the ID3 interaction with E 
proteins. The ID3 protein controls transcription of genes like p21Cip1, OCT4, SOX2, 
and NANOG by binding to the E-proteins and preventing them from interacting with 
the E-box sequence on the DNA. 
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al., 1992; Ellmeier & Weith, 1995; Jen et al., 1997). Amongst PCB congeners, PCB153 
has been found to be one of the largest contributors to total PCB body burden in humans 
(Mullerova et al., 2008; Wahlang et al., 2013). We have previously demonstrated that 
PCB153 modulates ID3 expression and phosphorylation (Das & Felty, 2014c).  ID3 is 
highly expressed in the embryonic tissue and highly proliferating and undifferentiated 
adult cells (Lyden et al., 1999b). We and others have shown that PCB153 increases 
oxidative stress or ROS that mediate ID3 expression (Felty & Porther, 2008b; Mueller et 
al., 2002). Exposure to estrogenic chemicals have been shown to increase ROS in the 
nucleus in which they modify the surrounding DNA necessary for transcriptional 
activation of cell growth genes (Okoh, Felty, Parkash, Poppiti, & Roy, 2013; Parkash, 
Felty, & Roy, 2006c; Perillo et al., 2008). In other words, ROS that we have already 
shown to be induced by treatment with PCB153 may be involved in ID3 mediated 
transcription regulation. EEDs have been shown to increase ROS production in 
adipocytes. Di-(2-ethyl hexyl)phthalate (DEHP) increased ROS in rat adipocytes (Rajesh, 
Sathish, Srinivasan, Selvaraj, & Balasubramanian, 2013). Mitochondria are a major 
source of ROS production in mammalian cells (Wang, Zhang, Lu, & Liu, 2015).  
Although other endogenous ROS sources besides mitochondria such as NADPH oxidase 
exist, we have shown that estrogenic chemicals increase mitochondrial ROS (Felty et al., 
2005). Furthermore, the presence of ERα and ERβ in mitochondria may potentially be 
targets of EEDs contributing to oxidative stress (Chen, Delannoy, Cooke, & Yager, 2004; 
Chen, Eshete, Alworth, & Yager, 2004; Monje & Boland, 2001). Although there is 
evidence linking EEDs exposure to increased mitochondrial ROS, it is unclear whether it 
is responsible for redox sensitive phosphorylation of ID3 upon exposure to PCB153.  
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Exposure to EEDs may also exert negative health effects by altering epigenetic 
marks including DNA methylation and histone acetylation ultimately influencing gene 
expression in lung tissues. Epigenetic transgenerational effects has been demonstrated in 
animals exposed to EEDs: BPA and phthalates (Manikkam, Tracey, Guerrero-Bosagna, 
& Skinner, 2013). Early life exposures to EEDs like DES and PCB153 are known to alter 
DNA methyltransferase activity (Wu, Zhou, & Ohsako, 2006). Since altered DNA 
methylation have been found in PCB153 exposed cells (Sales et al., 2013), it is 
biologically plausible that chromatin modifications including acetylation/deacetylation of 
histones are another way for ID3 to regulate transcription. ID proteins have been shown 
to promote acetylation and transcriptional activity by recruiting histone acetyltransferase 
(HATs): i) CREB-binding protein (CBP), ii) p300 (E1A binding protein p300), and/or 
P300/CBP-associated factor (PCAF) to the chromatin (Knowell et al., 2013). Moreover, 
ID proteins interact with another chromatin modifying protein, ZRF1 (Aloia, Gutierrez, 
Caballero, & Di Croce, 2015). These evidences suggest that ID3 may regulate 
transcription through interactions with both transcription factors and chromatin 
modifying proteins.  
ID3 and Vascular Diseases 
ID3 involvement in vascular disease has been studied together with the 
lipoxygenase (12/15-LO) which is known to generate pro-inflammatory changes in blood 
vessels that precede the development of atherosclerosis (Chakrabarti, Cole, Wen, Keller, 
& Nadler, 2009). 12/15-LO is an important mediator of vascular smooth muscle cells 
(VSMC) growth and its growth-promoting effects were shown to be mediated by ID3 
transcription (Butany, Ahluwalia, Nair, & David, 2004). Increased expression of 12/15-
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LO in the vessel wall enhanced ID3-dependent cell proliferation, fibronectin deposition, 
and neointimal formation. Population-based studies have found SNP (single nucleotide 
polymorphisms) rs11574 in the coding region of the human ID3 gene associated with 
subclinical atherosclerosis in the Diabetes Heart Study (Doran et al., 2010). ID3 SNP 
rs11574 showed a significant association of coronary artery disease for Caucasians and to 
a lesser extent African Americans and Hispanics (Manichaikul et al., 2014). Ectopic 
expression of ID3 in VSMC regulates the cell cycle (Yang et al., 2013). ID3 has also 
been shown to play a complex role with atherosclerosis. ID3 expression is increased by 
hyperlipidemia and oxidized LDL (Taylor et al., 2006b). ID3 regulates angiotensin II and 
carotid intima-media thickness. Angiotensin II promotes hyperplasia through 
upregulating ID3 (Phillip & Iii, 2009). The ID3 SNP could be a potential loss of function 
mutation if it inhibits the functioning of E proteins, thus being an atheroprotective factor. 
As shown in Figure 3, ID3 may impact vascular cell dysfunction leading to intimal 
lesions. ID3 stimulates visceral adipose vascular endothelial growth factor A (VEGFA) 
expression, depot expansion, and microvascular blood volume (Cutchins et al., 2012). 
ID3 promotes angiogenesis in high fat diet - (HFD -) induced visceral adiposity (Cutchins 
et al., 2012). ID3 KO shows a protective effect from HFD induced visceral fat depot 
expansion. Furthermore, HFD-induced VEGFA expression in visceral adipose tissue was 
completely abolished by loss of ID3. BMP9 induces both ID1 and ID3 which are 
necessary for induction of Ephrin B2 (Kim, Peacock, George, & Hughes, 2012). A 
summary in Figure 4 shows an ID3 signaling pathway involved in vascular 
malformations. Similar to adipocytes, ID3 induced VEGF overexpression and Ephrin B2 
downregulation may be involved in endothelial cells. 
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Epigenetic imprinting of vascular progenitor or endothelial stem cells by ID3 in 
individuals exposed to EEDs is another plausible mechanism based on the following 
evidence. Specifically, we postulate that EEDs can induce ROS-mediated ID3 
phosphorylation and acetylation, histone acetylation, and DNA base oxidation 
collectively that control expression of ID3 target genes involved in vascular cells 
programming. This in turn controls the fate and epigenetic footprints of vascular 
progenitor cells. Reactive oxygen species like H2O2 are highly diffusible molecules. In 
addition to affecting ID3 signaling pathways, ROS can also facilitate histone acetylation 
and oxidize nuclear DNA resulting in chromatin modification. These modifications are 
significant because transcription in eukaryotes occurs in the context of DNA, packaged 
into chromatin. The basic unit of chromatin is the nucleosome, in which DNA is wrapped 
around the core histones H2A, H2B, H3, and H4. Acetylation of lysine in the histone tails 
can facilitate the opening of repressive chromatin structures in promoter regions to 
provide access for the transcription regulator ID3. In support of our concept that both 
histone acetylation and ROS-mediated DNA oxidation control the transcription of EED-
induced genes, we and others have shown that E2 and PCB153-induced ROS in the 
nucleus, particularly H2O2, modify the surrounding DNA (Okoh, Deoraj, & Roy, 2011; 
Parkash, Felty, & Roy, 2006a; Perillo et al., 2008). It has been recently shown that DNA 
oxidation through recruiting 8-oxoguanine–DNA glycosylase triggers chromatin and 
DNA conformational changes that are essential for estrogen-mediated transcription of 
genes (Perillo et al., 2008). ROS generating agents and inflammation have been shown to 
modulate chromatin-bound hSirT1 deacetylase activity on the promoters of several genes 
(Adcock, Cosio, Tsaprouni, Barnes, & Ito, 2005; Brunet et al., 2004; Moodie et al., 2004; 
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Pediconi et al., 2009). Taken together, EEDs through induction of ROS may increase 
histone acetylations by post-translational activation of acetylases and oxidation of DNA 
bases, which are necessary for ID3-mediated transcription regulation of target genes 
involved in vascular and metabolic complications. 
 Given the significant role of ID3 in stemness, it is possible that EEDs exposure 
may contribute to an increase in vascular progenitor cells. Epigenetic changes mediated 
by ID3 in the stem cells may ultimately increase the total number of endothelial cells that 
can be produced by an individual. Subsequent environmental exposures of these 
susceptible individuals who have a higher number of endothelial stem cells, to begin 
with, may potentially lead to pathological vascular remodeling including plexiform 
lesions. 
 
 
 
Figure 3- ID3 molecular mechanism and vascular diseases.  
Summary illustration of ID3 signaling involved in vascular disease pathogenesis. ID3 
signaling can lead to neointimal lesions or vascular remodeling by transcriptional 
regulation of the target genes described above (up- and down regulated genes by ID3). 
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Interaction of ID3 and EEDs 
In order to investigate how environmental exposures, affect human health at 
genetic and protein level, we used the Comparative Toxicogenomic Database (CTD). 
CTD is a public website, and research tool that consists of scientific data illustrating 
chemical-gene interactions and chemical-disease associations. CTD includes in vitro and 
in vivo data studies describing relationships between chemicals, genes, and diseases. The 
database was used to manually curates information about EEDs–gene/protein 
interactions, EEDs–disease and gene-disease associations. We used these public 
databases to investigate the role of ID3, especially in various metabolic pathways. This 
tool can be used to decipher gene-environment or gene-EEDs interactions involved in the 
generation of vascular diseases. 
Figure 4 - ID3 involvement in arteriovenous malformation.  
Summary of experimental studies showing impact of ID3 in vascular cell dysfunction. 
ID3 involved in VEGFR higher expression by inducing BMP9 and downregulation of 
Ephrin B. 
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We initially selected PCB as a chemical and chose hypertension as the disease. 
Our search results showed 29 genes associated with both the hypertension and PCBs. 
Because ID3 is our candidate gene, we created a list of genes related to ID3 and PCBs. 
We established that 38 genes are associated with this group in Table 1. Furthermore, we 
show an interaction between these genes, we additionally inputted them into STRING, a 
database of recognized and predicted protein-protein interactions. The interactions 
contain direct (physical) and indirect (functional) associations which stem from 
computational prediction, interactions aggregated from other (primary) databases, and 
from knowledge transfer between organisms. As seen in Figure 5 STRING provides a 
network of these proteins and furthermore provides a pathway description for the 
mutually represented proteins (Szklarczyk et al., 2015a). We created Table 2 with the 
help of STRING network, and it shows that the involvement of the ID3 protein in the 
various pathway.  
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PCBs and Hypertension related 
genes 
ID3 and PCBs related genes 
ABCA3 ATF3 
BMPR2 CDK2 
CAV1 CNOT3 
CBLN2 CSK 
CCL1 E2F4 
CCL2 ELSPBP1 
CXCL8 EMX1 
EDN1 FHL2 
EIF2AK4 GATA4 
FBLN5 GNB2 
FOXO1 ID3 
GUCY1A1 MLX 
HDAC1 MYOD1 
HDAC4 NPHP4 
HDAC5 PUF60 
HIF1A RND1 
HTR2B SMURF2 
KCNMA1 SREBF1 
LOX TCF3 
NOS3 TCF4 
NPPB UNK 
PRKG1 ZNF3 
RETNLA ZNF408 
SLC31A1 ZNF626 
SLC6A4 FAM74A1 
SMAD9 ID4 
SOD2 IKBKG 
TGFA NKX2-5 
TNF PAX5 
 PRDM14 
 SAP30 
 TCF12 
 VHL 
 CBFA2T2 
 COPS5 
 COPS6 
 COPS7A 
 ELOC 
 
 
Table 1- Genes involved ID3 -PCBs and PCBs -hypertension. 
CTD network curated information about genes involved in PCBs–ID3 protein 
interactions, PCBs–hypertension and ID3- hypertension associations. 
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Figure 5 - STRING network illustration of proteins involved in ID3 - PCBs 
and PCBs -hypertension. 
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Conclusion and Rationale of the Study 
Table 2- Summary of functional enrichments involved in the genes related to ID3 - 
PCBs and PCBs - hypertension 
 
Figure 6 - Central Hypothesis of study 
The diagram represents central hypothesis, which is based on background information 
and earlier studies. We hypothesize that the exposure of PCB153 increases ID3 
expression. ID3 may be involved in vascular reprogramming and hyperproliferation of 
endothelial cells. 
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 ID3 has been shown to promote vascular disorders in experimental models. 
Studies have reported associations between endothelial or vascular dysfunction in PAH 
and exposure to EEDs: BPA, DES, and PCBs. Based on the evidence discussed in this 
review, elevated exposure to EEDs or unopposed increase in the body burden of 
estrogens may increase the expression of the transcription regulator ID3. We propose that 
ID3 may be an additional molecular risk factor for vascular perturbations or PAH from 
environmental exposure to estrogenic chemicals. Emerging evidence demonstrated that 
ID3 can regulate mitochondrial function and morphology associated with changes in the 
expression of electron transport chain complex components and transcription factor A, 
mitochondrial (TFAM) (Bensellam, Montgomery, Luzuriaga, Chan, & Laybutt, 2015b). 
We have previously shown that ER independent mitochondrial ROS signaling contributes 
to the growth of cells treated with 17β-estradiol (Felty et al., 2005; Felty & Roy, 2005; 
Parkash, Felty, & Roy, 2006b). Therefore, ID3 mediated vascular programming of 
mitochondria may be dysregulated by exposure to EEDs and increase susceptibility to 
PAH or vascular disorder. In addition, the ID3 dependent production of cytokines and 
recruitment of macrophages in lung tissue are suggested to play an important role in the 
inflammatory process to enhance susceptibility to complications.  
In closing, we have systematically reviewed the existing evidence to illustrate the 
association between ID3, EEDs, & PAH. Furthermore, we extended this understanding of 
how ID3 and vascular perturbations by environmental factors such as EEDs can increase 
the risk of PAH. Research is warranted to better define the influence of EEDs and ID3 
alongside gene-environment interactions on PAH. A better understanding of how ID3 & 
EEDs affect the risk of PAH may open up new avenues for prevention and treatment of 
24 
 
diseases. We have shown previously that PCB153 and natural estrogen 17β-estradiol 
increase ID3 expression in endothelial cells. Based on our findings, we postulate that ID3 
is a molecular target of EEDs like PCB153 in lung tissue and a better understanding of 
this relationship may help to explain how EEDs can lead to the transcriptional 
programming of deviant endothelial cells. Thus, the purpose of this dissertation will be to 
discuss the current understanding of ID3 in vascular reprogramming and to consider the 
potential for PCB153 to influence susceptibility to pulmonary or vascular disorders via 
ID3 signaling as shown in Figure 6.  
 
 
References-  
 
Achour, A., Derouiche, A., Barhoumi, B., Kort, B., Cherif, D., Bouabdallah, S., 
Tebourbi, O. (2017). Organochlorine pesticides and polychlorinated biphenyls in 
human adipose tissue from northern Tunisia: Current extent of contamination and 
contributions of socio-demographic characteristics and dietary habits. 
Environmental Research, 156, 635–643. http://doi.org/10.1016/j.envres.2017.04.021 
Adcock, I. M., Cosio, B., Tsaprouni, L., Barnes, P. J., & Ito, K. (2005). Redox Regulation 
of Histone Deacetylases and Glucocorticoid-Mediated Inhibition of the 
Inflammatory Response. Antioxidants & Redox Signaling, 7(1–2), 144–152. 
http://doi.org/10.1089/ars.2005.7.144 
Albro, P. W., & Fishbein, L. (1972). Intestinal absorption of polychlorinated biphenyls in 
rats. Bulletin of Environmental Contamination and Toxicology, 8(1), 26–31. 
http://doi.org/10.1007/BF01684500 
Aloia, L., Gutierrez, A., Caballero, J. M., & Di Croce, L. (2015). Direct interaction 
between Id1 and Zrf1 controls neural differentiation of embryonic stem cells. EMBO 
Reports, 16(1), 63–70. http://doi.org/10.15252/embr.201439560 
Assaggaf, H., & Felty, Q. (2017, April 2). Gender, estrogen, and obliterative lesions in 
the lung. International Journal of Endocrinology. Hindawi. 
https://doi.org/10.1155/2017/8475701. 
ASTDR. (2000). Toxicological Profile for Polychlorinated Biphenyls (PCBs). Agency for 
Toxic Substances and Disease Registry, (November), 1–948. Retrieved from 
https://www.atsdr.cdc.gov/toxprofiles/tp17.pdf 
25 
 
Phillips, J. A. (2009). Alterations in oestrogen metabolism: implications for higher 
penetrance of familial pulmonary arterial hypertension in females. The European 
Respiratory Journal, 34(5), 1093–1099. http://doi.org/10.1183/09031936.00010409 
Badesch, D. B., Raskob, G. E., Elliott, C. G., Krichman, A. M., Farber, H. W., Frost, A. 
E., McGoon, M. D. (2010a). Pulmonary Arterial Hypertension. Chest, 137(2), 376–
387. http://doi.org/10.1378/chest.09-1140 
Badesch, D. B., Raskob, G. E., Elliott, C. G., Krichman, A. M., Farber, H. W., Frost, A. 
E., McGoon, M. D. (2010b). Pulmonary arterial hypertension: baseline 
characteristics from the REVEAL Registry. Chest, 137(2), 376–387. 
http://doi.org/10.1378/chest.09-1140 
Ballschmiter, K., & Zell, M. (1980). Fmenius Zeitschrift fur Analysis of Polychlorinated 
Biphenyls (PCB) by Glass Capillary Gas Chromatography Composition of 
Technical Aroclor-and Clophen-PCB Mixtures. Fresenius Z. Anal. Chem, 302, 20–
31. Retrieved from 
https://link.springer.com/content/pdf/10.1007%2FBF00469758.pdf 
Bastos Sales, L., Kamstra, J. H., Cenijn, P. H., van Rijt, L. S., Hamers, T., & Legler, J. 
(2013). Effects of endocrine disrupting chemicals on in vitro global DNA 
methylation and adipocyte differentiation. Toxicology in vitro, 27(6), 1634–1643. 
http://doi.org/10.1016/j.tiv.2013.04.005 
Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L., & Weintraub, H. (1990). The 
protein Id: A negative regulator of helix-loop-helix DNA binding proteins. Cell, 
61(1), 49–59. http://doi.org/10.1016/0092-8674(90)90214-Y 
Bensellam, M., Montgomery, M. K., Luzuriaga, J., Chan, J. Y., & Laybutt, D. R. (2015). 
Inhibitor of differentiation proteins protect against oxidative stress by regulating the 
antioxidant–mitochondrial response in mouse beta cells. Diabetologia, 58(4), 758–
770. http://doi.org/10.1007/s00125-015-3503-1 
Benza, R. L., Gomberg-Maitland, M., Miller, D. P., Frost, A., Frantz, R. P., Foreman, A. 
J., McGoon, M. D. (2012). The REVEAL Registry risk score calculator in patients 
newly diagnosed with pulmonary arterial hypertension. Chest, 141(2), 354–362. 
http://doi.org/10.1378/chest.11-0676 
Betsholtz, C. (2015). Lipid transport and human brain development. Nature Genetics, 
47(7), 699–701. http://doi.org/10.1038/ng.3348 
Bjermo, H., Darnerud, O., Lignell, S., Pearson, M., Rantakokko, P., Nälsén, C., … 
Glynn, A. (2013). Fish intake and breastfeeding time are associated with serum 
concentrations of organochlorines in a Swedish population. Environment 
International, 51, 88–96. http://doi.org/10.1016/j.envint.2012.10.010 
Bondar, G., Kuo, J., Hamid, N., & Micevych, P. (2009). Estradiol-Induced Estrogen 
Receptor-  Trafficking. Journal of Neuroscience, 29(48), 15323–15330. 
http://doi.org/10.1523/JNEUROSCI.2107-09.2009 
                Austin, E. D., Cogan, J. D., West, J. D., Hedges, L. K., Hamid, R., Dawson, E. P.,
26 
 
Bonefeld-Jorgensen, E. C., Andersen, H. R., Rasmussen, T. H., & Vinggaard, A. M. 
(2001). Effect of highly bioaccumulated polychlorinated biphenyl congeners on 
estrogen and androgen receptor activity. Toxicology, 158(3), 141–153. 
http://doi.org/10.1016/S0300-483X(00)00368-1 
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Greenberg, 
M. E. (2004). Stress-Dependent Regulation of FOXO Transcription Factors by the 
SIRT1 Deacetylase. Science, 303(5666), 2011–2015. 
http://doi.org/10.1126/science.1094637 
Butany, J., Ahluwalia, M. S., Nair, V., & David, T. E. (2004). Cryopreserved pulmonary 
homograft: Postimplant changes. Cardiovascular Pathology, 13(1), 59–61. 
http://doi.org/10.1016/S1054-8807(03)00092-9 
CDC Centers for Disease Control and Prevention. (2017). Centers for Disease Control 
and Prevention (CDC). National Center for Health Statistics (NCHS). National 
Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department 
of Health and Human Services, Centers for Disease Control and Preventio. 
Chakrabarti, S. K., Cole, B. K., Wen, Y., Keller, S. R., & Nadler, J. L. (2009). 12/15-
Lipoxygenase products induce inflammation and impair insulin signaling in 3t3-l1 
adipocytes. Obesity, 17(9), 1657–1663. http://doi.org/10.1038/oby.2009.192 
Chao, H.-R., Wang, S.-L., Lin, T.-C., & Chung, X.-H. (2006). Levels of organochlorine 
pesticides in human milk from central Taiwan. Chemosphere, 62(11), 1774–1785. 
http://doi.org/10.1016/j.chemosphere.2005.07.036 
Chen, J. Q., Delannoy, M., Cooke, C., & Yager, J. D. (2004). Mitochondrial localization 
of ER  and ER  in human MCF7 cells. AJP: Endocrinology and Metabolism, 286(6), 
E1011–E1022. http://doi.org/10.1152/ajpendo.00508.2003 
Chen, J. Q., Eshete, M., Alworth, W. L., & Yager, J. D. (2004). Binding of MCF-7 cell 
mitochondrial proteins and recombinant human estrogen receptors ? and ? to human 
mitochondrial dna estrogen response elements. Journal of Cellular Biochemistry, 
93(2), 358–373. http://doi.org/10.1002/jcb.20178 
Chen, P. H., Luo, M. L., Wong, C. K., & Chen, C. J. (1982). Comparative rates of 
elimination of some individual polychlorinated biphenyls from the blood of PCB-
poisoned patients in Taiwan. Food and Chemical Toxicology, 20(4), 417–425. 
http://doi.org/10.1016/S0278-6915(82)80107-5 
Commission, T. H. E., The, O. F., Communities, E., & Facts, T. H. E. (1999). Official 
Journal of the European Communities. Analytical Proceedings, 21(6), 196. 
http://doi.org/10.1039/ap9842100196 
Cutchins, A., Harmon, D. B., Kirby, J. L., Doran, A. C., Oldham, S. N., Skaflen, M., … 
McNamara, C. A. (2012). Inhibitor of Differentiation-3 Mediates High Fat Diet-
Induced Visceral Fat Expansion. Arteriosclerosis, Thrombosis, and Vascular 
Biology, 32(2), 317–324. http://doi.org/10.1161/ATVBAHA.111.234856 
27 
 
Das, J. K., & Felty, Q. (2014). PCB153-induced overexpression of ID3 contributes to the 
development of microvascular lesions. PLoS ONE, 9(8). 
http://doi.org/10.1371/journal.pone.0104159 
Das, J. K., Voelkel, N. F., & Felty, Q. (2015). ID3 contributes to the acquisition of 
molecular stem cell-like signature in microvascular endothelial cells: Its implication 
for understanding microvascular diseases. Microvascular Research, 98, 126–138. 
http://doi.org/10.1016/j.mvr.2015.01.006 
Diamanti-Kandarakis, E., Bourguignon, J.-P., Giudice, L. C., Hauser, R., Prins, G. S., 
Soto, A. M., … Gore, A. C. (2009). Endocrine-disrupting chemicals: an Endocrine 
Society scientific statement. Endocrine Reviews, 30(4), 293–342. 
http://doi.org/10.1210/er.2009-0002 
Dobson, S. (Stuart), Esch, G. J. van., International Program on Chemical Safety., United 
Nations Environment Programme., International Labour Organisation., & World 
Health Organization. (1993). Polychlorinated biphenyls and terphenyls. World 
Health Organization. 
Doran, A. C., Lehtinen, A. B., Meller, N., Lipinski, M. J., Slayton, R. P., Oldham, S. N., 
McNamara, C. A. (2010). Id3 Is a novel atheroprotective factor containing a 
functionally significant single-nucleotide polymorphism associated with intima-
media thickness in humans. Circulation Research, 106(7), 1303–1311. 
http://doi.org/10.1161/CIRCRESAHA.109.210294 
Du, L., Sullivan, C. C., Chu, D., Cho, A. J., Kido, M., Wolf, P. L., Thistlethwaite, P. A. 
(2003). Signaling Molecules in Nonfamilial Pulmonary Hypertension. New England 
Journal of Medicine, 348(6), 500–509. http://doi.org/10.1056/NEJMoa021650 
Duncan, M., DiCicco-Bloom, E. M., Xiang, X., Benezra, R., & Chada, K. (1992). The 
gene for the helix-loop-helix protein, Id, is specifically expressed in neural 
precursors. Developmental Biology, 154(1), 1–10. http://doi.org/10.1016/0012-
1606(92)90042-F 
Elabbas, L. E., Esteban, J., Barber, X., Hamscher, G., Nau, H., Bowers, W. J., 
Håkansson, H. (2014). In Utero and Lactational Exposure to a Mixture of 
Environmental Contaminants Detected in Canadian Arctic Human Populations 
Alters Retinoid Levels in Rat Offspring with Low Margins of Exposure. Journal of 
Toxicology and Environmental Health, Part A, 77(5), 223–245. 
http://doi.org/10.1080/15287394.2013.861776 
Ellmeier, W., & Weith, A. (1995). Expression of the helix loop helix gene Id3 during 
murine embryonic development. Developmental Dynamics, 203(2), 163–173. 
http://doi.org/10.1002/aja.1002030205 
European Food Safety Authority. (2005). Opinion of the Scientific Panel on 
Contaminants in the Food Chain on a Request From the Commission Related To the 
Presence of Non Dioxin-Like Polychlorinated Biphenyls (Pcb) in Feed and Food. 
Efsa Journal, 284(11), 1–137. http://doi.org/10.2903/j.efsa.2005.284 
28 
 
Farber, H. W., & Loscalzo, J. (2004). Pulmonary Arterial Hypertension. New England 
Journal of Medicine, 351(16), 1655–1665. http://doi.org/10.1056/NEJMra035488 
Felty, Q., & Porther, N. (2008a). Estrogen-induced redox sensitive Id3 signaling controls 
the growth of vascular cells. Atherosclerosis, 198(1), 12–21. 
http://doi.org/10.1016/j.atherosclerosis.2007.12.048 
Felty, Q., & Porther, N. (2008b). Estrogen-induced redox sensitive Id3 signaling controls 
the growth of vascular cells. Atherosclerosis, 198(1), 12–21. 
http://doi.org/10.1016/j.atherosclerosis.2007.12.048 
Felty, Q., & Roy, D. (2005). Estrogen, mitochondria, and growth of cancer and non-
cancer cells. Journal of Carcinogenesis, 4(1), 1. http://doi.org/10.1186/1477-3163-
4-1 
Felty, Q., Xiong, W.-C., Sun, D., Sarkar, S., Singh, K. P., Parkash, J., & Roy, D. (2005). 
Estrogen-induced mitochondrial reactive oxygen species as signal-transducing 
messengers. Biochemistry, 44(18), 6900–9. http://doi.org/10.1021/bi047629p 
Filardo, E. J., Quinn, J. A., Bland, K. I., & Frackelton, A. R. (2000). Estrogen-Induced 
Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled Receptor Homolog, 
GPR30, and Occurs via Trans -Activation of the Epidermal Growth Factor Receptor 
through Release of HB-EGF. Molecular Endocrinology, 14(10), 1649–1660. 
http://doi.org/10.1210/mend.14.10.0532 
Gaine, S. P., & Rubin, L. J. (1998). Primary pulmonary hypertension. The Lancet, 
352(9129), 719–725. http://doi.org/10.1016/S0140-6736(98)02111-4 
Gorosito, S. V., Lorenzo, A. G., & Cambiasso, M. J. (2008). Estrogen receptor α is 
expressed on the cell-surface of embryonic hypothalamic neurons. Neuroscience, 
154(4), 1173–1177. http://doi.org/10.1016/j.neuroscience.2008.05.001 
Grimm, F., Hu, D., Kania-Korwel, I., Lehmler, H., Ludewig, G., Hornbuckle, K., … 
Robertson, L. W. (2015). Metabolism and metabolites of polychlorinated biphenyls 
(PCBs) HHS Public Access. Crit Rev Toxicol, 45(3), 245–272. 
http://doi.org/10.3109/10408444.2014.999365 
Hamid, R., Cogan, J. D., Hedges, L. K., Austin, E., Phillips, J. A., Newman, J. H., & 
Loyd, J. E. (2009). Penetrance of pulmonary arterial hypertension is modulated by 
the expression of normal BMPR2 allele. Human Mutation, 30(4), 649–654. 
http://doi.org/10.1002/humu.20922 
He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Evans, R. M. (2003). 
Adipose-specific peroxisome proliferator-activated receptor   knockout causes 
insulin resistance in fat and liver but not in muscle. Proceedings of the National 
Academy of Sciences, 100(26), 15712–15717. 
http://doi.org/10.1073/pnas.2536828100 
 
29 
 
He, Y., Peng, L., Huang, Y., Peng, X., Zheng, S., Liu, C., & Wu, K. (2017). Association 
of breast adipose tissue levels of polychlorinated biphenyls and breast cancer 
development in women from Chaoshan, China. Environmental Science and 
Pollution Research, 24(5), 4778–4790. http://doi.org/10.1007/s11356-016-8208-6 
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Gustafsson, 
J.-A. (2007). Estrogen Receptors: How Do They Signal and What Are Their Targets. 
Physiological Reviews, 87(3), 905–931. http://doi.org/10.1152/physrev.00026.2006 
Hereditary leiomyomatosis and renal cell cancer | Genetic and Rare Diseases Information 
Center (GARD) – an NCATS Program. (). Retrieved March 20, 2018, from 
https://rarediseases.info.nih.gov/diseases/7501/pulmonary-arterial-hypertension 
Hevener, A. L., He, W., Barak, Y., Le, J., Bandyopadhyay, G., Olson, P., Olefsky, J. 
(2003). Muscle-specific Pparg deletion causes insulin resistance. Nature Medicine, 
9(12), 1491–1497. http://doi.org/10.1038/nm956 
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Simonneau, 
G. (2006). Pulmonary arterial hypertension in France: results from a national 
registry. American Journal of Respiratory and Critical Care Medicine, 173(9), 
1023–1030. http://doi.org/10.1164/rccm.200510-1668OC 
International Union of Pure and Applied Chemistry. Commission on the Nomenclature of 
Organic Chemistry., J., Rigaudy, J., Klesney, S. P., & International Union of Pure 
and Applied Chemistry. (1979). Nomenclature of organic chemistry. Pergamon 
Press. 
Irey, N., pathology, H. M.-A. of, & 1973,  undefined. (). Intimal vascular lesions 
associated with female reproductive steroids. Popline.org. Retrieved from 
https://www.popline.org/node/491301 
Irey, N. S., & Norris, H. J. (1973). Intimal vascular lesions associated with female 
reproductive steroids. Archives of Pathology, 96(4), 227–234. 
Itoh, T., Nagaya, N., Ishibashi-Ueda, H., Kyotani, S., Oya, H., Sakamaki, F., Nakanishi, 
N. (2006). Increased plasma monocyte chemoattractant protein-1 level in idiopathic 
pulmonary arterial hypertension. Respirology, 11(2), 158–163. 
http://doi.org/10.1111/j.1440-1843.2006.00821.x 
JECFA. (2007). Safety evaluation of certain food additives and contaminants. WHO Food 
Additives Series, (48), 692 p. http://doi.org/10.1021/jf60163a014 
Jen, Y., Manova, K., & Benezra, R. (1997). Each member of the Id gene family exhibits a 
unique expression pattern in mouse gastrulation and neurogenesis. Developmental 
Dynamics, 208(1), 92–106. http://doi.org/10.1002/(SICI)1097-
0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X 
 
 
30 
 
Kaplan, J. L., Marshall, M. A., McSkimming, C. C., Harmon, D. B., Garmey, J. C., 
Oldham, McNamara, C. A. (2015). Adipocyte progenitor cells initiate monocyte 
chemoattractant protein-1-mediated macrophage accumulation in visceral adipose 
tissue. Molecular Metabolism, 4(11), 779–794. 
http://doi.org/10.1016/j.molmet.2015.07.010 
Khalil, R. A. (2013). Estrogen, vascular estrogen receptor and hormone therapy in 
postmenopausal vascular disease. Biochemical Pharmacology, 86(12), 1627–1642. 
http://doi.org/10.1016/j.bcp.2013.09.024 
Kim, J. H., Peacock, M. R., George, S. C., & Hughes, C. C. W. (2012). BMP9 induces 
EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-
dependent pathway: Implications for hereditary hemorrhagic telangiectasia type II. 
Angiogenesis, 15(3), 497–509. http://doi.org/10.1007/s10456-012-9277-x 
Kimbrough, R. D., & Krouskas, C. A. (2003). Human exposure to polychlorinated 
biphenyls and health effects: a critical synopsis. Toxicological Reviews, 22(4), 217–
33. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15189045 
Kleiger, R., Boxer, M., Ingham, R., Chest, D. H.-, (1976). Pulmonary hypertension in 
patients using oral contraceptives: a report of six cases. Journal.chestnet.org. 
Retrieved from http://journal.chestnet.org/article/S0012-3692(16)56125-X/abstract 
Knowell, A. E., Patel, D., Morton, D. J., Sharma, P., Glymph, S., & Chaudhary, J. 
(2013). Id4 dependent acetylation restores mutant-p53 transcriptional activity. 
Molecular Cancer, 12(1), 161. http://doi.org/10.1186/1476-4598-12-161 
Kopeć, G., Waligóra, M., Tyrka, A., Jonas, K., Pencina, M. J., Zdrojewski, T., … 
Podolec, P. (2017). Low-density lipoprotein cholesterol and survival in pulmonary 
arterial hypertension. Scientific Reports, 7, 41650. http://doi.org/10.1038/srep41650 
Korach, K. S., Sarver, P., Chae, K., McLachlan, J. A., & McKinney, J. D. (1988). 
Estrogen receptor-binding activity of polychlorinated hydroxybiphenyls: 
conformationally restricted structural probes. Molecular Pharmacology, 33(1), 120–
6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3122017 
Lagrange, A. H., Ronnekleiv, O. K., & Kelly, M. J. (1997). Modulation of G protein-
coupled receptors by an estrogen receptor that activates protein kinase A. Molecular 
Pharmacology, 51(4), 605–12. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9106625 
Lasorella, A., Benezra, R., & Iavarone, A. (2014). The ID proteins: master regulators of 
cancer stem cells and tumour aggressiveness. Nature Reviews Cancer, 14(2), 77–91. 
http://doi.org/10.1038/nrc3638 
Lasserre, J. P., Fack, F., Revets, D., Planchon, S., Renaut, J., Hoffmann, L., Bohn, T. 
(2009). Effects of the endocrine disruptors atrazine and PCB153 on the protein 
expression of MCF-7 human cells. Journal of Proteome Research, 8(12), 5485–
5496. http://doi.org/10.1021/pr900480f 
31 
 
Lazorchak, A., Jones, M. E., & Zhuang, Y. (2005, June 1). New insights into E-protein 
function in lymphocyte development. Trends in Immunology. Elsevier Current 
Trends. http://doi.org/10.1016/j.it.2005.03.011 
Lehrke, M., & Lazar, M. A. (2005). The Many Faces of PPARγ. Cell, 123(6), 993–999. 
http://doi.org/10.1016/j.cell.2005.11.026 
Lyden, D., Young, A. Z., Zagzag, D., Yan, W., Gerald, W., O’Reilly, R., Benezra, R. 
(1999a). Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization 
of tumour xenografts. Nature, 401(6754), 670–677. http://doi.org/10.1038/44334 
Lyden, D., Young, A. Z., Zagzag, D., Yan, W., Gerald, W., O’Reilly, R., … Benezra, R. 
(1999b). Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization 
of tumour xenografts. Nature, 401(6754), 670–677. http://doi.org/10.1038/44334 
Machado, R. D., Pauciulo, M. W., Thomson, J. R., Lane, K. B., Morgan, N. V, Wheeler, 
L., Nichols, W. C. (2001). BMPR2 haploinsufficiency as the inherited molecular 
mechanism for primary pulmonary hypertension. American Journal of Human 
Genetics, 68(1), 92–102. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11115378 
Manichaikul, A., Rich, S. S., Perry, H., Yeboah, J., Law, M., Davis, M., Taylor, A. M. 
(2014). A Functionally Significant Polymorphism in ID3 Is Associated with Human 
Coronary Pathology. PLoS ONE, 9(3), e90222. 
http://doi.org/10.1371/journal.pone.0090222 
Manikkam, M., Tracey, R., Guerrero-Bosagna, C., & Skinner, M. K. (2013). Plastics 
Derived Endocrine Disruptors (BPA, DEHP and DBP) Induce Epigenetic 
Transgenerational Inheritance of Obesity, Reproductive Disease and Sperm 
Epimutations. PLoS ONE, 8(1), e55387. 
http://doi.org/10.1371/journal.pone.0055387 
Massaro, D., Clerch, L. B., & Massaro, G. D. (2007). Estrogen receptor-alpha regulates 
pulmonary alveolar loss and regeneration in female mice: morphometric and gene 
expression studies. American Journal of Physiology. Lung Cellular and Molecular 
Physiology, 293(1), L222-228. http://doi.org/10.1152/ajplung.00384.2006 
Matthews, H. B., & Dedrick, R. L. (1984a). Pharmacokinetics of PCBs. Annual Review of 
Pharmacology and Toxicology, 24(1), 85–103. 
http://doi.org/10.1146/annurev.pa.24.040184.000505 
Matthews, H. B., & Dedrick, R. L. (1984b). Pharmacokinetics of PCBs. Annual Review 
of Pharmacology and Toxicology, 24(2), 85–103. 
http://doi.org/10.1146/annurev.pa.24.040184.000505 
Monje, P., & Boland, R. (2001). Subcellular distribution of native estrogen receptor alpha 
and beta isoforms in rabbit uterus and ovary. Journal of Cellular Biochemistry, 
82(3), 467–79. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11500923 
 
32 
 
Moodie, F. M., Marwick, J. A., Anderson, C. S., Szulakowski, P., Biswas, S. K., Bauter, 
M. R., … Rahman, I. (2004). Oxidative stress and cigarette smoke alter chromatin 
remodeling but differentially regulate NF- B activation and proinflammatory 
cytokine release in alveolar epithelial cells. The FASEB Journal, 18(15), 1897–9. 
http://doi.org/10.1096/fj.04-1506fje 
Morse, J. H., Horn, E. M., & Barst, R. J. (1999). Hormone Replacement Therapy: A 
Possible Risk Factor in Carriers of Familial Primary Pulmonary Hypertension. 
Chest, 116(3), 847. http://doi.org/10.1378/CHEST.116.3.847 
Mueller, C., Baudler, S., Welzel, H., Böhm, M., & Nickenig, G. (2002). Identification of 
a novel redox-sensitive gene, Id3, which mediates angiotensin II-induced cell 
growth. Circulation, 105(20), 2423–8. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/12021231 
Mullerova, D., Kopecky, J., Matejkova, D., Muller, L., Rosmus, J., Racek, J., Matejovic, 
M. (2008). Negative association between plasma levels of adiponectin and 
polychlorinated biphenyl 153 in obese women under non-energy-restrictive regime. 
International Journal of Obesity, 32(12), 1875–8. 
http://doi.org/10.1038/ijo.2008.169 
Murre, C., McCaw, P. S., & Baltimore, D. (1989). A new DNA binding and dimerization 
motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. 
Cell, 56(5), 777–783. http://doi.org/10.1016/0092-8674(89)90682-X 
Nadal, A., Ropero, A. B., Laribi, O., Maillet, M., Fuentes, E., & Soria, B. (2000). 
Nongenomic actions of estrogens and xenoestrogens by binding at a plasma 
membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. 
Proceedings of the National Academy of Sciences, 97(21), 11603–11608. 
http://doi.org/10.1073/pnas.97.21.11603 
Okoh, V., Deoraj, A., & Roy, D. (2011). Estrogen-induced reactive oxygen species-
mediated signalings contribute to breast cancer. Biochimica et Biophysica Acta 
(BBA) - Reviews on Cancer, 1815(1), 115–133. 
http://doi.org/10.1016/j.bbcan.2010.10.005 
Okoh, V. O., Felty, Q., Parkash, J., Poppiti, R., & Roy, D. (2013). Reactive Oxygen 
Species via Redox Signaling to PI3K/AKT Pathway Contribute to the Malignant 
Growth of 4-Hydroxy Estradiol-Transformed Mammary Epithelial Cells. PLoS 
ONE, 8(2), e54206. http://doi.org/10.1371/journal.pone.0054206 
Parkash, J., Felty, Q., & Roy, D. (2006). Estrogen Exerts a Spatial and Temporal 
Influence on Reactive Oxygen Species Generation that Precedes Calcium Uptake in 
High-Capacity Mitochondria:  Implications for Rapid Nongenomic Signaling of Cell 
Growth . Biochemistry, 45(9), 2872–2881. http://doi.org/10.1021/bi051855x 
 
 
33 
 
Parkash, J., Felty, Q., & Roy, D. (2006). Estrogen Exerts a Spatial and Temporal 
Influence on Reactive Oxygen Species Generation that Precedes Calcium Uptake in 
High-Capacity Mitochondria:  Implications for Rapid Nongenomic Signaling of Cell 
Growth . Biochemistry, 45(9), 2872–2881. http://doi.org/10.1021/bi051855x 
Parkash, J., Felty, Q., & Roy, D. (2006). Estrogen exerts a spatial and temporal influence 
on reactive oxygen species generation that precedes calcium uptake in high-capacity 
mitochondria: Implications for rapid nongenomic signaling of cell growth. 
Biochemistry, 45(9), 2872–2881. http://doi.org/10.1021/bi051855x 
Patrone, C., Cassel, T. N., Pettersson, K., Piao, Y.-S., Cheng, G., Ciana, P., Nord, M. 
(2003). Regulation of postnatal lung development and homeostasis by estrogen 
receptor beta. Molecular and Cellular Biology, 23(23), 8542–8552. 
Peacock, A. J., Murphy, N. F., McMurray, J. J. V., Caballero, L., & Stewart, S. (2007). 
An epidemiological study of pulmonary arterial hypertension. European Respiratory 
Journal, 30(1), 104–109. http://doi.org/10.1183/09031936.00092306 
Pediconi, N., Guerrieri, F., Vossio, S., Bruno, T., Belloni, L., Schinzari, V., Levrero, M. 
(2009). hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in 
response to DNA damage. Molecular and Cellular Biology, 29(8), 1989–98. 
http://doi.org/10.1128/MCB.00552-08 
Per, L., & Anderss, S. (1987). Transport of Polychlorinated Biphenyls ( PCBs ) In 
Freshwater From Sediment To Water, 36, 33–46. 
Perillo, B., Ombra, M. N., Bertoni, A., Cuozzo, C., Sacchetti, S., Sasso, A., 
Avvedimento, E. V. (2008). DNA Oxidation as Triggered by H3K9me2 
Demethylation Drives Estrogen-Induced Gene Expression. Science, 319(5860), 202–
206. http://doi.org/10.1126/science.1147674 
Perillo, B., Ombra, M. N., Bertoni, A., Cuozzo, C., Sacchetti, S., Sasso, A., 
Avvedimento, E. V. (2008). DNA Oxidation as Triggered by H3K9me2 
Demethylation Drives Estrogen-Induced Gene Expression. Science, 319(5860). 
Retrieved from http://science.sciencemag.org/content/319/5860/202 
Phillip, A., & Iii, O. (2009). Angiotensin Ii Induction Of Regional Effects In Murine 
Vasculature. University of Kentucky Doctoral Dissertations. Retrieved from 
https://uknowledge.uky.edu/gradschool_diss/683 
Polder, A., Odland, J. O., Tkachev, A., Føreid, S., Savinova, T. N., & Skaare, J. U. 
(2003). Geographic variation of chlorinated pesticides, toxaphenes and PCBs in 
human milk from sub-arctic and arctic locations in Russia. Science of The Total 
Environment, 306(1–3), 179–195. http://doi.org/10.1016/S0048-9697(02)00492-8 
 
 
 
34 
 
Qiu, J., Bosch, M. A., Tobias, S. C., Grandy, D. K., Scanlan, T. S., Ronnekleiv, O. K., & 
Kelly, M. J. (2003). Rapid signaling of estrogen in hypothalamic neurons involves a 
novel G-protein-coupled estrogen receptor that activates protein kinase C. The 
Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 
23(29), 9529–40. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14573532 
Rajesh, P., Sathish, S., Srinivasan, C., Selvaraj, J., & Balasubramanian, K. (2013). 
Diethyl Hexyl Phthalate (DEHP) is associated with insulin resistance in adipose 
tissue of male rat: Protective role of antioxidant vitamins (C & E). Journal of 
Cellular Biochemistry, 114(3), 558–569. http://doi.org/10.1002/jcb.24399 
Rasier, G., Parent, A.-S., Gérard, A., Lebrethon, M. C., & Bourguignon, J.-P. (2007). 
Early Maturation of Gonadotropin-Releasing Hormone Secretion and Sexual 
Precocity after Exposure of Infant Female Rats to Estradiol or 
Dichlorodiphenyltrichloroethane1. Biology of Reproduction, 77(4), 734–742. 
http://doi.org/10.1095/biolreprod.106.059303 
Ritter, R., Scheringer, M., MacLeod, M., Moeckel, C., Jones, K. C., & Hungerbühler, K. 
(2011). Intrinsic human elimination half-lives of polychlorinated biphenyls derived 
from the temporal evolution of cross-sectional biomonitoring data from the United 
Kingdom. Environmental Health Perspectives, 119(2), 225–31. 
http://doi.org/10.1289/ehp.1002211 
Safe, S. H. (1994). Polychlorinated Biphenyls (PCBs): Environmental Impact, 
Biochemical and Toxic Responses, and Implications for Risk Assessment. Critical 
Reviews in Toxicology, 24(2), 87–149. http://doi.org/10.3109/10408449409049308 
Selene, C. H., & Chou, J. (2003). Concise International Chemical Assessment Document 
53: Hydrogen sulfide: Human health aspects. IPCS Concise International Chemical 
Assessment Documents. Retrieved from 
http://www.who.int/ipcs/publications/cicad/en/cicad55.pdf 
Shanle, E. K., & Xu, W. (2010). Selectively targeting estrogen receptors for cancer 
treatment. Advanced Drug Delivery Reviews, 62(13), 1265–1276. 
http://doi.org/10.1016/j.addr.2010.08.001 
Shiraia, J. H., & Kissel, J. C. (1996). Uncertainty in estimated half-lives of PCBS in 
humans: impact on exposure assessment. The Science of the Total Environment, 187, 
199–210. Retrieved from https://ac.els-cdn.com/004896979605142X/1-s2.0-
004896979605142X-main.pdf?_tid=c0c9d064-c7f8-11e7-80cb-
00000aab0f26&acdnat=1510525865_b7eeeb174a31e95e6ec9166133d25ff4 
Skipper, J. K., Young, L. J., Bergeron, J. M., Tetzlaff, M. T., Osborn, C. T., & Crews, D. 
(1993). Identification of an isoform of the estrogen receptor messenger RNA lacking 
exon four and present in the brain. Proceedings of the National Academy of Sciences 
of the United States of America, 90(15), 7172–5. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8346231 
 
35 
 
Sun, X. H. (2004, January 1). Multitasking of helix-loop-helix proteins in lymphopoiesis. 
Advances in Immunology. Academic Press. http://doi.org/10.1016/S0065-
2776(04)84002-1 
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., 
… Von Mering, C. (2015). STRING v10: Protein-protein interaction networks, 
integrated over the tree of life. Nucleic Acids Research, 43(D1), D447–D452. 
http://doi.org/10.1093/nar/gku1003 
Taylor, A. M., Li, F., Thimmalapura, P., Gerrity, R. G., Sarembock, I. J., Forrest, S., 
McNamara, C. A. (2006a). Hyperlipemia and Oxidation of LDL Induce Vascular 
Smooth Muscle Cell Growth: An Effect Mediated by the HLH Factor Id3. Journal 
of Vascular Research, 43(2), 123–130. http://doi.org/10.1159/000090131 
Taylor, A. M., Li, F., Thimmalapura, P., Gerrity, R. G., Sarembock, I. J., Forrest, S., 
McNamara, C. A. (2006b). Hyperlipemia and oxidation of LDL induce vascular 
smooth muscle cell growth: an effect mediated by the HLH factor Id3. Journal of 
Vascular Research, 43(2), 123–30. http://doi.org/10.1159/000090131 
Thomas, P., & Dong, J. (2006). Binding and activation of the seven-transmembrane 
estrogen receptor GPR30 by environmental estrogens: A potential novel mechanism 
of endocrine disruption. Journal of Steroid Biochemistry and Molecular Biology, 
102(1–5 SPEC. ISS.), 175–179. http://doi.org/10.1016/j.jsbmb.2006.09.017 
Toran-Allerand, C. D., Guan, X., MacLusky, N. J., Horvath, T. L., Diano, S., Singh, M., 
Tinnikov, A. A. (2002). ER-X: a novel, plasma membrane-associated, putative 
estrogen receptor that is regulated during development and after ischemic brain 
injury. The Journal of Neuroscience : The Official Journal of the Society for 
Neuroscience, 22(19), 8391–401. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/12351713 
Ussavarungsi, K., Thomas, C. S., & Burger, C. D. (2015). Prevalence of metabolic 
syndrome in patients with pulmonary hypertension. The Clinical Respiratory 
Journal, n/a-n/a. http://doi.org/10.1111/crj.12406 
Veldhuizen, R., Nag, K., Orgeig, S., & Possmayer, F. (1998). The role of lipids in 
pulmonary surfactant. Biochimica et Biophysica Acta, 1408(2–3), 90–108. 
http://doi.org/10.1016/S0925-4439(98)00061-1 
Wahlang, B., Barney, J., Thompson, B., Wang, C., Hamad, O. M., Hoffman, J. B., 
Hennig, B. (2017). PCB126 Exposure Increases Risk for Peripheral Vascular 
Diseases in a Liver Injury Mouse Model. Toxicological Sciences, 1–12. 
http://doi.org/10.1093/toxsci/kfx180 
Wahlang, B., Falkner, K. C., Gregory, B., Ansert, D., Young, D., Conklin, D. J., Cave, 
M. (2013). Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens 
nonalcoholic fatty liver disease in male C57BL6/J mice. Journal of Nutritional 
Biochemistry, 24(9), 1587–1595. http://doi.org/10.1016/j.jnutbio.2013.01.009 
36 
 
Wang, W., Zhang, Y., Lu, W., & Liu, K. (2015). Mitochondrial Reactive Oxygen Species 
Regulate Adipocyte Differentiation of Mesenchymal Stem Cells in Hematopoietic 
Stress Induced by Arabinosylcytosine. PLOS ONE, 10(3), e0120629. 
http://doi.org/10.1371/journal.pone.0120629 
Watson, C., Bulayeva, N., Wozniak, A., & Finnerty, C. (2005). Signaling from the 
membrane via membrane estrogen receptor-α: Estrogens, xenoestrogens, and 
phytoestrogens. Steroids, 70(5–7), 364–371. 
http://doi.org/10.1016/j.steroids.2005.03.002 
Wu, Q., Zhou, Z.-J., & Ohsako, S. (2006). Effect of environmental contaminants on DNA 
methyltransferase activity of mouse preimplantation embryos. Wei Sheng Yan Jiu = 
Journal of Hygiene Research, 35(1), 30–2. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/16598927 
Yang, J., Li, X., Li, Y., Southwood, M., Ye, L., Long, L., Morrell, N. W. (2013). Id 
proteins are critical downstream effectors of BMP signaling in human pulmonary 
arterial smooth muscle cells. American Journal of Physiology-Lung Cellular and 
Molecular Physiology, 305(4), L312–L321. 
http://doi.org/10.1152/ajplung.00054.2013 
Yang, W.S., Jeng, C.Y., Wu, T. J., Tanaka, S., Funahashi, T., Matsuzawa, Y., Chuang, 
L.M. (2002). Synthetic peroxisome proliferator-activated receptor-gamma agonist, 
rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. 
Diabetes Care, 25(2), 376–80. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11815513 
Zebedee, Z., & Hara, E. (2001). Id proteins in cell cycle control and cellular senescence. 
Oncogene, 20(58), 8317–8325. http://doi.org/10.1038/sj.onc.1205092 
Zsarnovszky, A., Le, H. H., Wang, H. S., & Belcher, S. M. (2005). Ontogeny of Rapid 
Estrogen-Mediated Extracellular Signal-Regulated Kinase Signaling in the Rat 
Cerebellar Cortex: Potent Nongenomic Agonist and Endocrine Disrupting Activity 
of the Xenoestrogen Bisphenol A. Endocrinology, 146(12), 5388–5396. 
http://doi.org/10.1210/en.2005-0565 
 
 
 
 
 
 
 
 
 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
Lung endothelial cell dysfunction from exposure to polychlorinated biphenyl 153 
(PCB153) contributes to lung toxicity. 
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Abstract 
ID3, a transcription regulator, has been shown to contribute to the aggressive spread of 
endothelial cells by facilitating the generation of tumor blood vessels. Tumor vascular 
cells characterized as CD133+ endothelial stem/progenitor cells are associated with poor 
prognosis in lung cancer and pulmonary artery hypertension. Previously, we have shown 
that ID3 overexpression reprograms adult endothelial cells to acquire vascular stem 
markers including CD133. However, little is known regarding the molecular contribution 
of ID3 to tumor vascular reprogramming and how this may impact the aggressive growth 
of lung cancer. In the current project, we evaluated ID3 mediated vascular 
reprogramming upon PCB exposure. This idea is consistent with the literature, which 
shows that PCBs accumulate in the human lung; PCBs produce pathological vascular 
remodeling; high levels of PCBs are found in human lung tissue; and epidemiological 
studies associating lung toxicity with PCBs. Recent studies identify PCB153 as one of the 
largest contributors for total PCB body burden in humans. Using human lung endothelial 
and smooth muscle cells, we exposed ID3 overexpressing and vector control cells to 
PCB153. We observed a significant increase in cell proliferation as determined by the 
BrdU incorporation assay and Fluorescence activated cell sorting (FACS) analysis. 
Similarly, a 3D HuBiogel model, which mimics in vivo conditions, showed a significant 
increase in size and number of vascular spheres upon PCB153 treatment. Pluripotent 
vascular stem cells showed the loss of VE-cadherin and gain of MMP9, N-cadherin, and 
vimentin, which are markers of endothelial-mesenchymal transition. In summary, our 
findings show that persistent environmental pollutant PCB153 induces ID3 expression 
that plays a critical role in regulating survival and hyper-proliferation of lung endothelial 
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cells. Implications of our research include a new paradigm by which PCBs may 
contribute to lung vascular toxicity through pathological vascular remodeling and/or 
angiogenesis. 
Key words- ID3, endocrine disruptors, Lung endothelial cells, plexiform lesions. 
Introduction- 
PCBs are ubiquitous man-made aromatic chlorinated hydrocarbons considered as an 
organic persistent pollutants. Being lipophilic in nature, PCBs have been shown to bio-
accumulate in the food chain and tissues of living organisms. High levels of PCBs are 
found in human lung tissue and epidemiological studies have shown the association of 
lung toxicity by chronic exposure to PCBs. PCB153 is one of the 209 congeners of the 
PCBs most often found in human foods and lipid-rich human tissues. PCB153 has been 
shown to be involved in pathological vascular remodeling and selective bioaccumulation 
in lung in the experimental models. Our earlier study on investigation of the effects of 
exposure of PCB153 to primary cells, human umbilical vein endothelial cells (HUVECs) 
and normal human dermal fibroblasts (NHDF) demonstrated  PCB-induced ROS 
contributed to neovascularization in endothelial cells dysfunction (Das & Felty, 2015; 
Doke, Felty, & Das, 2017). Epidemiological studies have reported that women who 
received hormone replacement therapy (HRT) show higher risk to PAH when compared 
to women with no HRT (Irey et al., 1973 ; Kleiger et al., 1976; Morse et al., 1999). In 
addition to this, women are 2-4 times more prone to pulmonary disorder or PAH than 
men (Badesch et al., 2010a). So, the extra estrogen or synthetic estrogen present in the 
form environmental pollutants maybe responsible for pulmonary vascular disease in 
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humans. Since, the aerosols or vapors containing highly lipophilic PCBs may enter 
through inhalation and tend to accumulate in lipid rich tissues like lungs, brain and breast 
(ASTDR, 2000b). Epidemiological studies have associated PCBs with cardiovascular 
disease (Perkins, Petriello, Newsome, & Hennig, 2016). Therefore, the present study 
aims to investigate the effect of environmental pollutants on neo-vascularization in 
human pulmonary lung endothelial cells, which are exposed to environmentally relevant 
concentrations (ppb) of PCB153, and physiological concentrations of 17β-estradiol. 
 
Materials and Methods 
Cell culture and treatment conditions  
Primary cells, Human pulmonary microvascular endothelial cells or human lung 
endothelial cells (HPMEC-ST1.6R). HPMEC cells were maintained in DMEM-F12 
medium supplemented with 5% FBS. Cells were cultured at 37 ºC in a humidified 
atmosphere with 5% CO2. We also used pulmonary smooth muscle cell line (SMC) 
purchased from Lonza Inc.  
Estrogenic chemical treatments  
Stock solutions of PCB153 and 17β-estradiol were prepared in dimethyl sulfoxide 
(DMSO). The same amount of DMSO as in PCB and estradiol-treated cells were added 
to control cultures. The level of DMSO in experimental media was less than 0.1%. PCB 
blood levels have been reported to reach approximately 1000 ng/mL (∼3 μM) in 
occupationally exposed individuals (Wassermann, Cucos, & Miller, 1979). Our 
unpublished data showed a significant increase in PCB- induced vascularization with 
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PCB153 concentrations of 10–100 ng/mL. Based on known PCB blood levels from 
occupational exposure and our preliminary results; we chose a PCB dose of 100 ng/mL 
(∼0.3 µM) to expose endothelial cells. Our previous studies also showed endothelial cell 
proliferation and vascular tube formation at physiological doses of 17β-estradiol (Das & 
Felty, 2014a; Felty, 2006; Felty & Porther, 2008b) therefore, HPMEC and HPMEC ID3+ 
were exposed to estradiol at 100 ng/mL (∼3.6 nM). PCB congeners 2,2′,4,4′,5,5′-
hexachlorobiphenyl (PCB153) were purchased from AccuStandard (NewHaven, CT) and 
dissolved in dimethyl sulfoxide (DMSO). All other chemicals and reagents were 
purchased from Sigma (St. Louis, MO). 
ID3 overexpression 
The HPMEC cells were stably transfected with either Precision LentiORF for ID3 
(Thermo Scientific Open Biosystems) or empty vector lentiviral pLEX-JRED/TurboGFP 
by the trans-lentiviral packaging kit with Express-in transfection reagent according to the 
manufacturer’s instructions. We used the MOI (multiplicity of infection) of 25 and 
selected cells that overexpressed ID3 with blasticidin S (5 mg/mL) as per manufacturer’s 
instructions. Cells expressing TurboGFP were identified by fluorescence microscopy. 
Cell migration assay 
The cell migration assay was performed to quantify and compare the rate of migration of 
cells between wild-type lung endothelial cells and ID3 overexpressing lung endothelial 
cells. Lung EC and lung EC ID3+ cells were cultured in DMEM-F12 media with 5% fetal 
bovine serum in six-well plates to create a confluent monolayer, and an equal size scratch 
was created by manually scraping the cell monolayer with a sterile plastic p200-pipette 
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tip in the middle area of the well as a line. Then lung EC and lung EC ID3+ cells were 
treated with 0.1% DMSO as a control, E2 (100 ng/mL), PCB153 (100 ng/mL) and 
combination treatment of E2 + PCB153 in separate wells and incubated in growth 
medium for 12h. The initial cell migration quantification was performed on images 
collected 0h after scratching when the scratch size had stabilized. Additional images were 
collected randomly from the scratched areas at 6 and 12h after scratching. Pictures were 
taken under a microscope at 40X magnification and the results were analyzed using 
ImageJ Launcher. This experiment was carried out in triplicate. 
Endothelial spheroid assay 
HPMEC and HPMEC ID3+ cells were suspended in serum-free DMEM/F12 (1:1) culture 
medium supplemented with B27. For EC spheroid formation, approximately 100–150 
HPMEC and HPMEC ID3+ cells were seeded separate well in an ultra-low attachment 
96-well plate (Corning Inc. Lowell, MA) followed the published protocol of our 
laboratory (Das & Felty, 2014a). The effect of estrogenic chemical PCB153 was 
determined by pre-treating the cells with 100 ng/mL E2 2h prior to exposure with 100 
ng/mL (∼0.3 µM) PCB153 on the day of seeding cells. Endothelial spheroids were grown 
for 10 days in liquid culture in the absence or presence of PCB153. A total of 15 
endothelial spheroids with a minimum diameter of 50 µm were counted in each 
experimental group. Pictures were taken on 5d and 10d after seeding. We counted 
number and size of spheroids on 5d and 10d. Data were analyzed by ANOVA; Turkey 
HSD test for multiple comparisons. 
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MTT assay 
To determine the effect of E2 and extra estrogen environmental pollutant PCB153 on the 
metabolic activity of lung endothelial cells, we performed cell viability and cell 
proliferation assays. For cell viability measurement, we performed MTT assay which is 
colorimetric assay and measures the metabolic activity of cells. Actually, MTT is a 
tetrazolium dye known as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. 
NAD(P)H-dependent oxidoreductase enzymes present in mitochondria of metabolically 
active and dividing cells. This enzyme catalyses tetrazolium dye and converts into 
insoluble formazan, which gives a purple colour (Berridge & Tan, 1993; Berridge, Herst, 
& Tan, 2005). The intensity of the purple colour that can be measured at an optical 
density (OD) of 590 nm and its proportional to a number of metabolic active cells. We 
seeded HPMEC and HPMEC ID3+ cells with 50% confluence in 96 well clear walled 
plate. We allowed the cells to grow for 24h in 5% FBS culture medium. After 24 hours, 
we gave treatments, 0.1% DMSO (control), E2 (100 ng/mL), PCB153 (100 ng/mL) and 
combination treatment of E2 + PCB153 to make total volume 100 µL in each well. We 
measured the metabolic activity of cells after 48h with the addition of MTT dye and 
evaluating the purple colour intensity at 590 nm.  
SRB assay 
The sulforhodamine B (SRB) assay is used for measurement of the total cellular protein 
content of adherent cells in a 96-well format. This assay is useful in the determination of 
cellular proliferation and growth. We seeded HPMEC and HPMEC ID3+ cells with 50% 
confluence in 96 well clear-walled plate. We allowed the cells to grow for 24h in 5% 
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FBS culture medium. After 24 hours, we gave treatments, 0.1% DMSO (control), E2 
(100 ng/mL), PCB153 (100 ng/mL) and combination treatment of E2 + PCB153 to make 
total volume 100 µL in each well. After an incubation of 48h, cell monolayers were fixed 
with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye 
is removed by washing repeatedly with 1% (vol/vol) acetic acid. The protein-bound dye 
is dissolved in 10 mM Tris base solution for OD determination at 590 nm using a 
microplate reader (Vichai & Kirtikara, 2006). 
BrdU assay- BrdU assay is a direct method for evaluation of cell proliferation. In this 
rapid method, Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) a synthetic 
nucleoside that is an analogue of thymidine gets incorporated into DNA synthesis of 
proliferating cells. It is a suitable method for detection and quantification of the 
stimulatory effect of environmental chemicals (Russo et al., 1984). For BrdU assay, we 
used Roche’s kit and followed the manual instructions. 
We seeded HPMEC and HPMEC ID3+ cells in 5% FBS DMEM F-12 media with 50% 
confluence and cultured with addition of BrdU in 96 well clear-walled plate. After 24 
hours, we gave treatments, 0.1% DMSO (control), E2 (100 ng/mL), PCB153 (100 
ng/mL) and combination treatment of E2 + PCB153 to make total volume 100 µL in each 
well. After an incubation of 48h, cell monolayers fixed with FixDenat. Followed by 
fixation we added anti- BrdU-POD, which binds to BrdU in newly synthesized DNA. 
This immune complex detected by a plate reader at 450 nm. 
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Whole cell lysates were prepared with lysis buffer containing 25 mM Tris-HCl buffer
(pH 8.0), 150 mM NaCl, 0.2% NP-40, 10% glycerol, 8 mM b-glycerophosphate, 2.5 mM
sodium pyro- phosphate, 10 mM NaF, 0.2 mM Na3VO4, 1 mM DTT and 10 ml/ml 
protease inhibitor cocktail (Sigma-Aldrich) followed the published protocol of our
laboratory (Das & Felty, 2014a). Proteins were quantified using the Bradford assay
reagent (Bio-Rad) according to the manufacturer’s instructions. Proteins (35–75 mg) 
were separated by 15%, 7.5% and 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) 
membranes (Millipore). Membranes were blocked with 5% nonfat milk and incubated 
with the following antibodies: ID3 (Cal BioReagent), VE-cadherin-2 antibody (F-4): sc- 
515467 mouse monoclonal Ab, vimentin antibody (V9): sc-6260 mouse monoclonal Ab,
N-cadherin antibody (H-63): sc-7939 and B-actin (Cell Signaling). Antibody dilutions 
used were according to manufacturer’s recommendations for detection by immunoblot.
Membranes were then incubated with horseradish peroxidase-conjugated secondary IgG
antibodies and visualized with ECL plus Western blot reagents (GE Healthcare, 
Amersham). The membranes were re-probed for b-actin as a loading control. 
Electrochemiluminescence (ECL) intensity of detected target proteins was imaged and 
quantified with a Bio-Rad Versa Doc instrument. All immunoblots have completed a 
minimum of three times for each experiment.
Western blot
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We seeded approximately 200–250 HPMEC and HPMEC ID3+ cells in 8 chambered 
slide. We allowed the cells to grow for 24h. Then we gave treatment 0.1% DMSO 
(control), E2 (100 ng/mL), PCB153 (100 ng/mL) in both the cell lines. Then we fixed 
samples in 2% paraformaldehyde made in PBS for 15 minutes at room temperature. 
Washed monolayer 2 times in PBS to remove residual paraformaldehyde, store samples 
submerged in PBS at 4oC until use. Permeabilized cells with 0.1% Triton X-100 made in 
PBS solution for 15 min. Washed monolayer 5 times with a PBS + 0.5% BSA (PBB). 
Then blocked with 2% BSA for 45 minutes. Cells were then incubated with primary 
antibodies and alexa fluor-conjugated secondary antibodies. The confocal fluorescence 
images were scanned on a Nikon TE2000U inverted microscope. The DRAQ-5 was used 
to label the nucleus. The confocal images were acquired on a Nikon C1 laser scanning 
confocal microscope (Melville, NY, USA). MMP-9 was determined by 
immunofluorescent labelling with rabbit anti-MMP9 polyclonal antibody bs-4593R 
(Alexa Fluor 566-conjugated secondary antibody). VE-Cadherin was determined by 
immunofluorescent labelling with mouse monoclonal IgG1 sc-9989 (Alexa Fluor 633- 
conjugated secondary antibody). Vimentin was determined by immunofluorescent 
labelling with polyclonal goat IgG AF2105.
Zebrafish Xenograft
We purchased xenotransplantation Zebrafish embryos from Zebrafish International 
Resource Center (ZIRC), University of Oregon, Eugene. Albino embryos are completely 
transparent. Prior to injecting HPMEC and HPMEC ID3+ cells on 2 days post fertilization 
(dpf), albino zebrafish were maintained at 28 ºC. During injection, zebrafish were
Immunofluorescence
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anaesthetized with MESAB (0.5 mM 3-aminobenzoic acid ethyl ester, 2 mM Na2HPO) 
and then placed in a 15 mm Petri dish on their sides on a ramp comprised of 1% agarose. 
Approximately 50 HPMEC and HPMEC ID3+ cells were injected into the yolk sac and 
zebrafish were then transferred in fresh fish water to an incubator and maintained at 37 ºC 
for up to 7 days post injection (dpi) when the experiments were terminated and animals 
were euthanized by overexposure to MESAB. 
Assessment of temperature effect on zebrafish development 
Normally, zebrafish are incubated at 28 ºC. To accommodate human EC proliferation, an 
incubation temperature close to 37 ºC was desirable. We purchased xenotransplantation 
Zebrafish embryos from Zebrafish International Resource Center (ZIRC), University of 
Oregon, Eugene. Albino embryos are completely transparent. Prior to injecting HPMEC 
and HPMEC ID3+ cells on 2 dpf, albino zebrafish were maintained at 28 ºC. During 
injection, zebrafish were anaesthetized with MESAB (0.5 mM 3-aminobenzoic acid ethyl 
ester, 2 mM Na2HPO) and then placed in a 15 mm Petri dish on their sides on a ramp 
comprised of 1% agarose. Approximately 50 HPMEC and HPMEC ID3+ cells were 
injected into the yolk sac and zebrafish were then transferred in fresh fish water to an 
incubator and maintained at 37 ºC for up to 7 dpi when the experiments were terminated 
and animals were euthanized by overexposure to MESAB. 
Cell preparation for transplant 
Cells were detached from the culture flask by incubating with 2 mL dispase (Invitrogen) 
at 37 ºC for 45 min, pelleted by centrifugation at 2500 rpm for 5 min, and resuspended in 
2.5 mL HBSS. Cells were labeled with CM-DiI, a lipophilic fluorescent tracking dye 
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(Invitrogen). According to manufacturer’s instructions, CM-DiI is transferred from 
mother to daughter cells but not between other cells. The cells were incubated with CM-
DiI dissolved in DMSO (final concentration: CM-DiI: 4.8 lg/mL, DMSO: 0.4%) for 4 
min at 37 ºC, followed by 15 min at 4 ºC. CM-DiI labeled cells were loaded into a pulled 
glass micropipette that was drawn on an electrode puller and then trimmed to form a 
needle with a 15 μm internal and a ~18 μm external diameter. The microneedle was 
attached to an air driven Cell Tram micro injector. The tip of the needle was inserted into 
the animals and cells were delivered in a single injection. A sharp needle cut in the yolk 
will reclose with little to no loss of contents. Any injection site in the yolk is suitable. 
Using 30–100 milliseconds pulse time and 8 pounds per square inch (psi) positive 
pressure, we optimized the number of cells injected at ~50, which we confirmed by 
dispensing cells onto a microscope slide and visually counting. The volume of material 
injected is approximately 20–50 nL. After injection, zebrafish were maintained for 1 h at 
28 ºC, examined for the presence of a fluorescent cell mass of ~50 cells localized at the 
injection site in the yolk sac, and then transferred to an incubator and maintained at 37 
ºC. On 1 dpi, zebrafish were examined by fluorescence microscopy (Haldi, Ton, Seng, & 
McGrath, 2006). 
Flow Cytometry 
For cell cycle analysis, cells were harvested, rinsed with PBS, and fixed in suspension in 
73% ethanol for 20h at −20 °C. After incubation at −20 °C, the cells were washed with 
PBS containing 1% BSA, stained with PI (10 μg/mL) in PBS containing RNase A (250 
μg/mL), and incubated at 37 °C for 30 min in the dark before FACS analysis. Cell cycle 
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distribution was analyzed with the Guava easyCyte™ using the CytoSoft software 
program according to the manufacturer's instructions. The percent DNA content was 
determined by FACS analysis using PI staining. 
Statistical analysis 
All experiments were performed at least three times and data are expressed as mean ± 
standard deviation Graphpad prism version 5.01 was used to perform graphics and the 
two-tailed student’s t-test was used to compare statistical significance. P<0.05 was set as 
a statistical significance. Data were analyzed by ANOVA; Tukey HSD test for multiple 
comparisons.  
Results: 
ID3 overexpression in wild type lung endothelial  
We previously demonstrated that E2 treatment increased ID3 phosphorylation and ID3 
protein stability; and that E2-induced cell proliferation was dependent on oxidant 
sensitive ID3 signalling (Felty & Porther, 2008b). We have also demonstrated that 
exogenous estrogen or estrogenic PCBs like PCB153 increases ID3 protein expression 
which eventually gives stemness markers to the human cerebral microvascular 
endothelial cell line HCMEC/D3 (Das & Felty, 2014c). Given the biological significance 
of ID3 proteins for the maintenance of stemness, we asked whether overexpression of 
ID3 could induce a molecular stem-cell signature in adult lung ECs HPMEC-ST1.6R cell 
line. To direct this question, human HPMECs were transduced using an MOI of 25 with 
either the Precision LentiORF for ID3 overexpression or control empty lentiviral vector 
pLEX-JRED/TurboGFP according to the manufacturer's instructions. Cells were then 
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seeded at clonal density and selected with blasticidin S (5 μg/mL). Cells that overexpress 
ID3 will be selected for culture and referred to as HPMEC ID3+ as shown in Figure 7. 
 
 
 
Figure 7. ID3 overexpression in Lung EC   
HPMEC cells were stably transfected with Precision LentiORF for ID3 (Thermo 
Scientific Open Biosystems). Selected cells that overexpressed ID3 with blasticidin S (5 
mg/ml) as per manufacturer’s instructions. Cells expressing TurboGFP in HPMEC ID3+ 
cells were identified by fluorescence microscopy. We also shown phase contrast image of 
HPMEC ID3+ cells along with it. 
 
Cell migration (Wound healing) assay 
In order to study and distinguish between the wild-type lung endothelial cell line HPMEC 
and newly transfected stable ID3 overexpressed HPMEC ID3+ cell line, we did some 
experiments to detect the phenotypic behaviour in these two cell lines. We evaluated the 
effect of ID3 overexpression had on cell migration using a wound healing or cell 
migration assay. A cell monolayer consisting of HPMEC wild type or HPMEC ID3+ 
overexpressing cell was mechanically scratched to create a wound. Then HPMEC and 
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HPMEC ID3+ cells with wound were treated with 0.1% DMSO as a control, E2 (100 
ng/mL), PCB153 (100 ng/mL) in separate wells and incubated in growth medium for 12 
h, we examined the extent of wound closure up to 12h. We took images of wound healing 
at 6h and 12h intervals. We analyzed the cell migration rate by using ImageJ Launcher 
software. By measuring the wound area compared with the initial wound area, we 
measured the number of cells migrated into scratched area. By measuring the migration 
rate of both the cell lines, we found that the ability of HPMEC ID3+ cells to migrate to 
the wound area was significantly greater than HPMEC cells. Images were captured after 
the wound at the 6h interval. The number of HPMEC ID3+ cells migrated in the scratched 
area were significantly (p < 0.0001) higher than HPMEC cells in 0.1% DMSO (control) 
itself (Figure 8). Migration of HPMEC ID3+ cells was higher when compared to HPMEC 
cells. Likewise, we saw that treatments of E2 (100 ng/mL) and PCB153 (100 ng/mL) 
significantly increase the number of HPMEC ID3+ cells migrated in the scratched area (p 
< 0.0001) compared to HPMEC cells. At the 12h interval, HPMEC ID3+ cells completely 
migrated to the scratched area and filled out the wound in all treatments except 
0.1%DMSO (control). In case of HPMEC cells, all treatments E2 (100 ng/mL), PCB153 
(100 ng/mL) showed significant (p < 0.0001) results compared to 0.1% DMSO (control) 
in terms of cell migration into scratched area (Fig. 8 and 9).  
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Figure 8- Wound healing assay 
Representative images showing migration of both lung EC & EC ID3+ cells. When both 
the cells lines treated with control, E2 and PCB153.  E2 and PCB153 increased the 
migration rate of cells compared to control in 6h and 12h intervals.  Magnification X200 
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MTT, SRB and BrdU assay of HPMEC and HPMEC ID3+ cells  
We tested the lung endothelial cell proliferation in presence of estrogenic chemicals by 
MTT, SRB and BrdU assay. Since researchers have shown that lung endothelial cells 
possess estrogen receptors, the HPMEC and HPMEC ID3+ cells were showing a 
stimulatory effect in terms of cell proliferation and growth when they treated with E2 
(100 ng/mL) and PCB153 (100 ng/mL). Our data revealed that treatments with E2 (100 
ng/mL) and PCB153 (100 ng/mL) significantly increased cell growth when compared to 
Figure 9- Cell migration 
Higher migration of lung ECs overexpressing ID3. Experimental treatments: vehicle, 
E2, PCB153. Treatments with E2 and PCB153 increased the migration of ID3 
overexpressing lung ECs compared to control at 6h and 12h intervals.  Graph shows 
number of cells migrated in 6h and 12h intervals. Error bars represent the mean 
number of cells migrated ± SD in 5 wells. E2 & PCB153= 100 ng/mL. **p<0.01 
PCB153 & E2 vs DMSO for lung EC ID3+. Data were analyzed by ANOVA; Tukey 
HSD test for multiple comparisons.  
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vehicle control. Cell growth was determined by the MTT and SRB assays and 
corroborated by BrdU assay. The data from SRB and BrdU assays reported that 
treatments E2 (100 ng/mL), PCB153 (100 ng/mL) showed a significant increase in 
numbers of cells compared to control. In terms of SRB assay, the total protein content of 
treated cells was significantly higher than control. The BrdU assay data results showed 
the synthesis of new DNA in proliferating cells was significantly higher in treatments 
than control. These results show that PCB153 (100 ng/mL) drives endothelial cell 
proliferation. In addition to this,  we determined the contribution of ID3 to endothelial 
proliferation upon treatment with E2 (100 ng/mL), PCB153 (100 ng/mL) than HPMEC 
cells in the Figures 10, 11, and 12. 
Since estrogenic chemicals like PCB153 shows their growth stimulating endothelial cell 
survival effects on HPMEC and HPMEC ID3+ cells, we investigated signaling 
mechanism action of PCB153. Felty et al. showed that PCB153 increases microvascular 
lesions in HUVEC cells through ROS pathway. To address this question we assessed the 
effects of ER blocker and ROS scavengers on HPMEC and HPMEC ID3+ cells in 
presence of E2 and PCB153 treatment. 
To investigate whether ER was involved in the E2 and PCB153-mediated 
hyperproliferation of HPMEC ID3+ cell, cells were treated with the known ER 
antagonist, tamoxifen. Tamoxifen is a nonsteroidal triphenylethylene derivative that 
binds to the estrogen receptor (Jordan, et al., 1980.). It acts as a selective estrogen 
receptor modulator. Although tamoxifen prevents the growth of estrogen-sensitive tissue, 
the researchers have shown that tamoxifen treatment has been clinically effective in triple 
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negative breast cancer patients (Adjuvant Trial Organisation, 1988). We treated HPMEC 
and HPMEC ID3+ cells with single treatment of tamoxifen (5 µM) dose as wells as co-
treatment with E2 + tamoxifen, PCB153 + tamoxifen. We carried out MTT, SRB and 
BrdU assays and analyzed the data. We found that tamoxifen (5 µM) significantly 
(P<0.01) inhibit the growth of cells in both the HPMEC and HPMEC ID3+ cell lines 
compare to control. In addition to this, our data showed that co-treatment of E2 
+tamoxifen and PCB153 + tamoxifen showed significant (P<0.01) reduction in growth of 
cells compared to E2 (100 ng/mL) and PCB153 (100 ng/mL) respectively. These data 
suggests that tamoxifen may be blocking metabolism and redox cycling of estrogen, 
PCB153 and acts as free radical scavengers as previously reported by researchers in 
MDA cell line which is triple negative breast cancer cell line  (Arteaga, Villaseca, 
Bianchi, Rojas, & Marshall, 2003) as shown in Figure 13, 14 and 15.  
To determine whether E2 and PCB153 increases the number of HPMEC and HPMEC 
ID3+ cells by either estrogen receptor or ROS signaling pathway. Fulvestrant is drug 
treatment for hormone receptor-positive metastatic breast cancer in postmenopausal 
women with disease progression following anti-estrogen therapy. It is a complete 
estrogen receptor antagonist with no agonist effects, which in addition, accelerates the 
proteasomal degradation of the estrogen receptor. We found the similar results like 
Fulvestrant drug treatment. We carried out MTT, SRB and BrdU assays and analyzed the 
data. We found that Fulvestrant (5 µM) significantly (P<0.01) inhibit the growth of cells 
in both the HPMEC and HPMEC ID3+ cell lines compare to control. In addition to this, 
our data showed that co-treatment of E2 + Fulvestrant, PCB153 + Fulvestrant showed 
significant (P<0.01) reduction in growth of cells compared to E2 (100 ng/mL) and 
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PCB153 (100 ng/mL) respectively (as shown in Figure 10, 11 and 12). 
To investigate the E2 and PCB153 increases number and new DNA synthesis of HPMEC 
and HPMEC ID3+ cells through ROS signaling, we used antioxidant like ebselen. It is an 
organoselenium compound and acts as a mimic of glutathione peroxidase (Kumar, Bullet, 
& Tomar, 2014). Interestingly, we found the similar results like tamoxifen and 
Fulvestrant drug treatment. We carried out MTT, SRB and BrdU assays and analyzed the 
data. We found that Ebselen (10 µM) significantly (P<0.01) inhibit the growth of cells in 
both the HPMEC and HPMEC ID3+ cell lines compare to control. In addition to this, our 
data showed that co-treatment of E2 + Ebselen, PCB153+Ebselen showed significant 
(P<0.01) reduction in growth of cells compared to E2 (100 ng/mL) and PCB153 (100 
ng/mL) (as shown in Figure 16, 17 and 18). ID3 overexpression increased the growth and 
DNA synthesis of lung ECs upon exposure to mitogens PCB153 and E2. ID3 
overexpression make these cells resistant to Tamoxifen, Ebselen and fulvestrant when 
compared to vector alone. ID3 give these cells advantage so they grow or proliferate 
more than vector.  
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Fulvestrant 
 
 
 
Figure 10- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+ 
cells using MTT assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased cell 
growth. HPMEC and HPMEC ID3+ cells exposed to 17β-estradiol and/or PCB153. E2 
& PCB153= 100 ng/mL. Graph of cell survival determined by MTT assay 24 h after 
exposure. All treatment groups showed significant increase in growth b**p<0.01 for 
HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs control. Fulvestrant (1 µM) is 
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both HPMEC 
and HPMEC ID3+ cells compared to control. Co-treatment of E2+Fulvestrant 
(c**p<0.01), PCB153+Fulvestrant (d**p<0.01) showed significant reduction in 
growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in 
HPMEC cells. Co-treatment of E2+ Fulvestrant (e**p<0.01), PCB153+Fulvestrant 
(f**p<0.01) showed significant reduction in growth of cells compared to E2 (100 
ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were analyzed 
by ANOVA; Tukey HSD test for multiple comparisons.  
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Figure 11- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+ 
cells using SRB assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by SRB assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. Fulvestrant (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit 
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-treatment 
of E2+ Fulvestrant (c**p<0.01), PCB153 + Fulvestrant (d**p<0.01) showed 
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 
ng/mL) respectively in HPMEC cells. Co-treatment of E2+ Fulvestrant (e**p<0.01), 
PCB153 + Fulvestrant (f**p<0.01) showed significant reduction in growth of cells 
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ 
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Figure 12- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+ 
cells using BrdU assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by BrdU assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. Fulvestrant (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit 
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-
treatment of E2 + Fulvestrant (c**p<0.01), PCB153 + Fulvestrant (d**p<0.01) 
showed significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 
(100 ng/mL) respectively in HPMEC cells. Co-treatment of E2 + Fulvestrant 
(e**p<0.01), PCB153 + Fulvestrant (f**p<0.01) showed significant reduction in 
growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in 
HPMEC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for multiple 
comparisons. 
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Tamoxifen 
 
 
 
 
 
 
 
Figure 13- Measuring the effect of Tamoxifen on HPMEC and HPMEC ID3+ 
cells using MTT assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by MTT assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. Tamoxifen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit 
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-
treatment of E2+ Tamoxifen (c**p<0.01), PCB153 + Tamoxifen (d**p<0.01) showed 
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 
ng/mL) respectively in HPMEC cells. Co-treatment of E2+ Tamoxifen (e**p<0.01), 
PCB153 + Tamoxifen (f**p<0.01) showed significant reduction in growth of cells 
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ 
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Figure 14- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+ 
cells using SRB assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by SRB assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. Tamoxifen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit 
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-
treatment of E2+ Tamoxifen (c**p<0.01), PCB153 + Tamoxifen (d**p<0.01) showed 
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 
ng/mL) respectively in HPMEC cells. Co-treatment of E2+ Tamoxifen (e**p<0.01), 
PCB153 + Tamoxifen (f**p<0.01) showed significant reduction in growth of cells 
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ 
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Figure 15- Measuring the effect of Fulvestrant on HPMEC and HPMEC ID3+ 
cells using BrdU assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by BrdU assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. Tamoxifen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit 
the growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-
treatment of E2+ Tamoxifen (c**p<0.01), PCB153 + Tamoxifen (d**p<0.01) showed 
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 
ng/mL) respectively in HPMEC cells. Co-treatment of E2+ Tamoxifen (e**p<0.01), 
PCB153 + Tamoxifen (f**p<0.01) showed significant reduction in growth of cells 
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ 
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Ebselen 
 
 
 
 
 
 
 
Figure 16- Measuring the effect of Ebselen on HPMEC and HPMEC ID3+ cells 
using MTT assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by MTT assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. Ebselen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit the 
growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-treatment of 
E2+ Ebselen (c**p<0.01), PCB153 + Ebselen (d**p<0.01) showed significant 
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) 
respectively in HPMEC cells. Co-treatment of E2 + Ebselen (e**p<0.01), PCB153 + 
Ebselen (f**p<0.01) showed significant reduction in growth of cells compared to E2 
(100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were 
analyzed by ANOVA; Tukey HSD test for multiple comparisons.  
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Figure 17- Measuring the effect of Ebselen on HPMEC and HPMEC ID3+ cells 
using SRB assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by SRB assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. Ebselen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit the 
growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-treatment of 
E2+ Ebselen (c**p<0.01), PCB153 + Ebselen (d**p<0.01) showed significant 
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100ng/mL) 
respectively in HPMEC cells. Co-treatment of E2 + Ebselen (e**p<0.01), PCB153 + 
Ebselen (f**p<0.01) showed significant reduction in growth of cells compared to E2 
(100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were 
analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Figure 18- Measuring the effect of Ebselen on HPMEC and HPMEC ID3+ cells 
using BrdU assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by BrdU assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. Ebselen (1 µM) is estrogen receptor agonist significantly (P<0.01) inhibit the 
growth of both HPMEC and HPMEC ID3+ cells compared to control. Co-treatment of 
E2+ Ebselen (c**p<0.01), PCB153 + Ebselen (d**p<0.01) showed significant 
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) 
respectively in HPMEC cells. Co-treatment of E2 + Ebselen (e**p<0.01), PCB153 + 
Ebselen (f**p<0.01) showed significant reduction in growth of cells compared to E2 
(100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were 
analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Smooth muscle cells (SMC) 
Researchers have shown that presence of ERs in SMC and involvement of SMCs in 
plexiform lesions and atherosclerotic plaque along with lung endothelial cells (Bennett, 
1999; Doran, Meller, & McNamara, 2008; Rosenthal, 2001). We evaluated the 
combination effect of E2 and PCB153 on SMC using MTT, SRB and BrdU assays. 
Similar to lung endothelial cells, we seeded SMCs in a 96 well plate and gave treatments 
E2 (100 ng/mL), PCB153 (100 ng/mL). The results showed that all treatments induced 
significant (P<0.01) increase in numbers of SMCs compared to control. We also checked 
the effects of tamoxifen, Ebselen and Fulvestrant treatment SMCs. We found out that 
tamoxifen, Ebselen and Fulvestrant treatments significantly (P<0.01) inhibit the growth 
of SMCs compare to control as wells as in treatments E2 (100 ng/mL) and PCB153 (100 
ng/mL). Given the biological significance of ID3 proteins for the maintenance of 
stemness, we questioned whether overexpression of ID3 could induce a molecular stem-
cell like a signature in adult lung SMCs cell line. To direct this question, human SMCs 
were transduced using an MOI of 25 with either the Precision LentiORF for ID3 
overexpression or control empty lentiviral vector pLEX-JRED/TurboGFP according to 
the manufacturer's instructions. Cells were then seeded at clonal density and selected with 
blasticidin S (5 μg/mL). Cells that overexpress ID3 will be selected for culture and 
referred to as SMC ID3+ for Ebselen as shown in Figure 20, 21 and 22. Similarly, for 
tamoxifen (as shown in Figure 23, 24 and 25) and Fulvestrant (as shown in Figure 26, 27 
and 28). 
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Figure 19- ID3 overexpression in Lung SMC 
SMC cells were stably transfected with Precision LentiORF for ID3 (Thermo Scientific 
Open Biosystems). Selected cells that overexpressed ID3 with blasticidin S (5 mg/ml) as 
per manufacturer’s instructions. Cells expressing TurboGFP in SMC ID3+ cells were 
identified by fluorescence microscopy. We also shown phase contrast image of SMC 
ID3+ cells along with it. 
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Ebselen 
 
 
Figure 20- Measuring the effect of Ebselen on SMC and SMC ID3+ cells using 
MTT assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by MTT 
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 
for SMC vs control and a**p<0.01 for SMC ID3+ vs control. Ebselen (1 µM) is 
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and 
SMC ID3+ cells compared to control. Co-treatment of E2 + Ebselen (c**p<0.01), 
PCB153 + Ebselen (d**p<0.01) showed significant reduction in growth of cells 
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-
treatment of E2 + Ebselen (e**p<0.01), PCB153 + Ebselen (f**p<0.01) showed 
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey 
HSD test for multiple comparisons. 
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Figure 21- Measuring the effect of Ebselen on SMC and SMC ID3+ cells using 
SRB assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by SRB assay 
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC 
vs control and a**p<0.01 for SMC ID3+ vs control. Ebselen (1 µM) is estrogen 
receptor agonist significantly (P<0.01) inhibit the growth of both SMC and SMC ID3+ 
cells compared to control. Co-treatment of E2 + Ebselen (c**p<0.01), PCB153 + 
Ebselen (d**p<0.01) showed significant reduction in growth of cells compared to E2 
(100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+ 
Ebselen (e**p<0.01), PCB153 + Ebselen (f**p<0.01) showed significant reduction in 
growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in 
SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for multiple 
comparisons. 
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Figure 22- Measuring the effect of Ebselen on SMC and SMC ID3+ cells using 
BrdU assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by BrdU 
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for 
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Ebselen (1 µM) is estrogen 
receptor agonist significantly (P<0.01) inhibit the growth of both SMC and SMC ID3+ 
cells compared to control. Co-treatment of E2+ Ebselen (c**p<0.01), PCB153 + 
Ebselen (d**p<0.01) showed significant reduction in growth of cells compared to E2 
(100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+ 
Ebselen (e**p<0.01), PCB153 + Ebselen (f**p<0.01) showed significant reduction in 
growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in 
SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for multiple 
comparisons. 
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Tamoxifen 
 
 
 
 
 
 
 
 
 
Figure 23- Measuring the effect of Tamoxifen on SMC and SMC ID3+ cells using 
MTT assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by MTT 
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for 
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Tamoxifen (1 µM) is 
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and 
SMC ID3+ cells compared to control. Co-treatment of E2+ Tamoxifen (c**p<0.01), 
PCB153 + Tamoxifen (d**p<0.01) showed significant reduction in growth of cells 
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-
treatment of E2+ Tamoxifen (e**p<0.01), PCB153 + Tamoxifen (f**p<0.01) showed 
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD 
test for multiple comparisons. 
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Figure 24- Measuring the effect of Tamoxifen on SMC and SMC ID3+ cells using 
SRB assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by SRB assay 
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC 
vs control and a**p<0.01 for SMC ID3+ vs control. Tamoxifen (1 µM) is estrogen 
receptor agonist significantly (P<0.01) inhibit the growth of both SMC and SMC ID3+ 
cells compared to control. Co-treatment of E2+ Tamoxifen (c**p<0.01), PCB153 + 
Tamoxifen (d**p<0.01) showed significant reduction in growth of cells compared to 
E2 (100ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+ 
Tamoxifen (e**p<0.01), PCB153 + Tamoxifen (f**p<0.01) showed significant 
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) 
respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for 
multiple comparisons. 
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Figure 25- Measuring the effect of Tamoxifen on SMC and SMC ID3+ cells using 
BrdU assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by BrdU 
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for 
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Tamoxifen (1 µM) is 
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and 
SMC ID3+ cells compared to control. Co-treatment of E2+ Tamoxifen (c**p<0.01), 
PCB153 + Tamoxifen (d**p<0.01) showed significant reduction in growth of cells 
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-
treatment of E2+ Tamoxifen (e**p<0.01), PCB153 + Tamoxifen (f**p<0.01) showed 
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD 
test for multiple comparisons. 
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Fulvestrant 
 
 
 
 
 
 
 
 
 
Figure 26- Measuring the effect of Fulvestrant on SMC and SMC ID3+ cells using 
MTT assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by MTT 
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for 
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Fulvestrant (1 µM) is 
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and 
SMC ID3+ cells compared to control. Co-treatment of E2+ Fulvestrant (c**p<0.01), 
PCB153 + Fulvestrant (d**p<0.01) showed significant reduction in growth of cells 
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-
treatment of E2+ Fulvestrant (e**p<0.01), PCB153 + Fulvestrant (f**p<0.01) showed 
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD 
test for multiple comparisons. 
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Figure 27- Measuring the effect of Fulvestrant on SMC and SMC ID3+ cells using 
SRB assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by SRB assay 
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC 
vs control and a**p<0.01 for SMC ID3+ vs control. Fulvestrant (1 µM) is estrogen 
receptor agonist significantly (P<0.01) inhibit the growth of both SMC and SMC ID3+ 
cells compared to control. Co-treatment of E2+ Fulvestrant (c**p<0.01), PCB153 + 
Fulvestrant (d**p<0.01) showed significant reduction in growth of cells compared to 
E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of 
E2+ Fulvestrant (e**p<0.01), PCB153 + Fulvestrant (f**p<0.01) showed significant 
reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) 
respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD test for 
multiple comparisons. 
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Figure 28- Measuring the effect of Fulvestrant on SMC and SMC ID3+ cells using 
BrdU assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by BrdU 
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for 
SMC vs control and a**p<0.01 for SMC ID3+ vs control. Fulvestrant (1 µM) is 
estrogen receptor agonist significantly (P<0.01) inhibit the growth of both SMC and 
SMC ID3+ cells compared to control. Co-treatment of E2+ Fulvestrant (c**p<0.01), 
PCB153 + Fulvestrant (d**p<0.01) showed significant reduction in growth of cells 
compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-
treatment of E2+ Fulvestrant (e**p<0.01), PCB153 + Fulvestrant (f**p<0.01) showed 
significant reduction in growth of cells compared to E2 (100 ng/mL), PCB153 (100 
ng/mL) respectively in SMC ID3+ cells. Data were analyzed by ANOVA; Tukey HSD 
test for multiple comparisons. 
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SU5416 treatment to HPMEC ID3+ and SMCs 
Researchers have shown in vivo and in vitro studies of exposure to SU5416 reported to 
produce endothelial stem cell markers in lung endothelial cells which give rise to lung 
vascular lesions (Das et al., 2015). In addition to this, many PAH studies showed the 
upregulated levels of ID3 protein in plexiform lesions (Yu, Wilson, Taylor, & Polgar, 
2015). Therefore, we compared the endothelial types HPMEC and HPMEC ID3+ to 
determine the effect of SU5416 exposure which is a chemical inducer of molecular stem 
cell-like signature. We tested the lung endothelial cell proliferation in presence of 
estrogenic chemicals and SU5416 by MTT, SRB and BrdU assay. We treated HPMEC 
and HPMEC ID3+ cells with single treatment of SU5416 (1 µM) dose as wells as co-
treatment with E2 + SU5416, PCB153 + SU5416. We carried out MTT, SRB and BrdU 
assays and analyzed the data. We found that SU5416 (5µM) significantly (P<0.01) 
induce the growth of cells in both the HPMEC and HPMEC ID3+ cell lines compare to 
control. In addition to this, our data showed that co-treatment of E2 + SU5416, PCB153 
+ SU5416, showed significant (P<0.01) increase in growth of cells compared to E2 (100 
ng/mL) and PCB153 (100 ng/mL) respectively as shown in Figure 29, 30 and 31. 
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Figure 29- Measuring the effect of SU5416 on HPMEC and HPMEC ID3+ cells 
using MTT assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by MTT assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. SU5416 (1 µM) is VEGF receptor antagonist. Co-treatment of E2+ SU5416 
(c**p<0.01), PCB153 + SU5416 (d**p<0.01) showed significant increase in growth 
of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC 
cells. Co-treatment of E2+ SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01), 
showed significant increase in growth of cells compared to E2 (100 ng/mL) and 
PCB153 (100 ng/mL) respectively in HPMEC ID3+ cells. Data were analyzed by 
ANOVA; Tukey HSD test for multiple comparisons.  
79 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30- Measuring the effect of SU5416 on HPMEC and HPMEC ID3+ cells 
using SRB assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100ng/mL. Graph of cell survival 
determined by SRB assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. SU5416 (1 µM) is VEGF receptor antagonist. Co-treatment of E2+ SU5416 
(c**p<0.01), PCB153 + SU5416 (d**p<0.01) showed significant increase in growth 
of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC 
cells. Co-treatment of E2+ SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01), 
E2+PCB153 + SU5416 (h**p<0.01) showed significant increase in growth of cells 
compared to E2 (100 ng/mL) and PCB153 (100 ng/mL) respectively in HPMEC ID3+ 
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Similarly, we tested the effect of SU5416 drug effect on SMCs. We found that SU5416 
(5 µM) significantly (P<0.01) induce the growth of cells in the SMCs compare to control. 
In addition to this, our data showed that co-treatment of E2 + SU5416, PCB153 + 
SU5416, showed significant (P<0.01) increase in growth of cells compared to E2 (100 
ng/mL), PCB153 (100 ng/mL) respectively as shown in Figure 32, 33 and 34. 
Figure 31- Measuring the effect of SU5416 on HPMEC and HPMEC ID3+ cells 
using BrdU assay 
In both HPMEC and HPMEC ID3+ cells, E2 and PCB153 treatment increased the 
survival and proliferation of cells. HPMEC and HPMEC ID3+ cells exposed to17β-
estradiol and/or PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival 
determined by BrdU assay 24 h after exposure. All the treatment showed significant 
increase b**p<0.01 for HPMEC vs control and a**p<0.01 for HPMEC ID3+ vs 
control. SU5416 (1 µM) is VEGF receptor antagonist. Co-treatment of E2+ SU5416 
(c**p<0.01), PCB153 + SU5416 (d**p<0.01) showed significant increase in growth 
of cells compared to E2 (100 ng/mL), PCB153 (100 ng/mL) respectively in HPMEC 
cells. Co-treatment of E2+ SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01), 
E2+PCB153 + SU5416 (h**p<0.01) showed significant increase in growth of cells 
compared to E2 (100 ng/mL) and PCB153 (100 ng/mL) respectively in HPMEC ID3+ 
cells. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Figure 32- Measuring the effect of SU5416 on SMC and SMC ID3+ cells using 
MTT assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153E2 & PCB153= 100 ng/mL. Graph of cell survival determined by MTT assay 
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC 
vs control and a**p<0.01 for SMC ID3+ vs control. SU5416 (1 µM) is VEGF receptor 
antagonist. Co-treatment of E2+ SU5416 (c**p<0.01), PCB153 + SU5416 
(d**p<0.01) showed significant increase in growth of cells compared to E2 (100 
ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+ 
SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01), E2+PCB153 + SU5416 
(h**p<0.01) showed significant increase in growth of cells compared to E2 (100 
ng/mL) and PCB153 (100 ng/mL) respectively in SMC ID3+ cells. Data were analyzed 
by ANOVA; Tukey HSD test for multiple comparisons. 
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Figure 33- Measuring the effect of SU5416 on SMC and SMC ID3+ cells using 
SRB assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by SRB assay 
24 h after exposure. All the treatment showed significant increase b**p<0.01 for SMC 
vs control and a**p<0.01 for SMC ID3+ vs control. SU5416 (1µM) is VEGF receptor 
antagonist. Co-treatment of E2+ SU5416 (c**p<0.01), PCB153 + SU5416 
(d**p<0.01) showed significant increase in growth of cells compared to E2 (100 
ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+ 
SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01), E2+PCB153 + SU5416 
(h**p<0.01) showed significant increase in growth of cells compared to E2 (100 
ng/mL) and PCB153 (100 ng/mL) respectively in SMC ID3+ cells. Data were analyzed 
by ANOVA; Tukey HSD test for multiple comparisons. 
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Figure 34- Measuring the effect of SU5416 on SMC and SMC ID3+ cells using 
BrdU assay 
In both SMC and SMC ID3+ cells, E2 and PCB153 treatment increased the survival 
and proliferation of cells. SMC and SMC ID3+ cells exposed to17β-estradiol and/or 
PCB153. E2 & PCB153= 100 ng/mL. Graph of cell survival determined by BrdU 
assay 24 h after exposure. All the treatment showed significant increase b**p<0.01 for 
SMC vs control and a**p<0.01 for SMC ID3+ vs control. SU5416 (1µM) is VEGF 
receptor antagonist. Co-treatment of E2+ SU5416 (c**p<0.01), PCB153 + SU5416 
(d**p<0.01) showed significant increase in growth of cells compared to E2 (100 
ng/mL), PCB153 (100 ng/mL) respectively in SMC cells. Co-treatment of E2+ 
SU5416 (f**p<0.01), PCB153 + SU5416 (g**p<0.01), E2+PCB153 + SU5416 
(h**p<0.01) showed significant increase in growth of cells compared to E2 (100 
ng/mL) and PCB153 (100 ng/mL) respectively in SMC ID3+ cells. Data were analyzed 
by ANOVA; Tukey HSD test for multiple comparisons. 
84 
 
Endothelial spheroid assay 
In spite of endothelial cells lined the innermost layer of artery grows in monolayer, cells 
in plexiform lesions grow in the three-dimension structure resembles spheroid. These 
cells do not follow characteristics of the cells, which grow in a monolayer. The cells 
derived from tumour tissue alter their both genotype and phenotype characteristics once 
they cultured in monolayer (Lee et al., 2006). Therefore, we tried to imitate the 
conditions of tumour in vitro. In addition to this, recent data from our laboratory showed 
that ID3 induced a molecular stem cell-like signature—CD133+ VEGFR3+ CD34+ in 
microvascular ECs. We grew the cells in no FBS DMEM F-12 medium supplemented 
with B-27 reduced growth supplement. We used a stem cell sphere-forming assay to 
determine the effect of E2 and PCB153 on HPMEC ID3+ cells. HPMEC ID3+ spheroids 
were bigger in diameter than HPMEC spheroids. We also found the treatment with 
PCB153 (100 ng/mL) was statistically significant (P<0.01) than control HPMEC ID3+ 
spheroids in terms spheroid size and spheroid number. We found the similar results on 
the 10th day, all the treatments the treatment with PCB153 (100 ng/mL) was statistically 
significant (P<0.01) than control HPMEC ID3+ spheroids in terms spheroid size and 
spheroid number as shown in Figures 35, 36 and 37. 
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Figure 35- PCB153 increases spheroid formation 
It shows pictures of spheroid. PCB153 increased the size and number of spheroid 
compared to control in lung EC & lung EC ID3+. Scale bar= 10 µm.  
Fig 28. Schematic diagram of spheroid formation.  
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Figure 36- PCB153 increases spheroid number in HPMEC ID3+ 
In both lung EC & EC ID3+, PCB153 increased the number of spheroids compared to 
control. Magnification X200. Graph shows quantification of spheroid number. Error 
bars represent the mean sphere number ± SD in 5 wells. PCB153= 100 ng/mL. a 
**p<0.01 for lung EC; b **p<0.01 for lung EC ID3+ vs control at day 10 as well as 
*p<0.05 for lung EC vs control at day 10. Data were analyzed by ANOVA; Tukey 
HSD test for multiple comparisons.  
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Co-culture of HPMEC ID3+ and SMC ID3+ spheroid assay- 
Earlier, researchers have shown the involvement of SMCs along with lung endothelial 
cells in formation of plexiform lesions and tumors (Doran et al., 2008;. Lee et al., 1998). 
We decided to culture HPMEC ID3+ cells with SMCs in 1:8 ratio to get the best results 
(in press). We seeded and co-culture HPMEC ID3+ cells with SMC ID3+ in 1:8 ratio in an 
ultra-low attachment 96-well plate with no FBS DMEM F-12 medium supplemented with 
B-27 reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153 
(100 ng/mL) in separate wells. We analyzed the data on 5th and 10th day. We found that 
all the treatments E2 (100 ng/mL), PCB153 (100 ng/mL) were statistically significant 
Figure 37- PCB153 increases spheroid size in HPMEC ID3+ 
In both lung EC & EC ID3+, PCB153 increased the diameter of spheres compared to 
control. Magnification X200. Graph shows quantification of spheroid diameter. Error 
bars represent the mean sphere size ± SD in 5 spheres. PCB153= 100 ng/mL. 
Representative microphotographs of treatment groups are shown inset. Error bars 
represent the mean diameter of 5 spheroids ± SD. a **p<0.01 for lung EC; b **p<0.01 
for lung EC ID3+ vs control at day 10 as well as *p<0.05 for Lung EC ID3+ vs control 
at day 10. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.  
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(P<0.01) than control spheroids in terms spheroid size and spheroid number as shown in 
Figures 38-43.  
 
 
 
 
 
Figure 38- Images of co-culture of HPMEC ID3+ and SMC ID3+ spheroid at day5 
PCB153 and E2 increased the size and number of spheroid compared to control. Scale 
bar= 10µm.  
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Figure 39- PCB153 and E2 increased the size of spheroid co-culture of HPMEC 
ID3+ cells with SMC ID3+ at Day5 
Co-culture of HPMEC ID3+ cells with SMC ID3+ cells in 1:8 ratio in an ultra-low 
attachment 96-well plate with no FBS DMEM F-12 medium supplemented with B-27 
reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153 
(100 ng/mL) in separate wells. E2 and PCB153 increased the diameter of spheres 
compared to control. Magnification X200. Graph shows quantification of spheroid 
diameter. Error bars represent the mean sphere size ± SD in 15 spheres. E2 & 
PCB153= 100 ng/mL. Representative microphotographs of treatment groups are 
shown inset. E2 and PCB153= 100 ng/mL. **p<0.01 for Lung EC ID3+: SMC ID3+vs 
control at day 5 Data were analyzed by ANOVA; Tukey HSD test for multiple 
comparisons.  
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Figure 41- It shows pictures of co-culture of HPMEC ID3+ and SMC spheroid at 
Day10 
PCB153 and E2 increased the size and number of spheroid compared to control. Scale 
bar= 10µm.  
Figure 40- PCB153 and E2 increased the number of spheroid co-culture of HPMEC 
ID3+ cells with SMC ID3+ at Day5 
 Co-culture of HPMEC ID3+ cells with SMC ID3+ cells in 1:8 ratio in an ultra-low 
attachment 96-well plate with no FBS DMEM F-12 medium supplemented with B-27 
reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153 (100 
ng/mL) in separate wells. E2, PCB153 treatments increased the number of spheroids 
compared to control.  Magnification X200. Graph shows quantification of spheroid 
number. Error bars represent the mean sphere number ± SD in 5 wells. E2 & PCB153= 
100 ng/mL. **p<0.01 for lung EC ID3+: SMC ID3+ vs control at day 5 Data were 
analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Figure 42- PCB153 and E2 increased the size of spheroid co-culture of HPMEC 
ID3+ cells with SMC ID3+ at day10 
Co-culture of HPMEC ID3+ cells with SMC ID3+ cells in 1:8 ratio in an ultra-low 
attachment 96-well plate with no FBS DMEM F-12 medium supplemented with B-27 
reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153 
(100 ng/mL) in separate wells. E2 and PCB153 increased the diameter of spheres 
compared to control. Magnification X200. Graph shows quantification of spheroid 
diameter. Error bars represent the mean sphere size ± SD in 15 spheres. E2 & 
PCB153= 100 ng/mL. Representative microphotographs of treatment groups are 
shown inset. E2 & PCB153= 100 ng/mL. **p<0.01 for lung EC ID3+: SMC ID3+vs 
control at day 10 Data were analyzed by ANOVA; Tukey HSD test for multiple 
comparisons. 
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Figure 43- PCB153 and E2 increased the number of spheroid co-culture of 
HPMEC ID3+ cells with SMC ID3+ at day10 
Co-culture of HPMEC ID3+ cells with SMC ID3+ cells in 1:8 ratio in an ultra-low 
attachment 96-well plate with no FBS DMEM F-12 medium supplemented with B-27 
reduced growth supplement. Then we treated cells with E2 (100 ng/mL), PCB153 (100 
ng/mL) in separate wells. E2, PCB153 treatments increased the number of spheroids 
compared to control.  Magnification X200. Graph shows quantification of spheroid 
number. Error bars represent the mean sphere number ± SD in 5 wells. E2 & PCB153= 
100 ng/mL. **p<0.01 for lung EC ID3+: SMC ID3+ vs control at day 10 Data were 
analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Spheroid assay- MTT, SRB, BrdU assay 
Proliferative vascular lesions have been studied extensively using the VEGF─receptor 
antagonist, Sugen 5416 (SU5416), plus chronic hypoxia (SuHx) rodent model as shown 
in Figure 44. Therefore, the aim of this study was to determine whether SU5416 exposure 
of ECs become more sensitive to estrogen-induced cell growth. We exposed human 
pulmonary endothelial cell line HPMEC ID3+ to SU5416 to select for a sub-population of 
cells, which were then treated with 17β-estradiol and/or PCB153. We observed a 
significant increase of 2-3 fold change in cell growth and proliferation as determined by 
MTT, SRB, BrdU, analysis when SU5416 treated cells were exposed to estrogenic 
chemicals as shown in Figure 45, 46 and 47. 
 
Figure 44- Procedure of formation of spheroid by treatment of ID3+ 
overexpressing lung endothelial cells with SU5416 and then cultured these cells to 
measure survival and growth. 
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Figure 45- SU5416 treatment increased the survival and proliferation of HPMEC 
ID3+ cells. 
HPMEC ID3+ cells exposed to SU5416 for 72 h to select for a sub-population of cells, 
which were then grown with no FBS DMEM F-12 medium supplemented with B-27 
reduced growth supplement for 4 days. Then these cells treated with 17β-estradiol 
and/or PCB153. Graph of cell survival determined by MTT assay of endothelial 
spheroids 24 h after exposure. All the treatment showed significant increase**p<0.01 
for HPMEC ID3+ vs control  
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Figure 46- SU5416 treatment increased the survival and proliferation of HPMEC 
ID3+ cells. 
HPMEC ID3+ cells exposed to SU5416 for 72 h to select for a sub-population of cells 
which were then grown with no FBS DMEM F-12 medium supplemented with B-27 
reduced growth supplement for 4 days. Then these cells treated with 17β-estradiol and/or 
PCB153. Graph of cell survival determined by SRB assay of endothelial spheroids 24 h 
after exposure. All the treatment showed significant increase**p<0.01 for HPMEC ID3+ 
vs control  
 
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47- SU5416 treatment increased the survival and proliferation of HPMEC 
ID3+ cells. 
HPMEC ID3+ cells exposed to SU5416 for 72 h to select for a sub-population of cells 
which were then grown with no FBS DMEM F-12 medium supplemented with B-27 
reduced growth supplement for 4 days. Then these cells treated with 17β-estradiol and/or 
PCB153.  Graph of cell survival determined by BrdU assay of endothelial spheroids 24 h 
after exposure. All the treatment showed significant increase**p<0.01 for HPMEC ID3+ 
vs control 
97 
 
Flow Cytometry 
 
 
Figure 48- Analysis by flow cytometry of cell cycle profiles of HPMEC and HPMEC 
ID3+ 
The distribution of cells in the different phases of the cell cycle was analyzed in absence 
(control) or presence of PCB153 in both HPMEC and HPMEC ID3+ cell types.  
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The cell cycle is process in which cell undergo its division and duplication of its DNA 
(DNA replication) to produce two daughter cells. The cell cycle consists of four distinct 
phases: G1 phase, S phase (synthesis), G2 phase (collectively known as interphase) and 
M phase (mitosis). G0 is a resting phase where the cell has left the cycle and has stopped 
dividing. The cell cycle starts with this phase. G1 is first phase of interphase also called 
as growth phase where cell prepares itself to go under cell division. The cell increases its 
supply of proteins, increases the number of organelles (such as mitochondria, ribosomes), 
and grows in size.  The S phase starts when DNA synthesis commences; when it is 
complete, all of the chromosomes have been replicated, i.e., each chromosome has two 
(sister) chromatids. G2 phase occurs after DNA replication and is a period of protein 
synthesis and rapid cell growth to prepare the cell for mitosis.  
Our flow cytometry experiments revealed that approximately 82.4% of the DNA content 
in HPMEC ID3+ resided in the G0/G1 phase compared to only 78.6% of the wild-type 
cells. Thus, HPMEC ID3+ showed a statistically significant 4.7205% of difference and 
1.04 -fold increase in G0/G1 phase cells (Fig. 48). The percentage of DNA content in S 
phase decreased from approximately 8.1% in HPMEC to 2.1% in HPMEC ID3+. Thus, 
ID3 significantly reduced the number of cells in S phase by more than 2-fold (Fig. 48). 
The HPMEC ID3+ showed increase in percentage of DNA content in G2/M phase from 
approximately 13.3% in wild-type cells to 15.5% in the HPMEC ID3+ population (Fig. 
48).Our data suggest that in the HPMEC ID3+ population there is a significant increase in 
the number of cells that reside in the G0/G1 phase which is indicative of proliferative 
quiescence. Since a higher proliferative capacity may exhaust a stem cell population, this 
observed increase in G0/G1 phase by HPMEC ID3+ may help to maintain a stem cell-like 
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state by slowing cell cycle progression. Similarly, we found same trend in case of 
treatment with PCB153 to HPMEC and HPMEC ID3+. When both the cells treated with 
PCB153, we found that cells showed more DNA percentage reside in G0/G1 phase 
compared to the control. In case of HPMEC cells, PCB153 exposure increased DNA 
percentage from 78.6% to 90.4%. In case of HPMEC ID3+ cells, PCB153 exposure 
increased DNA percentage from 82.4% to 95.2%.  Since Felty et al. already shown, ID3 
overexpression gives stemness character to the cells and stem cells reside longer in the 
G0/G1 phase of the cell cycle. Proliferative quiescence is a state observed in stem cells 
which reside longer in the G0/G1 phase of the cell cycle; and it has been hypothesized 
that quiescence may prevent against the depletion of the stem cell population. Similarly, 
we found the same effect in SMC and SMC ID3+ cells. SMC ID3+ cells showed that their 
percentage of DNA reside more in G0/G1 phase and cells prepare for synthesis in S 
phase. In addition, we found that the exposure to PCB153 increases percentage of DNA 
in G0/G1 phase in SMC ID3+ compared to control (Figure 49).
100 
 
 
Figure 49- Analysis by flow cytometry of cell cycle profiles of SMC and SMC ID3+ 
The distribution of cells in the different phases of the cell cycle was analyzed in absence 
(control) or presence of PCB153 in both SMC and SMC ID3+ cell types.  
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Western blot  
Aim- To determine the effect of PCB153 on ID3 expression. 
We seeded the HPMEC and HPMEC ID3+ cells in four 100 mm petri dishes each. We 
added 0.1% DMSO (control), and PCB153 (100 ng/mL) to separate petri dishes. We 
analyzed that combination treatment of PCB153 increase 2-3-fold change in ID3 
expression in HPMEC ID3+ cells compared to control. PCB153 (100 ng/mL) treatment 
showed significant (P<0.01) increased than control as shown in Figure 50. We have also 
checked the expression of ID3 protein in SMC and SMC ID3+ cell line in Figure 51.  
 
 
 
 
 
102 
 
 
 
 
 
 
 
 
Figure 50- PCB153 increases ID3 expression in HPMEC cells.  
Detection of ID3 protein 17 KDa and Beta actin as a control 41 KDa in lung EC ID3+ 
cell line. Gel percentage 15%. Primary antibody ID3 monoclonal Ab- 1:2500 and 
Secondary Ab- 1:10000. PCB153 = 100 ng/mL. HPMEC and HPMEC ID3
+
 cells 
treated with 0.1% DMSO (control), PCB153 (100 ng/mL). All the treatment showed 
significant increase**p<0.01 for HPMEC ID3
+
 vs control. Antibody concentration = 
0.1 mg 
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Figure 51- ID3 expression in SMC and SMC ID3+ cells 
Detection of ID3 protein 17 KDa and Beta actin as a control 41 KDa in lung SMC ID3+ 
cell line. Gel percentage 15%. Primary antibody ID3 monoclonal Ab- 1:2500 and 
Secondary Ab- 1:10000. SMC and SMC ID3+ cells treated with 0.1% DMSO (control). 
Antibody concentration = 0.1 mg. 
EndMT markers expression in lung EC ID3+ 
Endothelial to mesenchymal transition (EndMT) is major event arrive when endothelial 
cells dramatically alter their shape and motile behavior as they differentiate into 
mesenchymal cells. In this process, cells detached from cell-cell junctions of neighboring 
cells and basement membrane (Larue & Bellacosa, 2005). During this transition, cells 
express and loose some protein markers. Interestingly, EndMT process is an integral part 
of tumor cells metastasis in which cells show alteration in some protein markers. 
Expression of VE cadherin, Vimentin, and Matrix metalloproteinase 9 proteins are the 
hallmark of EndMT process. VE-cadherin (CD144) is a cell-adhesion protein that 
maintains the cell-cell contacts (Kowalski, 2003). Matrix metalloproteinase 9 (MMP9) is 
a zinc finger dependent enzyme cuts cell-cell and basement membrane contact and 
promotes invasion, metastasis, and angiogenesis. Vimentin is cytoskeletal intermediate 
filaments (IFs) protein and is expressed more in mesenchymal transition. It has been 
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shown that Vimentin expression is also upregulated in wound healing in vitro culture 
system (Hendrix, Seftor, Seftor, & Trevort, 1997; Liu, Lin, Tang, & Wang, 2015). 
Moreover, Felty et al. 2014 showed that PCB153 along with ID3 over expression induced 
cell migration and endothelial spheroid growth in HUVEC cells. They also showed that 
ID3 overexpression regulates the upregulation of VEGFR3, which is marker of 
angiogenesis and neovascularization. Hence, we investigated the role of ID3 in case 
endothelial to mesenchymal transition of cells in presence of estrogenic chemical.   
We seeded the HPMEC and HPMEC ID3+ cells in eight chambered slide and added the 
treatments 0.1% DMSO (control) and PCB153 (100 ng/mL). We found that VE cadherin 
expressed more in HPMEC cells compared to HPMEC ID3+ in control. Vimentin and 
MMP-9 expressed more in HPMEC ID3+ cells compared to HPMEC cells. We also found 
that vimentin and MMP-9 expression of HPMEC ID3+ cells was significantly higher in 
PCB153 (100 ng/mL) than control as shown in Figure 52.  We have also showed the 
changes in expression of EndMT markers in ID3 overexpressing HPMEC cell line. We 
observed gain of N-Cadherin, Vimentin and loss of VE-Cadherin in Figures 53, 54 and 
55.  
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Figure 53- Detection of N-Cadherin protein 
Detection of N-Cadherin protein 132 KDa in HPMEC and HPMEC ID3+ cell line. Gel 
percentage 7.5%. Sample loaded per well = 50 microgram. N-cadherin- (H-63): sc-7939 
mouse monoclonal Ab- 1:2500 and Secondary Ab- 1:10000. Antibody concentration = 10 
µg/50 µl 
Figure 52- Immunofluorescence. ID3 altered expression of VE-cadherin, vimentin, 
and MMP-9 in lung endothelial cell line HPMEC ID3+. 
Cells were exposed to vehicle or PCB153 100 ng/mL for 24h. (A-B) Stable expression of 
ID3 showed a loss of endothelial marker VE-cadherin a characteristic of endothelial-to-
mesenchymal transition (EndMT). (E-F) ID3 increased expression of mesenchymal 
marker vimentin. (I-J) ID3 increased expression of mesenchymal marker matrix 
metalloproteinases 9 (MMP9).  
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Figure 54- Detection of VE-Cadherin protein 
Detection of VE-Cadherin protein 130 KDa in HPMEC and HPMEC ID3+ cell line. Gel 
percentage 7.5%. Sample loaded per well = 50 microgram. VE-cadherin-2 Antibody (F-
4): sc-515467 mouse monoclonal Ab- 1:2500 and Secondary Ab- 1:10000. Antibody 
concentration = 10 µg/50 µl 
 
Figure 55- Detection of Vimentin protein 
Detection of Vimentin protein 51 KDa in HPMEC and HPMEC ID3+ cell line. Gel 
percentage 10%. Sample loaded per well = 50 microgram. Vimentin Antibody (V9): sc-
6260 mouse monoclonal Ab- 1:2500 and Secondary Ab- 1:10000. Antibody 
concentration = 10 µg/50 µl 
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Zebrafish model to study role of ID3 in EC proliferation 
Our main objective of this research is to investigate the in vivo role of ID3 in the 
pathogenesis of proliferative vascular lesions in early stages of zebrafish embryos and in 
xenograft tumors. The purpose of this study is to develop a zebrafish xenograft model of 
metastasis by injecting Cancer Stem Cells (CSCs), or Tumor Initiating Cells (TICs) 
isolated from ID3 positive or negative or ID3 target gene(s) expressing in vitro cultured 
lung endothelial cells in early stages of zebrafish embryos. Endothelial cells in plexiform 
vascular lesions (a pathological hallmark of PAH) have been characterized as hyper-
proliferative and apoptosis resistant, which is consistent with a neoplastic hypothesis. 
This lesion is a major cause of high morbidity and mortality in severe end-stage IPAH 
patients because the pulmonary vascular lesion (PVL) progressively obliterate pulmonary 
arterioles and impinge upon the unobstructed vessels resulting in heart failure. Our 
research over the past 10 years has uncovered that the disruption of mitochondrial ROS 
production and redox signaling to nuclear regulatory pathways by estrogen or its 
metabolite, 4- hydroxy-estradiol contribute to the development of vascular lesions. In 
addition, our preliminary results in 2D and 3D model showed that ID3 seems to be 
essential for generation of stem-like cells and EndMT and cell migration, but the targets 
of ID3 gene are unknown. The present research is centered on the concept that activation 
of dynamic "rheostat" molecules in CSCs, or TICs regulate gene networks of 
chromosomal/genomic instability and they drive vascular lesion in pulmonary arterioles 
involving oxidative stress, apoptosis, and stemness. In line with this overall paradigm, we 
propose mechanistic studies targeting the redox response, involving ID3 gene shown to 
induce oxidative stress, anti-apoptosis, stemness and genomic instability. The 
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significance of the use of zebrafish model in this study is to identify the ID3 targets using 
both genetic and biochemical analyses for their ability to promote or inhibit non-
malignant vascular lesions in vivo. Zebrafish embryos will be used to develop xenograft 
vascular lesions to determine if essential effectors of ID3 and their potential targets are 
relevant drug targets that may epigenetically drives the formation of non-malignant 
vascular lesions from exposure to PCBs in vivo.  Our data showed that HPMEC ID3+ 
cells after injection show migration through blood vessels to thoracic and head part of the 
zebrafish as shown in Figure 56.  
 
 
 
 
 
 
Figure 56- Proliferation and migration of a human lung EC ID3+ cell line in 
zebrafish 
The lung ECs ID3+ of xenotransplantation in zebra fish embryo (2 dpf) showed that 
spread of the GFP fluorescent dye labeled lung ECs moved through blood vessels from 
the site of injection to the region of secondary target organ for metastasis lesions. The 
photomicrographs were captured by Nikon confocal microscopy. The treatment of 
PCB153 on lung ECs ID3+ group showed the more migratory cells for adhesion, micro 
invasion and metastasis. The red color showed injected all cells stained with the 
fluorescent dye, CellTracker™ CM-DiI (stained both GFP and non GFP cells ) which 
is well suited for monitoring all live cell movement in the blood vessel of the zebra 
fish embryo. 400X).  
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Discussion 
In the present study, we determined PCB-induced neovascularization with the aim of 
elucidating the role of environmental PCBs in lung endothelial dysfunction while focused 
on ID3. Enhanced neovascularization has been implicated in the development of 
plexiform lesions in idiopathic pulmonary arterial hypertension, and atherosclerotic 
lesions in cardiovascular disease. It is evident that humans have been and will continue to 
be exposed to PCBs due to deposition of harmful chemical contaminants in the 
environment through chemical industries waste, landfills and incinerators (Tanabe, 1988). 
PCB153 is included as a persistent non-dioxin-like polychlorinated biphenyl in PCB 
congeners, which are abundantly present in the food-chain and the environment. PCB153 
may cause deleterious public health effects because of their tendency to bioaccumulate to 
high concentrations due to their slow elimination from the human body. In adults, the 
estimated elimination half-life for PCB153 is 14.4 years (Ritter et al., 2011b).  
Our lab earlier showed that the PCB153 induced ROS formation increases ID3 protein 
expression in human microvascular endothelial cell line hCMEC/D3. We also showed in 
our earlier studies that the higher expression of ID3 protein increases neovascularization 
in human microvascular endothelial cells. The lung endothelial cells come into direct 
contact with blood in lung microenvironment. The human blood carries many dissolved 
gases, chemicals from environment, and these all directly come in contact with the 
innermost layer of lung endothelial cells, which lead to form lesions. Therefore, in 
presence of chemical inducers or inhibitors lung endothelial cells may undergo an 
alteration in the phenotype. In the study, we investigated the effect of PCB153 on lung 
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endothelial cells while focused on ID3.  We exposed lung endothelial cells with PCB153 
and studied the behavior of cells. In wound healing assay, our results showed that in 
presence of PCB153 the rate of cells migration to the wound area was significantly higher 
than control. In addition to this, in case of overexpressed ID3 lung endothelial cells 
showed higher rate of cell migration when treated with PCB153 compared to wild type 
cells. These results showed that overexpressed ID3 lung endothelial cells in presence of 
environmental contaminant of PCB153 showed higher cell proliferation behavior than 
wild type. To strengthen our claim regarding change in behavior of overexpressed ID3 
lung endothelial cells, we did endothelial spheroid assay, which mimics plexiform lesion 
formation in vivo model. We found that PCB153 increased the size and number of 
spheroid significantly in lung ECs ID3+ compared to wild type lung EC. We also cultured 
the spheroid from lung EC ID3+ cells and measured ell growth and proliferation 
determined by MTT, SRB, BrdU, analysis. We found that PCB153 increased growth and 
proliferation of lung EC ID3+ cells. Our western blot results also demonstrated the 
growth and proliferation effect at molecular level. ID3 protein expressed significantly 
higher when lung ECs ID3+ cells treated with PCB153. We also observed cell migration 
behavior at molecule level with immunofluorescence assay. In this process, cells 
detached from cell-cell junctions of neighboring cells and basement membrane (Larue & 
Bellacosa, 2005). During this transition, cells express and loose some protein markers. 
Interestingly, EndMT process is integral part of tumor cells metastasis in which cells 
shows alteration in some protein markers. Expression of VE cadherin, vimentin and 
Matrix metalloproteinase 9 (MMP9) proteins are hallmark of EndMT process. When we 
exposed lung ECs ID3+ cells with PCB153, we found that higher expression of vimentin 
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and MMP9 proteins. These results corroborate our hypothesis that environmental 
chemical PCB153 increases proliferation of cells by increasing ID3 expression as well as 
instigate stem cells like properties to lung EC cells.  
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CHAPTER 3 
 
The genome-wide mapping of ID3 target genes reveals the role of ID3 in the 
proliferation and dysregulation of lung endothelial cells. 
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Abstract 
Background: ID3 is a key gene implicated in maintaining the stemness of embryonic and 
adult stem cells, which lacks the basic DNA-binding domain. ID3 appears to re-activate 
in several human cancers like NSCLC and in diseases such as PAH. However, the 
detailed response programming of ID3 in HPMEC has not yet been defined. 
Results: We show that overexpression of the ID3 gene in HPMEC cells increases cell 
proliferation. We then comprehensively characterize the ID3 response program by an 
integrated analysis using advanced genomic technologies including Chromatin 
Immunoprecipitation Sequencing (ChIP-Seq) and RNA sequencing. Using ChIP-Seq 
technology, we identified 2336 ID3 binding regions (ChIP peaks) in the HPMEC ID3+ 
(ID3 overexpressing HPMEC cell line) cells genome. ID3 binding regions with the 
highest peak score demonstrated the sequence GAGAGAGAGAGAGAG that occurred a 
total of 900 instances in 2493 ID3 binding regions. We then further with the help of 
Genomic Regions Enrichment of Annotations Tool (GREAT) assigned biological 
meaning to 2493 regions. GREAT associated 2336 regions with 2834 genes. RNA-Seq 
analysis identified total of 1061 genes whose expression altered in response to ID3 
overexpression in HPMEC cells. Out of 1061 genes, 63 genes showed significant (>1 
log2 (FC)) fold change.  RNA Seq data demonstrated HSPA8, SH3BP5L, EEF2K 
proteins were down-regulated and proteins like EGR1, TNFAIP3, and KLF10 were up-
regulated. Furthermore, the combination of ChIP-Seq and transcriptome data analysis 
used as a compelling approach to decipher the regulation of gene expression with the help 
of Binding and expression target analysis (BETA) software. Integration of ChIP Seq with 
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differential gene expression data of RNA Seq to infer direct target genes of ID3 revealed 
interesting findings, which includes total of 26 genes significantly regulated by ID3.   
Conclusions: We present an integrated analysis of ChIP-Seq and RNA sequencing 
representing the ID3 response program responsible for HPMEC cells proliferation. The 
insights gained from our integrated analysis further our understanding of the potential 
actions of ID3 in carcinogenesis and serve as a useful resource to further develop 
pharmaceutical drugs targeting the ID3 protein. 
Key words: endocrine disruptors, ID3 Lung endothelial cells, PAH, plexiform lesions. 
 
Introduction- 
ID3 is one of the members of the ID protein family, which consists of four genes (ID1–
ID4). ID3 does not have DNA binding domain and interacts with other proteins via helix-
loop-helix (HLH) motif. It has been reported that ID3 acts as a transcription regulator 
which regulate transcription in a dominant-negative manner by dimerizing with basic 
HLH transcription factors like E12, E47, E2-2, and HEB (Benezra, Davis, Lockshon, 
Turner, & Weintraub, 1990; Doke, Avecilla, & Felty, 2018; Norton, 2000).  ID3 is a 
pleiotropic protein involved in the modulation of a variety of biological processes such as 
cell differentiation, cell proliferation, cell cycle control, senescence, apoptosis or 
angiogenesis, and metastasis (Lyden et al., 1999; Lyden et al., 1999b; Ruzinova & 
Benezra, 2003). Previously, we have shown that ID3 overexpression reprograms adult 
endothelial cells to acquire vascular stem markers including CD133. ID3 is mostly 
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implicated in maintaining the stemness of embryonic and adult stem cells while its 
expression is down-regulated as tissues mature (Lyden et al., 1999b). However, research 
studies showed reactivation of ID3 expression in mature prostate and breast tissues 
involved in aggressive growth of cancer (Gupta et al., 2007; Sharma, Patel, & Chaudhary, 
2012). The proliferative ECs have been reported to be an aggressive endothelial 
phenotype associated with a poor prognosis in non-small cell lung cancer and severe 
idiopathic pulmonary arterial hypertension (Tanaka et al., 2003; Tuder, Groves, Badesch, 
& Voelkel, 1994). We have also shown the exposure of E2 and EED like PCB153 to ECs 
increases ROS. Since ID3 is redox sensitive gene, it acts an important determinant of 
ROS-induced proliferation of E2 and PCB153 exposed ECs (Das & Felty, 2014a, 2014d; 
Felty & Porther, 2008b; Mueller et al., 2002). However, little is known regarding the 
molecular contribution of ID3 to vascular reprogramming and how it interacts with other 
transcription factors (TFs), which bind to DNA and regulate the transcriptional 
machinery to activate or repress the expression of target genes. In the current study, we 
used ChIP-Seq technology and conducted a genome-wide target identification for ID3 
binding in lung EC cells. In addition to this, we used RNA sequencing for accurate 
detection and measure of gene expression of differential expressed (DE) genes between 
HPMEC and ID3 overexpressed HPMEC. Further, we performed an integrated analysis 
of ChIP and RNA Seq data, which revealed key response programs that potentially may 
play important role in lung ECs proliferation. 
 
 
119 
 
Materials and Methods 
Cell culture and treatment conditions  
Primary cells, Human pulmonary microvascular endothelial cells or Human lung 
endothelial cells (HPMEC-ST1.6R). HPMEC cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM-F12) supplemented with 5% (v/v) fetal bovine serum 
(FBS). Cells were cultured at 37 ºC in a humidified atmosphere with 5% CO2.  
Estrogenic chemical treatments  
Stock solutions of PCB153 and 17β-estradiol were prepared in dimethyl sulfoxide 
(DMSO). The same amount of DMSO as in PCB and estradiol-treated cells were added 
to control cultures. The level of DMSO in experimental media was less than 0.1%. PCB 
blood levels have been reported to reach approximately 1000 ng/mL (∼3 μM) in 
occupationally exposed individuals (Wassermann et al., 1979). Our unpublished data 
showed a significant increase in PCB-induced vascularization with PCB153 
concentrations of 10–100 ng/mL. Based on known PCB blood levels from occupational 
exposure and our preliminary results; we chose a PCB dose of 100 ng/mL (∼0.3 µM) to 
expose endothelial cells. Our previous studies also showed endothelial cell proliferation 
and vascular tube formation at physiological doses of 17β-estradiol (Das & Felty, 2014a; 
Felty, 2006; Felty & Porther, 2008b) therefore, HPMEC and HPMEC ID3+ were exposed 
to estradiol at 100 ng/mL (∼3.6 nM). PCB congeners 2,2′,4,4′,5,5′-hexachlorobiphenyl 
(PCB153) were purchased from AccuStandard (Newhaven, CT) and dissolved in 
dimethyl sulfoxide (DMSO). All other chemicals and reagents were purchased from 
Sigma (St. Louis, MO). 
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ID3 overexpression 
The HPMEC cells were stably transfected with either Precision LentiORF for ID3 
(Thermo Scientific Open Biosystems) or empty vector lentiviral pLEX-JRED/TurboGFP 
by the trans-lentiviral packaging kit with Express-in transfection reagent according to the 
manufacturer’s instructions. We used the MOI (multiplicity of infection) of 25 and 
selected cells that overexpressed ID3 with blasticidin S (5 mg/ml) as per manufacturer’s 
instructions. Cells expressing TurboGFP were identified by fluorescence microscopy. 
Experiment procedure for Chromatin Immunoprecipitation (ChIP) Sequencing 
(ChIP-Seq) 
Chromatin-immunoprecipitation  followed by sequencing of the immuno-precipitated 
DNA is an expeditiously becoming a very important method for understanding the 
mechanisms of protein: DNA interactions. It was first introduced and described in 2007 
(Robertson et al., 2007). It is a powerful tool for understanding the mechanisms of gene 
regulation by transcription factors and modified histones. ChIP-Seq process is very 
tedious and time-consuming to perform, involving many steps and variables that must be 
optimized by each investigator in their model system. To perform ChIP-Seq, chromatin is 
isolated from cells or tissues and fragmented. Specific antibodies against chromatin-
associated proteins are used to enrich for specific chromatin fragments. The DNA is 
recovered, sequenced and aligned to a reference genome to determine specific protein 
binding loci.  
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ChIP sequencing makes use of the power of massively parallel or next-generation 
sequencing (NGS) which have increased our knowledge of transcription factor biology, 
DNA methylation and histone modifications. ChIP- Seq is a counting assay that uses only 
short reads to align to the genome, but requires millions of them to provide meaningful 
data.  
In order to perform ChIP-Seq analysis, we used QIAGEN Company made EpiTect ChIP 
OneDay Kit, which is designed to isolate and purify high-quality DNA bound to our 
protein of interest. The EpiTect ChIP OneDay Kit contains all buffers and components 
needed for immunoprecipitation, crosslink reversal, and genomic DNA purification for 
detection. To begin with chromatin immunoprecipitation, we seeded the cells and treated 
with treatment for 48 hours. Then, we cross-linked cells with formaldehyde. The 
chromatin containing covalent complexes between genomic DNA and all nuclear factors 
is isolated and sheared by sonication into 100-300 base pair (bp) sizes. 
Immunoprecipitation pulls down not only the target nuclear factor of interest but also any 
specifically bound genomic DNA sequences. Reversal of the chemical cross-linking and 
nucleic acid purification prepare the DNA for detection by sequencing. The sequencing 
of ChIP processed DNA is carried out by Center for Genome Technology (CGT) of John 
P. Hussman Institute for Human Genomics at University of Miami Miller School of 
Medicine. CGT facility used DNA SMART ChIP-Seq Kit (Clontech Laboratories, Inc.) 
which generated Illumina-compatible sequencing libraries from 100 pg–10 ng of single- 
stranded (ss) or double-stranded (ds) DNA resulting from chromatin immunoprecipitation 
experiments. Then we performed ChIP-Seq analysis using various tools available at 
Galaxy, which is an open source, web-based platform (Afgan et al., 2016). It begins with 
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mapping of trimmed sequence reads to a reference genome. Next, peaks are found using 
peak-calling algorithms. To further analyze the data, we performed differential binding 
and motif analyses, which are common end points of ChIP-Seq workflows. In order to 
perform ChIP-Seq analysis, we used QIAGEN Company made EpiTect ChIP OneDay 
Kit, which is designed to isolate and purify high-quality DNA bound to our protein of 
interest. ChIP samples were prepared from lung EC WT, lung EC ID3+, and lung EC 
ID3+ + E2 cells as follows: 80.0 x 106 cells from each of all the three cell lines were 
cross-linked with 1% formaldehyde for 10 minutes at room temperature. Cross- linking 
was stopped by the addition of harvesting buffer to a final concentration of 125 mM, and 
cells were washed twice with PBS. Centrifuged at 2000 rpm, removed supernatant. 
Added 800 μL to 1 mL Lysis buffer to ppt. The cell pellet was resuspended consecutively 
in ChIP lysis buffers and sonicated for 6 minutes, 12 cycles (30 seconds high frequency 
pulsing followed by 30 seconds resting) using the Bioruptor sonicator (Diagenode, 
Denville, NJ). In addition to this, added 10 μL of nuclease + 20 μL reaction mixture to 
the sample and incubate 20 min at 37 ºC. Added 40 μL Stop buffer to produce chromatin 
fragments of 100 – 300 bp on average.  Ran 1.2% agarose gel with sample and molecular 
marker to check whether the chromatin broken into appropriate sizes. Added 50 μL 
Protein A Beads for each IP Fraction. To prepare these beads, 100 μL of protein beads 
were incubated overnight with 10 μg SC-490 polyclonal ID3 antibody (SantaCruz 
Biotechnology), at 4 °C. The following day, the beads were rinsed and added to the 
sheared chromatin and incubated over- night at 4 °C. Samples were then rinsed one time 
each with buffer I,II,III,IV and V. The cross-linking of antibody with protein of interest- 
DNA complex was reversed by treating with RNAse A and Proteinase K. Procedure 
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controls included an input condition, obtained before DNA-protein complex sonication 
and further used during ChIP-Seq assays as normalization sample, and non-
immunoprecipitated DNA (non-IP DNA), which was obtained just prior to ID3 
immunoprecipitation. Added 400 μL Column Binding Buffer to each 200 μL IP Fraction 
sample. Mixed well by pipetting. Immediately transferred the entire supernatant to its 
own DNA Spin Column (in 2 mL Collection Tube) without wetting the rim, close the lid, 
and centrifuge at 11,000 × g for 1 min at room temperature. Added 600 μL Column Wash 
Buffer, containing ethanol, to each column, without wetting the rim, close the lid, and 
centrifuge at 11,000 × g for 1 min at room temperature. Placed the DNA Spin Column 
into a clean Elution Tube, and discarded the Collection Tube. Added 100 μL Elution 
Buffer to the center of the column membrane. This elution step with another 100 μL of 
Elution Buffer carried out for a final elution volume of 200 μL for each ChIP DNA 
Sample. The purified ChIP DNA Samples can be stored at -20°C. The purified DNA 
further processed with the help of Clean & Concentrator™ from ZYMO RESEARCH 
CORP for the rapid purification and concentration of high quality DNA. The ChIP DNA 
Clean & Concentrator™ employs a single buffer system that allows for efficient DNA 
adsorption to the matrix of the supplied Zymo-Spin™ Column. Then we measured the 
concentration of DNA in samples and inputs with the help of BioRad spectrophotometer. 
Experimental protocol for Chromatin Immunoprecipitation- 
 Aim- To determine genome-wide mapping of ID3 target genes by using ChIP-Seq 
experiment. ChIP Ready Chromatin Preparation: This section describes the preparation 
of ChIP Ready Chromatin. It covers cell cross- linking, harvesting, lysis, and chromatin 
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shearing based on adherent mammalian cell lines. Certain steps may need to be optimized 
for experiment-dependent performance. This protocol also provides several stopping 
points for the flexibility to optimize those steps. 
Things to do before starting- 
In order to immunoprecipitate the ID3 bound chromatin, we seeded the 20.0 x 106 cells of 
lung EC vector, lung EC ID3+, and lung EC ID3+  + E2 cells on each of four 150 mm 
petri dishes to achieve  80.0 x 106 cells for all three cell lines.  
 (i) Lung Vector Control (HPMEC), (ii) Lung ID3, (iii) Lung ID3 + E2. 
We treated cells with vehicle or E2 overnight. We did fixing and harvesting of chromatin 
from all plates - Total volume per sample = Follow the steps of Cross-Linking Cells with 
1% formaldehyde.  Add 1 mL cell harvesting buffer and centrifuge at 2000 rpm. Remove 
supernatant. Add 800 μL to 1 mL lysis buffer to ppt. We warmed IP Lysis Buffer to room 
temperature to prevent precipitation.  We thawed Protease Inhibitor Cocktail (PIC) at 
room temperature. This product contains DMSO and will remain frozen below 18.4 °C. 
Cross-Linking Cells- We prepared following buffers, scale up accordingly if necessary. 
i. 1 × PBS Buffer: 3.3 mL 10 × PBS to 29.7 ml ddH2O. Mixed well and placed on 
ice. 
ii. FRESH Fixing Buffer (1% Formaldehyde): We added 0.27 mL 37% 
Formaldehyde to 9.73 mL 1 × PBS Buffer. Mixed and stored at room temperature in a 
fume hood. 
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iii. Cell Harvesting Buffer: We added 15 μL Protease Inhibitor Cocktail (PIC) to 3 
mL ice-cold 1 × PBS Buffer. Mix well and place on ice. 
We aspirated cell culture medium from the dish. Add 10 mL FRESH Fixing Buffer to the 
dish. We incubated at 37 °C for 10 min. We added 1.1 mL Stop Buffer to the dish and 
swirl to mix thoroughly. We incubated at room temperature for 5 min. We aspirated 
buffer as much as possible. NOTE: From this point forward, keep the samples on ice at 
all times. We added 9 mL ice-cold 1 × PBS to wash the fixed cells, rocking the dish for 5 
seconds. We poured off the wash buffer. Repeat once more. b. Harvesting Cells- We 
added 1.5 mL ice-cold Cell Harvesting Buffer to the dish. We placed dish on ice at an 
angle and scrape cells down to one edge of the dish with a silicone cell scraper or rubber 
policeman. We centrifuged the Sonication Tube at 800 × g for 10 min at 4 °C to pellet the 
fixed cells. Remove the supernatant. Repeat harvesting and centrifugation steps as many 
times as necessary to collect all of the cells. Store the cell pellet at -80 °C.  
c. Cell Lysis 
We added 2.2 μL Protease Inhibitor Cocktail (PIC) to 420 μL IP Lysis Buffer in a 
standard 1.5 mL Eppendorf tube. Mix well by pipetting. We added entire volume of IP 
Lysis Buffer with PIC to the cell pellet. 100 μL IP Lysis Buffer is recommended to lyse 
0.5 to 1.5 million cells. We resuspended cells completely by pipetting. Incubate on ice for 
10 -15 min, mixing every 5 min. Continue with next step OR store the lysate at -80 °C. 
d. Shearing Chromatin- Chromatin Sonication: 800 μL total chromatin volume per 
sample sonicated for 6 min (12 cycles). We aliquot 800 uL volume into two 400 μL vials 
per sample. 800 μL = 2 x 400 μL vials per sample.  
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We stored one set of 400 μL samples in -80 ºC freezer.  We added 10 μL of nuclease + 20 
μL reaction mixture to the sample and incubated 20 min at 37 ºC. The added 40 μL Stop 
buffer. We ran 1.2% agarose gel with sample and molecular marker. Chromatin should be 
broken down by sonicator into DNA pieces of size ranges from 100 bp to 300 bp as 
shown in Figure 57. 
 
 
 
 
 
 
Figure 57- The picture of 1.2% agarose gel with sample and molecular marker 
by using UVITEC UVidoc instrument. 
Chromatin is broken down by sonicator into DNA pieces of size ranges from 100 bp 
to 300 bp for HPMEC (Control), HPMEC ID3+, and HPMEC ID3+ + E2 cell 
samples. 
127 
 
Chromatin Immunoprecipitation (ChIP) Introduction- 
In order to perform ChIP-Seq analysis, we used QIAGEN Company made EpiTect ChIP 
OneDay Kit, which is designed to isolate and purify high-quality DNA bound to our 
protein of interest. ChIP samples were prepared from lung EC WT, lung EC ID3+, and 
lung EC ID3+ + E2 cells as follows: 80.0 x 106 cells from each of all the three cell lines 
were cross-linked with 1% formaldehyde for 10 minutes at room temperature. Cross- 
linking was stopped by the addition of harvesting buffer to a final concentration of 125 
mM, and cells were washed twice with PBS. Centrifuged at 2000 rpm, removed 
supernatant. Added 800 μL to 1 mL Lysis buffer to ppt. The cell pellet was resuspended 
consecutively in ChIP lysis buffers and sonicated for 6 minutes, 12 cycles (30 seconds 
high frequency pulsing followed by 30 seconds resting) using the Bioruptor sonicator 
(Diagenode, Denville, NJ). In addition to this, added 10 μL of nuclease + 20 μL reaction 
mixture to the sample and incubate 20 min at 37 ºC. Added 40 μL Stop buffer to produce 
chromatin fragments of 100 – 300 bp on average.  Ran 1.2% agarose gel with sample and 
molecular marker to check whether the chromatin broken into appropriate sizes. Added 
50 μL Protein A Beads for each IP Fraction. To prepare these beads, 100 μL of protein 
beads were incubated overnight with 10 μg SC-490 polyclonal ID3 antibody (SantaCruz 
Biotechnology), at 4 °C. The following day, the beads were rinsed and added to the 
sheared chromatin and incubated over- night at 4 °C. Samples were then rinsed one time 
each with buffer I,II,III,IV and V. The cross-linking of antibody with protein of interest- 
DNA complex was reversed by treating with RNAse A and Proteinase K. Procedure 
controls included an input condition, obtained before DNA-protein complex sonication 
and further used during ChIP-Seq assays as normalization sample, and non-
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immunoprecipitated DNA (non-IP DNA), which was obtained just prior to ID3 
immunoprecipitation. Added 400 μL Column Binding Buffer to each 200 μL IP Fraction 
sample. Mixed well by pipetting. Immediately transferred the entire supernatant to its 
own DNA Spin Column (in 2 mL Collection Tube) without wetting the rim, close the lid, 
and centrifuge at 11,000 × g for 1 min at room temperature. Added 600 μL Column Wash 
Buffer, containing ethanol, to each column, without wetting the rim, close the lid, and 
centrifuge at 11,000 × g for 1 min at room temperature. Placed the DNA Spin Column 
into a clean Elution Tube, and discarded the Collection Tube. Added 100 μL Elution 
Buffer to the center of the column membrane. This elution step with another 100 μL of 
Elution Buffer carried out for a final elution volume of 200 μL for each ChIP DNA 
Sample. The purified ChIP DNA Samples can be stored at -20 °C. The purified DNA 
further processed with the help of Clean & Concentrator™ from ZYMO RESEARCH 
CORP for the rapid purification and concentration of high quality DNA. The ChIP DNA 
Clean & Concentrator™ employs a single buffer system that allows for efficient DNA 
adsorption to the matrix of the supplied Zymo-Spin™ Column. Then we measured the 
concentration of DNA in samples and inputs with the help of BioRad spectrophotometer. 
Illumina high-throughput Chromatin Immunoprecipitation -Sequencing (ChIP-Seq) 
Chromatin-immunoprecipitation (ChIP) followed by sequencing of the immuno-
precipitated DNA is an expeditiously becoming a very important method for 
understanding the mechanisms of Protein: DNA interactions and gene regulation by 
transcription factors. The sequencing of ChIP processed DNA is carried out by Center for 
Genome Technology (CGT) of John P. Hussman Institute for Human Genomics of Miller 
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School of Medicine at University of Miami. CGT facility used DNA SMART ChIP-Seq 
Kit (Clontech Laboratories, Inc.) which generated Illumina-compatible sequencing 
libraries from 100 pg–10 ng of single- stranded (ss) or double-stranded (ds) DNA 
resulting from chromatin immunoprecipitation (ChIP) experiments (Nos, 2012).  
Clontech’s template switching technology, known as SMART® (Switching Mechanism 
at 5’ End of RNA Template), has been used as a basis for cDNA synthesis for next-
generation sequencing (NGS) applications (Zhu, Machleder, Chenchik, Li, & Siebert, 
2001). The CGT facility generated ChIP-Seq libraries with the DNA SMART ChIP-Seq 
Kit, a priming site is first added to the 3’ end of the DNA template using the Terminal 
Deoxynucleotidyl Transferase. This is followed by annealing of a proprietary DNA 
SMART Poly(dA) Primer, which anneals to the T-tail added by the Terminal 
Deoxynucleotidyl Transferase. This primer is then used by the SMARTScribe™ Reverse 
Transcriptase (RT) to copy the DNA strand. When the SMARTScribe RT reaches the 5’ 
end of the DNA template, the enzyme’s terminal transferase activity adds a few 
additional nucleotides to the 3’ end of the newly synthesized DNA. The carefully 
designed DNA SMART Oligonucleotide base-pairs with these additional non-template 
nucleotides and creates an extended template, enabling the SMARTScribe RT to continue 
replicating to the end of the oligonucleotide. Sequencing libraries are then generated by 
PCR-mediated addition of Illumina adapters using primers compatible with regions on 
the DNA SMART Poly(dA) Primer and the DNA SMART Oligonucleotide  (“Illumina 
Adapter Sequences Illumina Adapter Sequences Illumina Adapter Sequences,” 2017). 
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Figure 58- The diagrammatic representation of workflow of ChIP-seq experiment 
carried out using HPMEC (Control), HPMEC ID3+, and HPMEC ID3+ + E2 cell 
samples. 
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After elution of DNA sample, we used the Chromatin Immunoprecipitation (ChIP) DNA 
Clean & Concentrator™ from ZYMO RESEARCH CORP. for the rapid purification and 
concentration of high quality DNA. The ChIP DNA Clean & Concentrator™ employs a 
single buffer system that allows for efficient DNA adsorption to the matrix of the 
supplied Zymo-Spin™ Column as shown in Figure 59.  
Reagent Preparation- 
Before starting, we added 24 mL 100% ethanol to the 6 mL DNA Wash Buffer 
concentrate to obtain the final DNA Wash Buffer solution. In 1.5 mL micro centrifuge 
tube, add 5 volumes of ChIP DNA Binding Buffer to each volume of sample (5:1). 
Mixed briefly. We transferred mixture to a provided Zymo-Spin™ Column in a 
Collection Tube. Centrifuged at ≥ 10,000 x g for 30 seconds.  
We added 200 µl Wash Buffer to the column. Centrifuge at ≥ 10,000 x g for 30 seconds. 
Repeat wash step. We added 6-100 µl Elution Buffer directly to the column matrix. 
Transfer the column to a new 1.5 mL micro centrifuge tube and centrifuge at ≥ 10,000 x 
g for 30 seconds to elute the DNA. Ultra-pure DNA is now ready for use for DNA 
quantification, sequencing and other molecular applications. 
 Figure 59- The diagrammatic representation of elution of clean DNA sample using 
the Chromatin Immunoprecipitation (ChIP) DNA Clean & Concentrator™ from 
ZYMO RESEARCH CORP. 
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Then we measured the concentration of DNA in samples and inputs with the help of 
BioRad spectrophotometer as shown in Table 3.  
 
DNA sequencing- 
We performed ChIP sample and input sequencing analysis at Center for Genome 
Technology (CGT) of University of Miami Miller School of Medicine. This genomic 
facility center used DNA SMART ChIP-Seq Kit (Clontech Laboratories, Inc. A Takara 
Bio Company) which generated Illumina-compatible sequencing libraries from 100 pg–
10 ng of single- stranded (ss) or double-stranded (ds) DNA resulting from chromatin 
immunoprecipitation (ChIP) experiments. 
Clontech’s template switching technology, known as SMART® (Switching Mechanism 
at 5’ End of RNA Template), has been used as a basis for cDNA synthesis for next-
generation sequencing (NGS) applications (Zhu, Machleder, Chenchik, Li, & Siebert, 
2001). The CGT facility generated ChIP-Seq libraries with the DNA SMART ChIP-Seq 
Sample details Sample 
Conc. 
Units Volume 
(uL) 
260/280 
Ratio 
Input vector 94.6295 pg 95µl 1.8603 
Input ID3 expressing 67.155 pg 95µl 1.8065 
Input ID3 expressing with estrogen 
treatment 
31.844 pg 95µl 1.8621 
Sample vector 195.9 pg 95µl 1.8292 
Sample ID3 expressing 76.1805 pg 95µl 1.8706 
Sample ID3 expressing with estrogen 
treatment 
53.694 pg 95µl 1.8867 
Table 3- The information about the sample like concentration, volume and quality. 
Table    
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Kit, a priming site is first added to the 3’ end of the DNA template using the Terminal 
Deoxynucleotidyl Transferase. This is followed by annealing of a proprietary DNA 
SMART Poly (dA) Primer, which anneals to the T-tail added by the Terminal 
Deoxynucleotidyl Transferase. This primer is then used by the SMARTScribe™ Reverse 
Transcriptase (RT) to copy the DNA strand. When the SMARTScribe RT reaches the 5’ 
end of the DNA template, the enzyme’s terminal transferase activity adds a few 
additional nucleotides to the 3’ end of the newly synthesized DNA. The carefully 
designed DNA SMART Oligonucleotide base-pairs with these additional non-template 
nucleotides and creates an extended template, enabling the SMARTScribe RT to continue 
replicating to the end of the oligonucleotide. Sequencing libraries are then generated by 
PCR-mediated addition of Illumina adapters using primers compatible with regions on 
the DNA SMART Poly(dA) Primer and the DNA SMART Oligonucleotide as shown in 
Figure 60  (“Illumina Adapter Sequences Illumina Adapter Sequences Illumina Adapter 
Sequences,” 2017). 
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Figure 60- The diagrammatic workflow represents addition of adapter sequences at 
both ends of ChIP DNA using Clontech’s template switching technology, known as 
SMART® 
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SAMPLE  SAMPLE 
ID 
PF 
Clusters 
Index Seq Clontech 
DUAL Index 
ligated 
(Lot#1511520a) 
TruSeq 
HT 
Input vector 201700231-
01 
22,746,865 ATTACTCG-
ATAGAGGC 
R1-F2 D701-
D502 
Input ID3 
expressing 
201700232-
01 
24,084,017 TCCGGAGA-
ATAGAGGC 
R2-F2 D702-
D502 
Input ID3 
expressing 
with estrogen 
treatment 
201700233-
01 
21,705,440 CGCTCATT-
ATAGAGGC 
R3-F2 D703-
D502 
Sample 
vector 
201700234-
01 
22,093,845 GAGATTCC-
ATAGAGGC 
R4-F2 D704-
D502 
Sample ID3 
expressing 
201700235-
01 
22,999,843 ATTCAGAA-
ATAGAGGC 
R5-F2 D705-
D502 
Sample ID3 
expressing 
with estrogen 
treatment 
201700236-
01 
24,738,084 GAATTCGT-
ATAGAGGC 
R6-F2 D706-
D502 
 
 
 
After adapter sequences addition at both ends of ChIP-Seq DNA, Illumina sequencing 
machine at CGT facility processed ChIP-Seq DNA information into computer files as 
shown in table 4. We received the raw ChIP-Seq input and sample files (.txt files) in the 
paired end sequenced format. Therefore, all the input and sample ChIP-Seq files have 
two files each (Part 1 and 2). All Illumina NGS (next-generation sequencing) systems are 
capable of paired-end sequencing as shown in Table 5. The paired-end sequencing reads 
are very crucial and significant in the case of detection of genomic rearrangements such 
as insertions, deletions, and inversions. It also facilitates users to detect the repetitive 
sequence elements, as well as gene fusions and novel transcripts. Essentially, it provides 
Table 4- It illustrates the list of Illumina adapters used to make sequencing 
libraries. 
These adapters are used for labeling the samples in sequence analyzer machine 
 
 
Table-2  
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superior alignment to a reference across DNA regions containing repetitive sequences, 
which improves the quality of the entire data set. It also produces longer contigs for de 
novo sequencing by filling gaps in the consensus sequence.  
 
Field Description Examples 
STUDY Official HIHG project name 
OR PI name for external 
AUT, PD, jHendrix 
SPECIES Species h.sapiens 
PREP_TYPE protocol used for sample 
preparation 
Agilent SS 38Mb exome, 
Nimblegen custom 1.5Mb, 
Illumina Multiplexing, whole 
genomic, ChIP-Seq, Illumina 
mRNAseq, Ribominus Whole 
Transcriptome, Nugene Whole 
Transcriptome, etc. 
PLATFORM platform GA, Solid, HiSeq 
RUN_TYPE single-read=1x, paired-
end=2x followed by read 
length;              Full, Quad, 
Octet Refer to spots on 
SOLiD slide 
1x36, 2x50, 2x75, Full 1x50, 
Octet 1x50 
ALIGN_TO reference used for alignment whole genome, custom, chr3 
only 
HIHG_ID HIHG generated sample 
number 
200425179-12 
CONCENTRATION Concentration 10 
CONC_UNIT Concentration unit ng/µL 
METHOD instrument used to measure 
concentration 
nanodrop, bioA, qubit, 
picogreen, qPCR 
VOLUME DNA Volume in above 
concentration unit 
55 
VOL_UNIT Volume unit µL 
 
 
 
Table 5- It illustrates the information about sequencing carried out by Illumina 
sequencing machine at CGT facility. 
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Methodology to analyze the ChIP-Sequencing data  
 
 
All Sanger format files saves the data in .txt files as shown in Figure 61. These files can 
be used as a raw data to process further analyses like peak finding, differential binding of 
protein of interest and comprehensive motif analysis (including motif discovery) of ChIP-
Seq workflows. We analyzed the ChIP-Seq data by using tools available at Galaxy 
platform (Afgan et al., 2016).  We uploaded the raw .txt files of input and samples in 
Galaxy server with the help of FileZilla which a free software, cross-platform file transfer 
protocol (FTP) application, consisting of FileZilla Client and FileZilla Server. We have 
used FileZilla to upload large sized .txt Sanger files to the Galaxy server as shown in 
Figure 62.  
Figure 61- It shows in pictorial format that what kind of information we get in the 
form FASTA format from sequencing machine. 
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• Step 1: Go to the web server, usegalaxy.org 
• Open a web browser and go to usegalaxy.org 
• Let’s Register 
• Click “User”  “Register” 
Figure 62- Diagrammatic representation of workflow of how to use Galaxy platform 
to upload the raw FASTA files from computer. 
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The FASTQ format files are saved in .txt files in local computers and contains DNA 
sequencing trace files. PHRED software evaluates and accredits certain quality value to 
the DNA sequences also known as bases (Ewing & Green, 1998). The quality value of 
each base is estimated in terms of probability of error. Sanger FASTQ format utilize 
ASCII 33–126 to encode PHRED qualities from 0 to 93 (i.e. PHRED scores with an 
ASCII offset of 33). In order to understand the file, Sanger FASTQ format restricted the 
choices to the ASCII printable characters 32–126 (decimal). The following example 
illustrates the application of PHRED score in Sanger FASTQ format files as shown in 
Figure 63.  
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 Figure 63- Diagrammatic illustrates the application of PHRED score in Sanger 
FASTQ format files. 
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Since the newer machines are in Sanger format 1.9, Galaxy requires 1.8. The uploaded 
.txt files converted using FASTQ Groomer within Galaxy in order to make Galaxy 
recognize the format (Blankenberg et al., 2010). We also ran FastQC analysis on these 
files. FastQC is a Java based quality control tool for raw high throughput sequence data ( 
Andrews, 2016). The following tables illustrate the FastQC analysis of our pair ended 
raw datasets as shown in table 6. FastQC tool produces a basic text and a HTML output 
file that contain all of the results, including the following (Andrews, 2010). We have 
discussed some of the outputs from the following list: 
 
 Basic statistics- It generates some simple composition statistics for the file 
analyzed. The following tables illustrate basic information of the ChIP-Seq files. 
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Name  Filename Encoding Total 
Sequences 
Sequence 
length 
%GC 
Sample 
vector 1 
qFelty_ID3chipseq_201700234-
01_S_8_1.txt 
Sanger / 
Illumina 
1.9 
22093845 35-125 40 
Sample 
vector 2 
qFelty_ID3chipseq_201700234-
01_S_8_2.txt 
Sanger / 
Illumina 
1.9 
22093845 35-125 36 
Sample ID3 
expressing 
qFelty_ID3chipseq_201700235-
01_S_8_1.txt 
Sanger / 
Illumina 
1.9 
22999843 35-125 41 
Sample ID3 
expressing 
2 
qFelty_ID3chipseq_201700235-
01_S_8_2.txt 
Sanger / 
Illumina 
1.9 
22999843 35-125 40 
Sample ID3 
expressing 
with 
estrogen 
treatment 1 
qFelty_ID3chipseq_201700236-
01_S_8_1.txt 
Sanger / 
Illumina 
1.9 
24738084 35-125 41 
Sample ID3 
expressing 
with 
estrogen 
treatment 2 
qFelty_ID3chipseq_201700236-
01_S_8_2.txt 
Sanger / 
Illumina 
1.9 
24738084 35-125 40 
 
 
 
 
 
 
 
 
 
Table 6- It illustrates the quality and information about sequences of ChIP Seq files 
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 Per base sequence quality – This output measures the overall range of quality 
values across all bases at each position in the FastQ file. 
 
 
For each position a Box Whisker type plot is drawn. The elements of the plot are as 
follows: 
 The central red line is the median value 
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 The yellow box represents the inter-quartile range (25-75%) 
 The upper and lower whiskers represent the 10% and 90% points 
 The blue line represents the mean quality 
The y-axis on the graph shows the quality scores. The higher the score the better the base 
call. The background of the graph divides the y-axis into very good quality calls (green), 
calls of reasonable quality (orange), and calls of poor quality (red). 
 Per sequence quality scores 
 
The per sequence quality score report allows to see if a subset of sequences have 
universally low quality values. A warning is raised if the most frequently observed mean 
quality is below 27 - this equates to a 0.2% error rate. 
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 Per Base Sequence Content- It plots out the proportion of each base position in a 
file for   which each of the four normal DNA bases has been called. 
 
 Per sequence GC content- This module measures the GC content across the whole 
length of each sequence in a file and compares it to a modelled normal 
distribution of GC content.  
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 Per base N content 
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 Sequence Duplication Levels 
 
 Kmer content 
 
Out of all the outputs generated from FastQC analysis, per base sequence quality and 
sequence duplication levels are the most significant and useful outputs for further 
analysis. The sequence quality is calculated and measured on the basis of PHRED score ( 
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Andrews, 2010; Cock, Fields, Goto, Heuer, & Rice, 2009). The bad quality sequences are 
removed from the raw Fastq files as shown in the following Figures by trimming the 
sequences. We used Trimmomatic tool to trim the bases in ChIP-Seq file. Trimmomatic 
tool is a more flexible, pair-aware and efficient preprocessing tool, optimized for Illumina 
NGS data (Bolger, Lohse, & Usadel, 2014). It is also equipped with the identification of 
short adapter sequences and quality filtering. It effectively removes the common ‘adapter 
read-through’ scenario, whereby the sequenced DNA fragment is shorter than the read 
length in both single and paired end data. In order to perform Trimmomatic operation on 
adapter sequence on our data, we selected TrySeq2 (paired-ended, for Illumina GAII) 
option.  
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The following diagrammatic process shows the Trimmomatic trimming tasks as shown in 
Figure 64. 
 
 
 
Figure 64- Diagrammatic representation of settings used in Trimmomatic software to 
trim the pair end adaptor sequences. 
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Trimmomatic process the paired end data in specific way and gives out the output of 
trimmed forward and reverse paired ended files. The following diagram reprenets process 
of Trimmomatic operation on paired end reads as shown in Figure 65 (Bolger et al., 
2014; Usadellab, ). We then used these trimmed forward and reverse paired ended files as 
sample input to align with reference human genome –Human Dec. 2013 (GRCh38/hg38) 
(hg38) (Miga et al., 2014a).  
 
 
 
Read alignment/mapping with BOWTIE2 
Bowtie2 is ultrafast read aligner and its algorithm coded by Ben Langmead. It is an 
ultrafast and memory-efficient tool for aligning sequencing reads to long reference 
sequences. Bowtie2 outputs alignments in BAM format, enabling interoperation with a 
Figure 65- Flow of reads in Trimmomatic Paired End mode. 
Trimmomatic process the paired end data in specific way and gives out the output 
of trimmed forward and reverse paired ended files 
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large number of other tools available at this site (Langmead and Salzberg, 2013). It 
combines strengths of the full-text minute index with the flexibility and speed of 
hardware-accelerated dynamic programming algorithms. We used Bowtie2 to align 
trimmed paired reads with hg38 reference genome and used following settings shown in 
the Figures 66 and 67.   
 
 
 
 
 
 
Figure 66- Paired end sequencing enabled both ends of fragments to be sequenced. 
The distance between each paired read is known, alignment algorithms can use this 
information to map the reads over repetitive regions more precisely. 
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Figure 67- Settings used in Bowtie2 for Paired end sequencing. 
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Bowtie2 gives output in the BAM format. The BAM format provides binary versions of 
store sequence data, both aligned as well as unaligned, but not in a human readable 
format. It is not easy to process by conventional text based processing programs, such as 
awk, sed, and python (Genome Analysis, 2013). Therefore, we converted BAM file into 
BED format with the help of bedtools, which converts sequence alignments in BAM 
format into BED, BED12, and/or BEDPE records as shown in Figure 68. We used 
following settings for bedtools. 
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Figure 68- Settings used in conversion BAM files from Bowtie2 software into 
BED format. 
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Peak Finding and Data Analysis 
Introduction- 
Peak calling is a very crucial step in ChIP-Seq workflow and study genome-wide protein-
DNA interactions. Peak calling is a computational method used to identify areas in a 
genome that have been enriched with aligned reads as a consequence of performing a 
ChIP-Sequencing experiment. These areas are those where a protein interacts with DNA 
(Pepke, Wold, & Mortazavi, 2009).When the protein is a transcription factor, the 
enriched area is its transcription factor binding site (TFBS).We used the powerful novel 
algorithm, named Model-based Analysis of ChIP-Seq (MACS), for identifying protein 
interest binding sites on DNA. MACS2 is capable of capturing enriched ChIP region and 
improves the spatial resolution of binding sites through combining the information of 
both sequencing tag position and orientation in spite of genome complexity. MACS2 
increases the specificity of callpeak function by comparing with the control. MACS2 
estimates reads for a given location by assuming mean of the Poisson from control 
experiment (background reads) in 5 Kbp or 10 Kbp around the examined location. If 
reads in sample file comes out more than would have expected from the Poisson (p < 
0.00005), then MACS2 calls a peak i.e. build model for peaks. ID3 ChIP was performed 
using SC-490 polyclonal Anti-ID3 antibody as described above. Two Illumina TruSeq 
ChIP libraries were constructed from ChIP and input control DNA and sequenced using 
Illumina HiSeq 2500 by Center for Genome Technology (CGT) of John P. Hussman 
Institute for Human Genomics of Miller School of Medicine at University of Miami.  We 
performed ChIP-Seq analysis using various tools available at Galaxy, which is an open 
source, web-based platform (Afgan et al., 2016). FASTQ reads were uploaded to the 
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galaxy server platform (Afgan et al., 2016) with the help of FileZilla which is a free 
software, cross-platform file transfer protocol (FTP) application, consisting of FileZilla 
Client and FileZilla Server. We also ran FastQC analysis on these files. FastQC is a Java 
based quality control tool for raw high throughput sequence data (Andrews, 2016). Then 
FASTQ file trimmed with identification of short adapter sequences and quality filtering 
by Trimmomatic software (Bolger et al., 2014). Then these reads mapped to the human 
genome –Human Dec. 2013 (GRCh38/hg38) (hg38) (Miga et al., 2014a) using Bowtie2 
with default settings (Langmead & Salzberg, 2012). Next, peaks are found using peak-
calling algorithms. Peak calling was performed using Model-based analysis for ChIP-Seq 
(MACS2 (2.1.0) options gsize 2451960000 --bw 300 --ratio 1.0 --slocal 1000 --llocal 
10000 --keep-dup 1 --bdg --qvalue 0.05 ‘‘--tsize=35 --, lower mfold=5, lower mfold= 50,   
--pvalue=1e-5’’) on each ChIP-Seq file against the matching input file (Feng, Liu, Qin, 
Zhang, & Liu, 2012; Zhang et al., 2008). For the analysis, peaks with a false discovery 
rate (FDR) of <5% were selected. MACS2 is very conducive and it yields detailed 
information for each peak, such as genome coordinates, p-value, FDR, fold enrichment, 
and summit (peak center). For further processing, we converted tabular format file of 
MACS2 call peak into interval type by modulating settings. We filtered the data file by 
setting cut off value for the fold enrichment of the peaks above 5. The summit of the peak 
represent maximum binding probability of transcription factor or protein of interest on 
the particular position of DNA. Therefore, we decided to select 200 base pairs region 
around summit location which is also called as summit region. In order to get summit 
region we subtracted and added 100 base pairs from summit location. Then cut down the 
three columns containing chromosome number, start site of summit region of peak and 
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end site of summit region of peak. This process resulted into 200 base pairs region of 
peak, which signifies most predictable binding sites of our protein of interest ID3. These 
peaks with start and end position associated with chromosome number were copied and 
pasted in tested region in the Genomic Regions Enrichment of Annotations Tool 
(GREAT). GREAT uses ChIP-Seq identified binding events as the TFs binding region on 
DNA. GREAT associates the proximal and distal transcription start site (TSS) of target 
gene to the genomic region and then annotates these genomic regions with gene 
ontologies. GREAT uses statistical algorithm to study enrichment analysis for the 
associations between genomic regions with annotations. GREAT requires statistical 
significance from binomial test, but also filters on fold enrichment to identify 
enrichments of large effect (McLean et al., 2010). GREAT works perfectly to annotate 
the peaks (genomic regions) with known genes but it uses Human: GRCh37 (UCSC 
hg19, Feb/2009) as a reference genome, which is earlier version of Human reference 
genome as shown in Figure 69. In order to annotate the peak regions with genes of 
updated version of human genome- Human Dec. 2013 (GRCh38/hg38) (hg38), we used 
RnaChipIntegrator. RnaChipIntegrator integrates analyses of genes (or other genomic 
feature data) against a set of peaks of ChIP data (Additional file 5), identifying the 
nearest peaks to each feature and vice versa (Briggs, Donaldson, 2010 ). 
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Method-  
The collections of aligned reads (three ChIP-Seq and three input controls) were 
normalized to the same sequencing depth by randomly removing aligned reads. 
Duplicated reads were removed before normalization. Peak finding was carried out by 
running MACS2 (Zhang et al. 2008; options ‘‘--tsize=35 --bw=110, lower mfold=5, 
lower mfold= 50,   --pvalue=1e-5’’) on each ChIP-Seq file against the matching input 
Figure 69- Diagrammatic representation of Peak finding analysis process of 
MACS2 software. (from Zhang et al. Model-based Analysis of ChIP-Seq 
(MACS). Genome Biology (2008) vol. 9 (9) pp. R137) 
MACS2 empirically models the shift size of ChIP-Seq tags, and uses it to improve 
the spatial resolution of predicted binding sites of protein of interest in this case ID3. 
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file. For the analysis, peaks with a false discovery rate (FDR) of <5% were selected. 
MACS2 is very conducive and yield detailed information for each peak, such as genome 
coordinates, p-value, FDR, fold enrichment, and summit (peak center) as shown in Figure 
70. 
 
 
 
Figure 70- Settings used in MACS2 software for peak finding analysis. 
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For further processing, we converted tabular format file of MACS2 call peak into interval 
type by modulating settings. We filtered the data file by setting cut off value for the fold 
enrichment of the peaks above 5 as shown in Figure 71. 
 
 
 
 
 Figure 71- Setting used for sorting the peak data. 
The cut off value for the fold enrichment of the peaks above 5 used in MACS2 software. 
161 
 
 
From the above table, we selected summit location of each peak region. The summit 
location is considered to be the center location of the peak. Each peak region generally 
consists of 500-600 base pairs. The above table shows the start and end location of the 
peak correspond to chromosome number. The summit of the peak represents maximum 
binding probability of transcription factor or protein of interest on the particular position 
of DNA. Therefore, we decided to select 200 base pairs region around summit location, 
which is also called as summit region. In order to get summit region we subtracted and 
added 100 base pairs from summit location. Then cut down the three columns containing 
chromosome number, start site of summit region of peak and end site of summit region of 
peak. This process resulted into 200 base pairs region of peak, which signifies most 
predictable binding sites of our protein of interest ID3. The process is shown in the 
following Figure 72.  
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Figure 72- Diagrammatic representation of workflow of setting use for selecting 
only 200 bp region around summit location of peaks and chromosome number of 
peaks. 
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These peaks with start and end position associated with chromosome number copied and 
pasted in tested region in the Genomic Regions Enrichment of Annotations Tool 
(GREAT). GREAT uses ChIP-Seq identified binding events as the TFs binding region on 
DNA. GREAT associates the proximal and distal transcription start site (TSS) of target 
gene to the genomic region and then annotates these genomic regions with gene 
ontologies. GREAT uses statistical algorithm to study enrichment analysis for the 
associations between genomic regions with annotations as shown in Figure 73. GREAT 
requires statistical significance from binomial test, but also filters on fold enrichment to 
identify enrichments of large effect (McLean et al., 2010).  
 
 
Figure 73- The Diagrammatic representation of workflow of setting used for peak 
data in GREAT software. 
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Motif discovery 
We used MEME-ChIP 4.3.0 (Bailey, 2011; Ma, Noble, & Bailey, 2014) to discover 
motifs. We selected 10% of the strongest peaks for each experiment (reads under peak). 
The location of the peak was extracted and extended by 100 bp on either side. MEME 
was instructed to report the top 10 motifs between 5 and 30 bases in length. We accepted 
all motifs that showed significant similarity (S. Gupta, Stamatoyannopoulos, Bailey, & 
Noble, 2007) to the reported motif (Mathelier et al., 2014; Sandelin, 2004), MA0074.1, 
P-value <1 × 10-5). MEME was instructed to report the top 10 motifs between 5 and 30 
bases in length. We accepted all motifs that showed significant similarity motifs present 
in HOmo sapiens COmprehensive MOdel COllection (HOCOMOCO) v11 database 
(Kulakovskiy et al., 2017). The options were set to perform MEME-ChIP (DREME E-
value ≤0.05, CentriMO score ≥5).  
Data Visualization  
We used Integrated Genome Browser (IGB) which is an open-source tool for visualizing 
of ChIP Seq datasets (Freese, Norris, & Loraine, 2016). To visualize the data, we selected 
human genome –Human Dec. 2013 (GRCh38/hg38) (hg38) as a refrence genome and 
then uploaded the Bowtie2 mapped aligned sequenced .BAM file and MACS2 generated 
ID3 peaks .BED file in the IGB. In order to visualize the peaks, we followed the IGB user 
guide instructions.  We viewed genomic sequence of peaks with highest peak score and 
peaks which fall into the promoter region of gene with the help of IGB Genomic 
Sequence Viewer. In order to check the peaks in the promoter region of the gene, we used 
RnaChipIntegrator (Briggs, Donaldson, 2010) which shows the information of 
overlapping peaks into the promoter region of the gene.  
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Results 
Global identification of ID3 binding sites in HPMEC and HPMEC cells by ChIP-
Seq analysis 
In order to understand the global binding patterns of ID3, we applied ChIP-Seq 
technology, which is a novel approach for identifying transcription factor binding sites 
genome-wide (Barski et al., 2007; Johnson, Mortazavi, Myers, & Wold, 2007). We 
performed experiment in replicates of HPMEC ID3+ ChIP and HPMEC ChIP samples. 
After sequencing analysis, we obtained a total of 45,999,686 and 44,187,690 sequence 
tags respectively for HPMEC ID3+ ChIP and HPMEC ChIP that were mapped uniquely 
using Bowtie2 to the reference human genome GRCh38 (hg38) by allowing two 
mismatches (Miga et al., 2014b; Univeristy of California Santa Cruz, 2013b) (Langmead 
& Salzberg, 2012) . Peak calling was performed on HPMEC ID3+ ChIP sample using 
Model-based analysis for ChIP-Seq (MACS2 (2.1.0) on each ChIP-Seq file against the 
matching input file (Feng et al., 2012; Zhang et al., 2008). The q-value =0.01 (minimum 
FDR) cutoff to call significant regions. Using MACS2, we identified a total of 2493 ID3 
peaks in HPMEC ID3+ ChIP using control ChIP-Seq data as the negative control. These 
mapped regions then associated with gene ontologies with the help of GREAT software 
which uses GRCh37 (hg19) as a reference genome (McLean et al., 2010). GREAT 
associated 2336 ID3 peak-binding regions (200 base pairs bp) around summit location of 
the peak) of HPMEC ID3+ ChIP sample to transcription start site (TSS) of 2834 known 
genes (Fig.68B) (Additional file 1). Out of 2834 known genes, 470 genes were associated 
with only one binding region, 1589 genes were associated with two regions and 1 gene 
was associated with three regions (Fig.75B). Results additionally showed 276 genes were 
not associated with any region. We calculated the distance of the ID3 binding regions to 
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TSS (transcription start sites) and then tabulated the frequency across the distance 
intervals before TSS and after TSS against region-gene association (Fig. 75A). Figure 
75A shows that distance of peak around the TSS sites. We found that about 4.19% ID3 
(153 of 3651) binding regions were mapped within ±5 Kb of TSS (Figure 68B), and 
about 24.92% (910 binding regions) were mapped within ± 50 Kb of TSS. Similarly, 
MACS2 identified 3603 ID3 binding regions i.e. peaks in HPMEC ChIP sample using 
control ChIP-Seq data as the negative control. GREAT associated 3516 ID3 peaks 
binding regions (200 bp around summit location of the peak) that were mapped to TSS 
(transcription start site) of 3935 known genes (Fig.76B) in HPMEC ChIP sample 
(Additional file 2). Out of 3935 known genes, 782 genes were associated with only one 
binding region, 2524 genes were associated with two regions per gene. While 208 genes 
were not associated with any region. We calculated the distance of the ID3 binding 
regions to TSS (transcription start sites) in HPMEC ChIP sample and then tabulated the 
frequency across the distance intervals before TSS and after TSS against region-gene 
association (Fig. 3A). Figure 76A shows that the distance of peak around the TSS sites. 
We found that about 3.86% ID3 (226 of 5841) binding regions were mapped within ±5 
kb of TSS (Figure 76B), and about 22.80% (1332 binding regions) were mapped within ± 
50 kb of TSS. Furthermore, we also checked the genome-wide protein-DNA interaction 
patterns for HPMEC ID3+ ChIP and HPMEC ChIP data with the help of CEAS (cis-
regulatory element annotation system) tool which provides summary statistics on ChIP 
peaks enrichment in important genomic regions such as individual chromosomes, 
promoters, gene bodies or exon (Shin, Liu, Manrai, & Liu, 2009) (Fig.77). Association of 
ID3 bound regions with annotated genomic features indicated that ID3 tends to localize 
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within intronic regions. A total of 37.4% and 41% peaks were found in HPMEC ID3+ 
ChIP and HPMEC ChIP samples respectively. Very small percentage of peaks were 
found in the coding exons which comprised of 0.6% and 0.5% in HPMEC ID3+ ChIP 
and HPMEC ChIP samples respectively. 5'-UTR regulatory regions showed 1.3% and 
0.3% of peaks in HPMEC ID3+ ChIP and HPMEC ChIP samples respectively (Figure 
77). In addition, ID3 binding sites were found to be localized in the promoter region of 
the gene in HPMEC ID3+ ChIP (3.7%) and HPMEC ChIP (3.6%) samples (Figure 77). 
We identified ID3 target genes by GREAT and compared the genes between HPMEC 
ID3+ ChIP and HPMEC ChIP samples in Fig. 78. We found total of 1240 ID3 gene 
targets between both ChIP Seq samples. We found only 22.4% similarity in the genes 
associated with binding regions of ID3 in both ChIP Seq samples. These findings may 
suggest that ID3-depedent binding to DNA is different in the HPMEC (wild type) and 
HPMEC ID3+ cell lines. 
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Figure 75 A- The graphical representation of MACS2 generated peaks for 
HPMEC ID3+ cell sample binned by orientation and distance to TSS. B) The 
graphical representation of number of gene associated per ID3 binding peak 
regions by GREAT tool.   
Figure 74- The Diagrammatic representation of workflow of ChIP-Seq experiment 
carried out using HPMEC (Control), HPMEC ID3+, and HPMEC ID3 + E2 cell 
samples. 
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Figure 76A) The graphical representation of MACS2 generated peaks for 
HPMEC cell sample binned by orientation and distance to TSS.  B) The 
graphical representation of number of gene associated per ID3 binding peak 
regions by GREAT tool. 
Figure 77- Diagrammatic representation of MACS2 identified ChIP peaks 
characteristics created with the help of CEAS tool. Diagrams show percentage of 
peaks overlapping with gene features for ChIP-Seq HPMEC and HPMEC ID3+ cell 
samples. 
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Snyder et al. recently used ChIP Seq to map binding sites of eGFP-ID3 and other key TFs 
on human K562 cell line (ENCSR005NMT) and made data available at ENCODE. We 
used GEO accession: GSE91408 data from ENCODE to check ID3 binding regions 
(Dunham et al., 2012; Sloan et al., 2016). We processed 
GSE91408_ENCFF468VTJ_optimal_idr_thresholded_peaks_GRCh38.bigBed file to 
annotate the peak or binding regions of ID3 to gene annotation using GREAT. We found 
total of 9717 genes were associated with 24336 binding regions of ID3 in ENCODE data. 
When we compared the genes generated from HPMEC ID3+ ChIP Seq data with 
ENCODE ID3 – K562 ChIP data, 64.60% (1831 out of 2834 genes) of genes of HPMEC 
ID3+ ChIP seq data were overlapped with ENCODE ID3 – K562 ChIP data (Fig.79) 
(Additional file 3). The difference between numbers of genes associated with ID3 
binding region of HPMEC ID3+ ChIP-Seq data and ENCODE ID3 – K562 ChIP data 
could be due to the use of different cell line (HPMEC VS K562), different antibodies, 
Figure 78- A Venn diagram showing the overlap of ID3 target genes among 
HPMEC and HPMEC ID3+ cell samples. 
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Snyder et al. used the anti-GFP antibody (11814460001, Roche) or differences in the 
analysis pipeline and downstream analysis procedures. 
 
 
This suggests that there are common sets of genes regulated by ID3 in humans K562 cells 
and in HPMEC cells. However, we identified many ID3 binding sites that are only 
present in the HPMEC cell line, suggesting that ID3 targets different genes in the context 
of lung EC cells. These findings clearly validated ChIP-Seq as an efficient and powerful 
technique for mapping ID3 binding sites in HPMEC cells.  
Identification of the DNA binding consensus sequences of ID3 and other known TF 
binding sites in the ID3 bound regions of the ChIP data. The recognition of 
interaction of ID3 protein with TFs found from ChIP-Seq data. 
To find out the de novo ID3 binding sequence in the ID3 binding regions (peak regions) 
of HPMEC and HPMEC ID3+ cell ChIP samples, we used the MEME-ChIP suite 
Figure 79- A Venn diagram showing the overlap of ID3 target genes among 
ENCODE ID3 – K562 and HPMEC ID3+ ChIP data. 
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program (Bailey, 2011; Ma et al., 2014). We also checked whether other TFs have their 
own unique and enriched binding motifs in the ID3 binding regions of HPMEC ID3+ and 
HPMEC ChIP sample that we identified. We found a repeated sequence of 
GAGAGAGAGAGAGAGAGAGAGAGAGAGAGA with a very high E-value of 2E-62 Enriched 
motifs (E-value ≤ 10 using the binomial test) in HPMEC ID3+ ChIP sample. There are 
348 instances at which this motif found in 2493 ID3 binding regions. We also manually 
checked GAGAGAGAGAGA repeat sequences in peaks with highest peak score and 
peaks which fall into the promoter region of gene identified by RnaChipIntegrator 
(Briggs, Donaldson, 2010). The data is visualized with the help of Integrated genome 
browser (IGB) which is a visual analytics platform for ChIP seq data analysis (Freese et 
al., 2016). In addition, we also processed ID3 bound peak regions of HPMEC ChIP 
sample and found most significant, unknown motif 
TCCCAGCWMYTYGGGAGGCTGAGGCRGGAG sequence with a very high E-value 
Enriched motifs (E-value ≤ 10 using the binomial test) of 1.30E-05. There are 45 
instances of this motif found in 3603 ID3 binding regions. To identify possible 
interactions between ID3 and other TFs, MEME-ChIP suite containing DREME and 
Centrimo screening was performed to identify the other most over-represented motifs or 
consensus sequences of TFs in the ID3 binding regions identified by MACS2 (Bailey, 
2011; Ma et al., 2014). We found IRF1, BC11A, IRF4, PRDM1, FOXJ3, SMAD4, 
ZBTB6, GATA1, and STAT2 TFs binding motifs in the binding region of HPMEC ID3+ 
ChIP sample (Table 7). The consensus sequences with their associated TFs for HPMEC 
ID3+ ChIP sample are shown in Table 7. In addtion to this, the consensus sequences with 
their associated TFs ZBT7B, NKX28, TGIF1, RFX2, MYOG, ZBT18, MXI1, SOX2, 
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MAF, MEIS1, SOX3, SOX9 ,and TBX3 for HPMEC ChIP sample are shown in Table 8. 
We have shown all three samples MEME-ChIP generated output in additional file 4. 
Since ID3 lacks DNA binding domain, it regulates the transcription machinery in a 
dominant negative manner. ID3 binds to basic Helix-loop-helix I (bHLH I) proteins via 
the helix loop helix (HLH) motif. ID3 protein interactions block the DNA binding 
activity of basic HLH (bHLH) transcription factors (Doke et al., 2018). The molecular 
mechanism for the role of ID3 proteins in the transcriptional control was initially thought 
to be only dependent on its ability to dimerize with bHLH factors acting as dominant-
negative. Nevertheless, in addition to bHLH proteins, researchers have shown the 
interaction of ID3 with non-bHLH proteins. Researchers have shown that ID3 interaction 
with Pax-5 and ternary complex factor (TCF) subfamily of ETS-domain proteins 
(Roberts, Deed, Inoue, Norton, & Sharrocks, 2001; Yates, Atherton, Deed, Norton, & 
Sharrocks, 1999). Therefore, it is important to know that TFs could bind to the ID3 
binding regions that we identified and act as ID3 cooperators for the regulation of gene 
expression. We compared known TFs which were generated using MEME-ChIP suite 
analysis from HPMEC ID3+ and HPMEC ChIP samples. We did not find any TFs 
overlapped between both HPMEC ID3+ and HPMEC ChIP samples. Although we did 
find only one (GATA1) overlap of TF when we compared TFs generated from HPMEC 
ID3+ and ENCODE ID3 – K562 ChIP data. Researchers have already shown that 
interaction of GATA1 with E47 protein acts as the master regulators of hematopoiesis 
and binds to β-globin promoter in Id cDKO bone marrow cells (Zhao et al., 2016). This 
data may suggests that ID3 indirectly interacts with GATA1. It is interesting to see that 
there is no overlap of any TFs between HPMEC ID3+ and HPMEC ChIP samples. This 
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finding corroborates the idea that ID3 gene regulation with copartner TFs is different in 
ID3 overexpressed HPMEC than wild type HPMEC. Moreover, we tried to understand 
the connection between ID3 and 8 TFs generated from HPMEC ID3+  ChIP data using 
STRING database in the Fig. 80 and 81. The STRING netwok showed how this proteins 
are interconnected with various pathways (Szklarczyk et al., 2015b; Jensen et al., 2015). 
In addition to GATA1, other proteins like STAT2, SMAD4 and IRF1 did not show any 
direct connection with ID3 in Figure 82A. But Figure 82B showed indirect interaction of 
ID3 with SMAD4 throgh BMP2, as SMAD4 is central component of the BMP signalling 
and ID3 is direct target of BMP2 in a variety of cell types (Lim et al., 2015; 
O’Shaughnessy, Christiano, & Jahoda, 2004; Voorneveld et al., 2014). In case of STAT2-
JAK-IRF4 did  not show any type of interaction with ID3. But there is evidence of 
cytokine-mediated STAT activation directly modulate Id2 expression. Morover. 
researchers also suggested possibilty of  cytokines indirect regulatation of Id3 expression 
through modulation of Id2 expression in memory T cells of mice (Yang et al., 2011). 
However, in order to rule out any nonspecific effect of the ID3 antibody on the 
recognition of these transcription factors not related to ID3, we compared their amino 
acid sequences with the ID3 protein by means of the DNAStar alignment program. No 
significant similarities were observed among the considered proteins, thus ruling out any 
unspecific binding of the ID3 antibody. Although ID3 ChIP-Seq data demonstrated an 
enrichment of genomic regions with overrepresentation of general transcriptional 
regulatory TFs, functional experiments should be performed to demonstrate an 
interaction of ID3 with these TFs. Our data underscore the importance of synergistic 
interactions between ID3 and tissue-specific TFs to ultimately modulate gene expression. 
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Gene ID for optimal 
peaks
Species Quality Consensus 
E-value Enriched 
motifs (E-value 
≤ 10 using the 
binomial test)
Region 
Width 
Region 
Matches 
GAGAGAGAGAGAGA
GAGAGAGAGAGAGA
GA
2E-62 47 348
GAGAGAGAGAGAGA
GAGAGAG
8.8E-57 54 475
GAGAGAGAGAGAGA
G
1.60E-45 54 425
IRF1 HUMAN A
RAAASNGAAAGTGAAAS
TRR
4E-12 81 716
GGGAGAGA 1.9E-11 71 172
BC11A HUMAN C RAAAGAGGAAGTGARAV 1.2E-09 72 1014
IRF4 HUMAN C RRRGRGGAASTGARAS 8.7E-09 81 1061
PRDM1 HUMAN C RAAAGTGAAAGTGA 0.000000031 53 515
FOXJ3 HUMAN A TTGTTTATKKTTW 0.0035 70 340
SMAD4 HUMAN C STGTCTSDCACCT 0.0047 90 891
ZBTB6 HUMAN D VGRTGATRGAGCC 0.03 106 594
STAT2 HUMAN B TYASTTTCNBTTYCH 0.005 12 390
GATA1 HUMAN A CTGBNNVVBRSAGATAAGR 7.50E-03 76 251
ID Alt ID Consensus E-value 
Region 
Width 
Region 
Matches 
TCCCAGCWMYTYGGGAGGCTGAGGCRGG
AG
MEME-3
TCCCAGCWMYTYGGGAGGCTGAGGCRGG
AG
1.30E-05 39 45
ZBT7B HUMAN SSCSGTTGCCATGGVRACSGS 4.20E-03 12 34
NKX28 HUMAN TTCAAGKRC 7.40E-03 88 326
TGIF1 HUMAN TGACAGS 8.40E-03 84 620
RFX2 HUMAN CKGTTGCCATGGCRACVS 1.40E-02 5 15
AGTRGCTG
DREME-
6
AGTAGCTG 1.60E-02 9 15
MYOG HUMAN CHSCAGCTGYYYB 2.20E-02 94 215
ACAGGCRTGMGCCACCRYGCC MEME-5 ACAGGCRTGMGCCACCRYGCC 7.00E-02 48 45
AYTACAGG
DREME-
3
AYTACAGG 1.50E-01 21 21
ZBT18 HUMAN KCCAGMTGTKB 2.10E-01 84 416
MXI1 HUMAN SCCACGTGSYB 2.90E-01 100 457
SOX2 HUMAN BBCCTTTGTYYYB 4.00E-01 46 321
SOX2 HUMAN BCCWTTGTYATGYWRA 6.20E-01 55 360
MAF HUMAN VAAWBTGCTGASTHWGCMD 6.50E-01 86 483
MEIS1 HUMAN GMTGACAGV 6.60E-01 82 532
SOX3 HUMAN BCCWTTGTBYB 7.10E-01 48 293
SOX9 HUMAN YCWTTGKYY 8.40E-01 38 317
TBX3 HUMAN DRAGGTGBSAR 9.00E-01 90 609
Table 7- Main TFs binding motifs overrepresented in the ID3 binding regions of 
HPMEC ID3+ ChIP data. 
Table 1A -  
Table 8- Main TFs binding motifs overrepresented in the ID3 binding regions of 
HPMEC ChIP data. 
Table 1B - Main TFs binding motifs overrepresented in the ID3 binding regions of 
HPMEC ChIP data. 
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Figure 80- A Venn diagram showing there is no overlap of TFs copartners of ID3 in 
the ID3 binding regions among HPMEC ChIP and HPMEC ID3+ ChIP data. 
Figure 81- A Venn diagram showing the one overlap of TF copartner of ID3 in the 
ID3 binding regions among ENCODE ID3 – K562 and HPMEC ID3+ ChIP data. 
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Approved 
symbol 
Approved name HGNC ID Location 
BCL11A B cell CLL/lymphoma 
11A 
HGNC:13221 2p16.1 
IRF4 interferon regulatory 
factor 4 
HGNC:6119 6p25.3 
PRDM1 PR/SET domain 1 HGNC:9346 6q21 
FOXJ3 forkhead box J3 HGNC:29178 1p34.2 
SMAD4 SMAD family member 
4 
HGNC:6770 18q21.2 
ZBTB6 zinc finger and BTB 
domain containing 6 
HGNC:16764 9q33.2 
STAT2 signal transducer and 
activator of transcription 
2 
HGNC:11363 12q13.2 
GATA1 GATA binding protein 1 HGNC:4170 Xp11.23 
Figure 82- A) STRING protein network illustrates 8 proteins interaction with ID3 
protein and p= 0.00495 shows that interactions among the protein is significant. B) 
STRING has added a total of 5 proteins to network to show a network around our 
earlier 9 proteins 
Table 9- A detailed list of TFs binding in the peak regions of ID3 from HPMEC 
ID3+ ChIP sample. 
Table 2- A detailed list of TFs binding in the peak regions of ID3 of HPMEC ID3+ 
ChIP sample. 
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CHAPTER 4 
The whole transcriptome shotgun sequencing (RNA Sequencing) of ID3 target genes 
reveals the role of ID3 in the proliferation and dysregulation of lung endothelial 
cells. 
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Introduction- 
In recent years, next-generation sequencing methods, for instance, ChIP-Seq and RNA-
Seq, due to their distinct advantages in increasing specificity and sensitivity of gene 
expression, they have become a popular choice in biological studies. Specifically, RNA-
Seq has become an attractive alternative to microarrays in the inference of differential 
expression between several conditions or tissues, for it gives more accurate detection and 
measure of gene expression. The power of sequencing RNA lies in the fact that the twin 
aspects of discovery and quantification can be combined in a single high-throughput 
sequencing assay called RNA-sequencing (RNA-Seq). Every RNA-Seq experimental 
scenario could potentially have different optimal methods for transcript quantification, 
normalization, and ultimately differential expression analysis. 
 
Materials and Methods 
Cell culture and treatment conditions  
Primary cells, Human pulmonary microvascular endothelial cells or Human lung 
endothelial cells (HPMEC-ST1.6R).  HPMEC cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM-F12) supplemented with 5% (v/v) fetal bovine serum 
(FBS). Cells were cultured at 37 ºC in a humidified atmosphere with 5% CO2.  
Estrogenic chemical treatments  
Stock solutions of PCB153 and 17β-estradiol were prepared in dimethyl sulfoxide 
(DMSO). The same amount of DMSO as in PCB and estradiol-treated cells were added 
to control cultures. The level of DMSO in experimental media was less than 0.1%. PCB 
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blood levels have been reported to reach approximately 1000 ng/mL (∼3 μM) in 
occupationally exposed individuals (Wassermann et al., 1979). Our unpublished data 
showed a significant increase in PCB- induced vascularization with PCB153 
concentrations of 10–100 ng/mL. Based on known PCB blood levels from occupational 
exposure and our preliminary results; we chose a PCB dose of 100 ng/mL (∼0.3 µM) to 
expose endothelial cells. Our previous studies also showed endothelial cell proliferation 
and vascular tube formation at physiological doses of 17β-estradiol (Das & Felty, 2014a; 
Felty, 2006; Felty & Porther, 2008b) therefore, HPMEC and HPMEC ID3+ were exposed 
to estradiol at 100 ng/mL (∼3.6 nM). PCB congeners 2,2′,4,4′,5,5′-hexachlorobiphenyl 
(PCB153) were purchased from AccuStandard (NewHaven, CT) and dissolved in 
dimethyl sulfoxide (DMSO). All other chemicals and reagents were purchased from 
Sigma (St. Louis, MO). 
ID3 overexpression 
The HPMEC cells were stably transfected with either Precision LentiORF for ID3 
(Thermo Scientific Open Biosystems) or empty vector lentiviral pLEX-JRED/TurboGFP 
by the trans-lentiviral packaging kit with Express-in transfection reagent according to the 
manufacturer’s instructions. We used the MOI (multiplicity of infection) of 25 and 
selected cells that overexpressed ID3 with blasticidin S (5 mg/ml) as per manufacturer’s 
instructions. Cells expressing TurboGFP were identified by fluorescence microscopy. 
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The whole transcriptome shotgun sequencing (RNA-Sequencing) 
We extracted total RNA from the HPMEC (control), HPMEC ID3+ and HPMEC ID3+ + 
PCB153 cells with the help of Invitrogen™ TRIzol™ Reagent RNA extraction method 
Pub. No. MAN0001271 (Fisher Scientific Rio, Ares, Hannon, & Nilsen, 2010). The 
protocol required using TRIzol™ Reagent. TRIzol™ Reagent maintains the integrity of 
the RNA due to highly effective inhibition of RNase activity while disrupting cells and 
dissolving cell components during sample homogenization (Chomczynski P, 1983). After 
dislodging of growing monolayer of cells from petri-dishes with TRIzol™ Reagent, 
chloroform is added to cell sample, and is allowed to separate into a clear upper aqueous 
layer (containing RNA), an interphase, and a red lower organic layer (containing the 
DNA and proteins). RNA is precipitated from the aqueous layer with isopropanol. 
Isolated RNA is then used to prepare as a sample for RNA sequencing analysis. We 
performed RNA sequencing analysis at Center for Genome Technology (CGT) of 
University of Miami Miller School of Medicine. The CGT facility used Illumina: TruSeq 
Stranded mRNA Sample Preparation Guide for RNA sequencing analysis (TruSeq, 
2013). 
Experiment procedure for RNA Sequencing (RNA-Seq) 
Introduction- 
To begin with RNA sequencing, we extracted total RNA from the HPMEC (control), 
HPMEC ID3+ and HPMEC ID3+ + PCB153 cells with the help of Invitrogen™ TRIzol™ 
Reagent RNA extraction method Pub. No. MAN0001271 (Fisher Scientific Rio et al., 
2010). The protocol required using TRIzol™ Reagent, which is a monophasic solution of 
phenol, guanidine isothiocyanate, and other proprietary components helps the isolation of 
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a variety of RNA species of large or small molecular size. TRIzol™ Reagent maintains 
the integrity of the RNA due to highly effective inhibition of RNase activity while 
disrupting cells and dissolving cell components during sample homogenization 
(Chomczynski P, 1983). After dislodging of growing monolayer of cells from petri-
dishes with TRIzol™ Reagent, chloroform is added to cell sample, and is allowed to 
separate into a clear upper aqueous layer (containing RNA), an interphase, and a red 
lower organic layer (containing the DNA and proteins). RNA is precipitated from the 
aqueous layer with isopropanol. Isolated RNA is then used to prepare as a sample for 
RNA sequencing analysis.  
Method-  
1× 105–1 × 107 cells grown in monolayer in 3.5 cm culture dish (10 cm2). We added 0.3–
0.4 mL of TRIzol™ Reagent per 1 × 105—107 cells directly to the culture dish to lyse the 
cells. We did pipet the lysate up and down several times to homogenize. We centrifuged 
the lysate for 5 minutes at 12,000 × g at 4–10 °C, then transfer the clear supernatant to a 
new tube. We incubated for 5 minutes to permit complete dissociation of the 
nucleoproteins complex. We added 0.2 mL of chloroform per 1 mL of TRIzol™ Reagent 
used for lysis, then securely cap the tube. We centrifuged the sample for 15 minutes at 
12,000 × g at 4 °C. The mixture separates into a lower red phenol-chloroform, and 
interphase, and a colorless upper aqueous phase. We transferred the aqueous phase 
containing the RNA to a new tube by angling the tube at 45° and pipetting the solution 
out. 
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We separated phases. We then added 0.5 mL of isopropanol to the aqueous phase, per 1 
mL of TRIzol™ Reagent used for lysis. We centrifuged for 10 minutes at 12,000 × g at 
4°C.Total RNA precipitate forms a white gel-like pellet at the bottom of the tube. We 
discarded the supernatant with a micropipette. We resuspended the pellet in 1 mL of 75% 
ethanol per 1 mL of TRIzol™ Reagent used for lysis. Vortex the sample briefly, then 
centrifuge for 5 minutes at 7500 × g at 4°C. Vacuum or air dry the RNA pellet for 5–10 
minutes. We resuspended the pellet in 20–50 μL of RNase-free water, 0.1 mM EDTA, or 
0.5% SDS solution by pipetting up and down. We incubated in a water bath or heat block 
set at 55–60 °C for 10–15 minutes. We determined the RNA yield using absorbance 
method-Absorbance at 260 nm provides total nucleic acid content, while absorbance at 
280 nm determines sample purity. Since free nucleotides, RNA, ssDNA, and dsDNS 
absorb at 260 nm, they all contribute to the total absorbance of the sample. We diluted 
sample in RNase-free water, then measure absorbance at 260 nm and 280 nm. We 
calculated the RNA concentration using the formula A260 × dilution × 40 = μg RNA/mL. 
Calculate the A260/A280 ratio. A ratio of ~2 is considered pure. 
 
RNA sequencing- 
We performed RNA sequencing analysis at Center for Genome Technology (CGT) of 
University of Miami Miller School of Medicine. The CGT facility analyzed the quality of 
RNA samples by absorption method. The concentration of three RNA samples prior to 
use for sequencing are given as follows in table 10-   
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Project Prep 
volume 
(ul) 
bioA Conc 
(ng/ul) 
Total RNA input 
(ng) 
input 
volume 
(ul) 
qRNASeq1 
TruSeq 
219.46 84.20 500 5.94 
245.80 102.00 500 4.90 
232.01 91.1 500 5.49 
 
 
The CGT facility used Illumina: TruSeq Stranded mRNA Sample Preparation Guide for 
RNA sequencing analysis (TruSeq, 2013). They have used adapter sequence specific to 
each samples. The adapter sequences are listed in the following table 11. 
 
Lane Study_Project Sample Barcode sequence PF Clusters total PF Reads FC_ID
1 qFelty_qRNASeq1 201603252-01 ATCACG 4,551,510 160314_NS500167_0017_AHYF3HBGXX
2 qFelty_qRNASeq1 201603252-01 ATCACG 4,523,244 160314_NS500167_0017_AHYF3HBGXX
3 qFelty_qRNASeq1 201603252-01 ATCACG 4,654,605 160314_NS500167_0017_AHYF3HBGXX
4 qFelty_qRNASeq1 201603252-01 ATCACG 4,582,159 160314_NS500167_0017_AHYF3HBGXX
1 qFelty_qRNASeq1 201603252-01_ ATCACG 8,249,593 160325_NS500167_0018_AHY7TMBGXX
2 qFelty_qRNASeq1 201603252-01_ ATCACG 8,137,621 160325_NS500167_0018_AHY7TMBGXX
3 qFelty_qRNASeq1 201603252-01_ ATCACG 8,342,614 160325_NS500167_0018_AHY7TMBGXX
4 qFelty_qRNASeq1 201603252-01_ ATCACG 8,172,774 51,214,120 160325_NS500167_0018_AHY7TMBGXX
1 qFelty_qRNASeq1 201603253-01 TTAGGC 5,029,343 160314_NS500167_0017_AHYF3HBGXX
2 qFelty_qRNASeq1 201603253-01 TTAGGC 4,959,964 160314_NS500167_0017_AHYF3HBGXX
3 qFelty_qRNASeq1 201603253-01 TTAGGC 5,138,406 160314_NS500167_0017_AHYF3HBGXX
4 qFelty_qRNASeq1 201603253-01 TTAGGC 5,047,644 160314_NS500167_0017_AHYF3HBGXX
1 qFelty_qRNASeq1 201603253-01_ TTAGGC 9,095,323 160325_NS500167_0018_AHY7TMBGXX
2 qFelty_qRNASeq1 201603253-01_ TTAGGC 8,928,221 160325_NS500167_0018_AHY7TMBGXX
3 qFelty_qRNASeq1 201603253-01_ TTAGGC 9,219,859 160325_NS500167_0018_AHY7TMBGXX
4 qFelty_qRNASeq1 201603253-01_ TTAGGC 9,025,336 56,444,096 160325_NS500167_0018_AHY7TMBGXX
1 qFelty_qRNASeq1 201603254-01 ACTTGA 5,162,332 160314_NS500167_0017_AHYF3HBGXX
2 qFelty_qRNASeq1 201603254-01 ACTTGA 5,110,305 160314_NS500167_0017_AHYF3HBGXX
3 qFelty_qRNASeq1 201603254-01 ACTTGA 5,272,969 160314_NS500167_0017_AHYF3HBGXX
4 qFelty_qRNASeq1 201603254-01 ACTTGA 5,177,994 160314_NS500167_0017_AHYF3HBGXX
1 qFelty_qRNASeq1 201603254-01 ACTTGA 7,523,473 160325_NS500167_0018_AHY7TMBGXX
2 qFelty_qRNASeq1 201603254-01 ACTTGA 7,408,121 160325_NS500167_0018_AHY7TMBGXX
3 qFelty_qRNASeq1 201603254-01 ACTTGA 7,603,456 160325_NS500167_0018_AHY7TMBGXX
4 qFelty_qRNASeq1 201603254-01 ACTTGA 7,437,656 50,696,306 160325_NS500167_0018_AHY7TMBGXX
Table 10- It gives the information about the sample like concentration, volume, and 
quality. 
 
Table 11- It gives the information about sequencing reads obtained per the sample. 
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Methodology to analyze the RNA-sequencing data 
Illumina TruSeq RNA libraries were constructed and sequenced using Illumina HiSeq 
2000 at CGT. The CGT facility at UM sent us the data in the FASTA format single ended 
files. We received FASTA files for HPMEC (control), HPMEC ID3+, and HPMEC ID3+ 
+ PCB153 samples. The FASTA files were constructed for strand-specific Single-end 
cDNA sequencing on the Truseq sequencer (Illumina, UM, Miami). Low-quality 
sequences analyzed by FASTQC (Andrew, 2010) and adapter sequences were trimmed 
by Trimmomatic, v.0.33 (Bolger et al., 2014; Usadellab, 2013 ), and aligned to the 
reference human genome (GRCh38, GENCODE release 23 primary assembly) by the 
sequence alignment software Spliced Transcripts Alignment to a Reference, RNA STAR  
(Dobin et al., 2013), Bowtie2 (Langmead & Salzberg, 2012), and HISAT (Kim, 
Langmead, & Salzberg, 2015). We mapped the sample FASTQ files separately by three 
different mapping software to check the mapping efficiency of these various software and 
establish optimal pipeline strategy to analyze RNA Seq data to achieve correct 
interpretation.  Bowtie2 and HISAT are ungapped mapper. In other hand RNA STAR is a 
gapped mapper which able detect non-canonical splice junctions (Conesa et al., 2016). 
After all filtering and mapping, a high percentage of poor or unaligned reads were 
rejected and removed from further analysis. Overall, the mean number of raw reads was 
50 million per sample. Of the mean 5.6 million high-quality reads, 24.2% mapped to a 
unique location in the reference human genome. RNA STAR, Bowtie2, and HISAT 
mapping software aligned millions of short reads to the reference genome and outputs 
either SAM file (.sam) is a tab-delimited text file that contains sequence alignment data 
or a BAM file (.bam) is the binary version of a SAM file. SAM or BAM file can be used 
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as input for a read summarization program suitable for counting reads generated from 
RNA. We used featureCounts program which implements highly efficient chromosome 
hashing and feature blocking techniques. It is considerably faster than existing methods 
by an order of magnitude for gene-level summarization (Liao, Smyth, & Shi, 2014). 
FeatureCounts produces a table containing counted reads, per gene, per row. Optionally 
the last column can be set to be the effective gene-length. These tables are compatible 
with the DESeq2 Galaxy wrapper by IUC. Column names are added as metadata object. 
In order to make the expression levels of genes comparable and further conduct 
differential expression analysis, normalization is a crucial step in data processing. The 
normalization step aims to adjust the systematic technical effects and reduce the noise on 
the data as well. Mostly, to compare the transcriptome data, the null hypothesis is being 
tested on the logarithmic fold change (LFC) between treatment and control for a gene’s 
expression. The null hypothesis for the logarithmic fold change between treatment and 
control for a gene’s expression is considered to be exactly zero, i.e., that the gene is not at 
all affected by the treatment. The one way to normalize the raw RNA-Seq data by   reads 
per kilo base of exon model per million reads (RPKM) (Mortazavi, Williams, McCue, 
Schaeffer, & Wold, 2008) which is a within-sample normalization method that will 
remove the feature-length and library-size effects. RPKM and its subsequent derivatives 
fragments per kilo base of exon model per million mapped reads (FPKM), a within-
sample normalized transcript expression measure analogous to RPKs acts as a RNA-Seq 
gene expression values. Normalization with RPKM method performs poorly when 
samples have highly and differentially expressed features (Bullard, Purdom, Hansen, & 
Dudoit, 2009; Hansen, Brenner, & Dudoit, 2010). Ranking by fold change, on the other 
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hand, is complicated by the noisiness of LFC estimates for genes with low counts. 
Furthermore, the number of genes called significantly differentially expressed depends as 
much on the sample size and other aspects of experimental design (Boer et al., 2001). 
Inferential method is another way that treat each gene separately suffer from lack of 
power, due to the high uncertainty of within-group variance estimates and the small 
number of samples in typical high-throughput assay experiments – often as few as two or 
three replicates per condition. In high-throughput assay analysis, this limitation can be 
overcome by pooling information across genes, specifically, by estimating variance-mean 
dependence in count data and test for differential expression based on a model using the 
negative binomial distribution (Conesa et al., 2016). DEseq2 is software which uses 
negative binomial distribution statistics, which gives framework to facilitate gene ranking 
and visualization based on stable estimation of effect sizes, as well as testing of 
differential expression with respect biological significance. DESeq2, is a method for 
differential analysis of count data, using shrinkage estimation for dispersions and fold 
changes to improve stability and interpretability of estimates (Anders & Huber, 2010; 
Love, Huber, & Anders, 2014) as shown in Figure 83 and 84. This enables more 
quantitative analysis focused on the strength rather than the mere presence of differential 
expression. DESeq2 takes count tables that generated from the featureCounts as input. 
Count tables must be generated for each sample individually. DESeq2 internally corrects 
for library size, so it is important to provide un-normalized raw read counts as input. We 
used variance-stabilizing transformation to account for differences in sequencing depth. 
P-values were adjusted for multiple testing using the Benjamini-Hochberg procedure 
(Benjamini & Hochberg, 1995). A false discovery rate adjusted p-value (i.e., q-value) < 
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0.05 was set for the selection of DE genes. A nominal adjusted P value for each 
algorithm, which resulted in a median actual precision of 0.9 (FDR = 0.1). 
Inputs- The following table gives some examples of factors and their levels: 
Factor Factor level 1 
Factor level 
2 
Treatment Treated Untreated 
Condition Overexpression Wildtype 
Gender Female Male 
Output- DESeq2 generates a tabular file containing the different columns and optional 
visualized results as PDF. 
Column Description 
1 Gene Identifiers 
2 Mean normalized counts, averaged over all samples from both conditions 
3 Logarithm (to basis 2) of the fold change (See the note in inputs section) 
4 Standard error estimate for the log2 fold change estimate 
5 Wald statistic 
6 p value for the statistical significance of this change 
7 
p value adjusted for multiple testing with the Benjamini-Hochberg procedure 
which controls false discovery rate (FDR) 
 
 
 Figure 83- It illustrates the information about the approach of RNA Seq analysis 
used in this study. 
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Figure 84- It illustrates the setting used for DESeq2 analysis of differentially 
expressed genes in ID3 overexpressed sample VS vector control. 
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Integrative analysis of ChIP- and RNA- Seq data with Binding and expression 
target analysis (BETA) 
BETA is a software package that integrates ChIP-Seq data of TF with transcriptome 
quantification and then differential gene expression data to infer direct target genes. We 
used available open source at http:// cistrome.org/BETA.  We used BETA-minus 
software and input only binding data i.e. peak regions bed file generated from MACS2 
output which predicted target genes. The purpose of this protocol is to predict genes that 
are the direct targets of TFs or chromatin regulators. BT minus defined the targets as the 
genes with a high regulatory potential, derived only from TF binding within a specific 
region (100 kb default). BETA calculates regulatory potential for each gene using the 
equation . BETA minus is only equipped to predict TF target genes. It 
cannot predict whether the factor binding is activating or repressing gene expression (S. 
Wang et al., 2013). We checked the potential target genes output from BETA minus with 
DESeq2 differential expressed gene list and then sorted them into upregulated or 
downregulated genes list on the basis of fold change of ID3 overexpressed count data 
over HPMEC control count data. 
 
Results-  
To examine the global changes in the ID3 gene overexpression HPMEC cells by 
using whole transcriptome shotgun sequencing. 
We performed global transcriptome analysis on HPMEC and HPMEC ID3+ cells. We 
isolated RNA from HPMEC and HPMEC ID3+ cells and performed RNA Seq analysis 
comparing gene expression. We mapped FASTAQ files to a reference genome an 
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ungapped aligner Bowtie2. Mapping with gapped mapper allows for the identification of 
novel genes or transcripts. However, we did not require any novel transcript discovery, 
therefore we used Bowtie2. Bowtie2 mapped reads, then used for transcript identification 
and quantification. We found total of 1061 genes (significantly change over control with 
P < 0.05) were differentially expressed in HPMEC ID3+ than HPMEC cells (Additional 
file 8A). We then selected only selected differentially expressed genes with at least one 
fold change in expression. Therefore, out of of 1061 genes, we finally found 43 genes 
that were downregulated and 22 upregulated genes. DESeq2 normalized the gene 
expression counts taken from RNA Seq data of HPMEC ID3+ and HPMEC cells. An 
MA-plot is used to visualize differences between measurements taken in HPMEC ID3+ 
and HPMEC cells. An MA-plot is a plot of log-fold change (M-values, i.e., the log of the 
ratio of level counts for each gene between two samples) against the log-average (A-
values, i.e., the average level counts for each gene across the two samples) (Love et al., 
2014). The MA-plot is shown in Figure 85. We used volcano plots to show significance 
versus fold-change on the y and x axes, respectively. A volcano plot combines a measure 
of statistical significance from a statistical test (e.g., a p value from an ANOVA model) 
with the magnitude of the change, enabling quick visual identification of genes that 
display large magnitude changes that are also statistically significant.The green colour 
marked genes detected as differentially expressed and named at Padj<0.001 when 
Bonferroni correction testing adjustment is used (Figure 86). The dispersion estimates for 
normaized data is given in additional file 7. A representative heat map is shown in Figure 
87 (complete image of heat map is given in additional file). The complete list of raw data 
of expressed genes is given in additional file 8B. To further examine the biological 
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significance of the differentially expressed genes, we used FunRich which is an open 
access standalone functional enrichment and interaction network analysis tool (Pathan et 
al., 2015, 2017). G-protein NF-Kβ signaling pathway, immune response, DNA 
replication, cell proliferation, and MAPK cascade are topmost significant biological 
processes network were expressed after ID3 overexpression which shown in Figure 88 
(Additional file 9). The top 20 canonical pathways modulated by ID3 are shown in Figure 
82. We found that the topmost pathways modulated by ID3 were regulation of cell cycle 
checkpoints, oxidative stress response, EGFR dependent signaling network, biological 
oxidation and VEGF and VEGFR signaling network (Additional file 10). Further, 
analysis of molecular and cellular functions of the differentially expressed genes revealed 
that they are involved in protein-metal ion binding, enzyme binding, cadherin binding, 
sequence specific DNA binding, and transcription regulator activity (Figure 90) 
(Additional file 11). KEGG pathways were significantly enriched in these ID3-regulated 
genes, which included DNA/RNA events, cell cycle, cell-cell interactions (focal 
adhesions, adherent junctions), cancer-related pathways (MAPK, LKB1, mTOR and 
VEGF) signaling events. 
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Figure 85- The MA-plot 
It visualizes the differences between gene expression in HPMEC ID3+ and HPMEC 
(control) cells, by transforming the data onto M (log2 fold changes attributable to a 
gene expression in HPMEC ID3+ over the mean of normalized counts for both 
HPMEC ID3+ and HPMEC (control) cells. Points have been colored red whose 
adjusted p value is less than 0.1. 
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 Figure 86- Volcano plot 
It illustrates fold differences in individual gene expression in HPMEC ID3+ vs HPMEC 
(control) cells, and associated P values (negative log10), in RNA Seq experiment.  
201 
 
 
Figure 87- HeatMap 
Gene expression profiles of 
HPMEC ID3+ and HPMEC 
(control) cells are illustrated by 
heat map. Heat map of 
differentially expressed genes 
between control and ID3 
overexpressed cells is shown. 
Increased or decreased mRNA 
expression is represented by red 
or blue, respectively.  
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Figure 88- FunRich GEO Biological Process 
Differentially expressed genes were subjected to FunRich GO enrichment analysis to 
elucidate the biological processes and the top 20 biological processes are shown.  
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Figure 89- FunRich Molecular Function 
Differentially expressed genes were subjected to FunRich GO enrichment analysis to 
elucidate the molecular function of DE genes. The top 20 molecular functions in 
which DE genes involved are shown. 
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Figure 90- FunRich Biological Pathways 
Differentially expressed genes were subjected to pathway analysis using 
FunRich enrichment analysis and the top 20 biological pathways are shown.  
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Understanding ID3 gene regulatory mechanisms by integrating ChIP-Seq and RNA-
Seq data in HPMEC cells. 
To answer the question whether ID3 binding to the genomic regions has functional 
consequences through changes in the expression level of target genes, the ChIP-Seq data 
were integrated with the RNA Seq data. High-throughput technologies like, RNA-Seq 
and ChIP-Seq are widely used to measure gene expression and to obtain genome-wide 
maps of transcription factor occupancies (Angelini & Costa, 2014; Park, 2009; Wang, 
Gerstein, & Snyder, 2009). The interplay between transcriptomics and epigenomics is 
very important to understand the chromatin accessibility to the transcription machinery 
which regulates gene expression and, vice versa, some non-coding RNAs can affect local 
chromatin states (Wang et al., 2011) In the pipeline process of ChIP Seq data, MACS2 
and SICER10 are some of the peak caller tools uses to identify precise TF-binding sites 
called peak regions. These peak regions then associated with nearest gene. This peak-
based method to identify targets is to assign the proximal nearest gene or the gene 
containing peaks in its promoter region (Boyer et al., 2005; Rougemont & Naef, 2012). 
Researchers have shown that most of the TF ChIP-Seq data contain only a small 
percentage of binding at the promoter region. In addition the use of nearest peaks to 
assign target genes is very unreliable (Hua et al., 2008). Therefore, it is very important to 
integrate ChIP-Seq and RNA-Seq data to predict gene expression during various cellular 
and metabolic pathways (Angelini & Costa, 2014). We used BETA to predict precise 
gene targets of ID3 in HPMEC cells. We used BETA minus on Cistrome Galaxy 
platform, which predicted ID3 direct gene targets by using .BED peaks file of ID3 
binding regions. We gave two ranks (R) to every gene target predicted by BETA minus 
(g): one is based on decreasing regulatory potential (Rgb), such that is Rgb = 1 for the 
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gene with the largest regulatory potential score, and the other is based on the increasing 
of the P value (Rge), that is, Rge = 1 for the most strongly differentially expressed gene. 
Then the rank product of the gene (g), RPg = (Rgb/n)*(Rge/n). The RP can be interpreted 
as a P value; because it shows the probability that the gene has a regulatory potential rank 
≤Rgb and a differential expression changed rank ≤Rge. On the basis of RP, we judged the 
targets with an RP less than 10−3 will be more likely to be the true target genes of ID3 
(Breitling, Armengaud, Amtmann, & Herzyk, 2004). We found total of 27 most 
significant genes (RPg <0.001), which is supposed to be regulated by ID3 (Additional file 
13). We then further analyzed by using gene ontology–based tools such as STRING and 
FunRich to link functions to this set shown table 12, Figures 91 and 92. If we decrease 
the significance level up to RPg <0.05 then list increased to 493 genes. We also identified 
19 genes whose promoter region bound by ID3 and also differentially expressed in RNA 
Seq data. These data shows that 19 gene were directly regulated by ID3 (additional file 
14) (Thomas et al., 2003).  
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GO biological process complete Homo sapiens - 
REFLIST (21042) 
 (fold 
Enrichment) 
 (raw P-
value) 
 
(FDR
) 
cellular response to zinc ion (GO:0071294) 19 47.13 1.25E-08 1.93E
-04 
cellular response to cadmium ion 
(GO:0071276) 
31 24.07 3.89E-06 1.51E
-02 
response to zinc ion (GO:0010043) 54 16.58 2.91E-06 1.51E
-02 
cellular response to metal ion 
(GO:0071248) 
154 8.72 1.49E-06 1.16E
-02 
cellular response to inorganic substance 
(GO:0071241) 
178 7.55 4.62E-06 1.43E
-02 
positive regulation of RNA metabolic 
process (GO:0051254) 
1504 2.48 2.46E-05 4.24E
-02 
regulation of transcription, DNA-templated 
(GO:0006355) 
3680 1.87 1.74E-05 4.51E
-02 
regulation of nucleic acid-templated 
transcription (GO:1903506) 
3704 1.85 1.85E-05 4.11E
-02 
regulation of RNA biosynthetic process 
(GO:2001141) 
3712 1.85 1.90E-05 3.69E
-02 
regulation of RNA metabolic process 
(GO:0051252) 
3909 1.79 2.98E-05 4.62E
-02 
 
 
 
 
 
 
Table 12- A detailed list of GO biological processes associated with most 
significant genes identified by BETA software. 
Table 3- A detailed list of GO biological processes associated with most significant 
genes identified by BETA software. 
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Figure 91- FunRich GO enrichment analysis of ID3 regulated significant genes 
involved in molecular functions 
ID3 regulated significant genes were subjected to FunRich GO enrichment analysis to 
elucidate the molecular function. The top 10 molecular functions in which these genes 
involved are shown. 
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Figure 92- FunRich GO enrichment analysis of ID3 regulated significant 
genes involved in biological pathways 
ID3 regulated significant genes were subjected to FunRich GO enrichment 
analysis to elucidate the biological pathway. The top biological processes in 
which these genes involved are shown. 
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C) 
Figure 93- A,B,C ID3 regulated significant genes involved in EGFR, mTOR and 
Focal adhesion signaling biological pathway are shown using KEGG pathway 
database. 
Figure 94- The cell signaling biological pathways shown in diagram are involved in 
cell proliferation. 
212 
 
Discussion  
We applied ChIP-Seq technology to identify global ID3 binding regions in HPMEC and 
HPMEC ID3+ cells. To our best knowledge, this is the first global analysis of ID3’s 
binding regions in HPMEC cells. ID3 belongs to a family of HLH proteins identified and 
named over two decades ago for its dual role as both inhibitors of the differentiation 
process and inhibitors of DNA binding. We show here for the first time that ID3 is part of 
a more general mechanism of transcriptional regulation than was at first thought. Our 
ChIP Seq data show that ID3 binds to a subset of 1240 target genes shared by both 
HPMEC ChIP and HPMEC ID3+ ChIP samples (Figure 78). However, only a minor 
fraction (3.5-3.7%) of the ID3 binding sites identified which are close to TSSs. This 
moderate percentage may be explained by the ID3 binding site distribution, where most 
of the binding sites are related with orphan intergenic regions. In this regard, our study 
demonstrates ID3 binding sites in regions distal to TSSs, preferentially in distal 
intergenic regions, which highlights a potential role as a distal or alternative 
transcriptional regulator, although this does not rule out indirect regulation.  
MEME-ChIP showed that ID3 binds to statistically significant GAGAGAGAGA motif 
sequence on the genomic DNA. Researchers have not been confirmed yet any ID3 
binding sequences. However, Zaragoza et al. showed in genome wide mapping 
experiment that Id2 binds to individually as well as along with E2F4 on c-myc promoter 
of mouse liver cells (Ferrer-Vicens et al., 2014).  Id2 is one of the members of the ID 
family proteins, which lacks DNA binding domain similar to ID3. In addition, genome 
wide mapping (ChIP on chip) and then MEME analysis showed overrepresentation of 
similar GAGAGAGA motifs also known as GAF motif for polycomb/trithorax response 
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elements in Drosophila melanogaster (Ringrose, 2017; Ringrose, Rehmsmeier, Dura, & 
Paro, 2003). These evidences support the hypothesis of ID3 binding to the DNA. There is 
another possibility that ID3 may be regulating gene expression by interacting with other 
known TFs and then binding to DNA as a protein complex. This type of protein complex 
binding is also known as cofactor based targeting binding. Targeting of non-DNA-
binding cofactors to DNA was earlier viewed solely via protein–protein interactions with 
DNA-bound TFs. This is known as indirect interaction with DNA through the TFs. 
However, several studies have described a provocative alternative mechanism in which 
recruited cofactors interact directly with DNA when part of a larger, multi-protein 
complex (Babb, Huang, Aufiero, & Herr, 2001; Siggers, Duyzend, Reddy, Khan, & 
Bulyk, 2011). The non-DNA-binding cofactors mediate sequence-specific interactions 
that preferentially stabilize the binding to composite DNA sites containing specific 
auxiliary motifs. This represents yet another mechanism to enhance the DNA sequence 
specificity of multi-protein regulatory complexes. The regulation of sulfur metabolism 
genes in yeast involves a multi-protein complex composed of a sequence-specific TF 
Cbf1 and two non-DNA-binding cofactors Met28 and Met4 (Blaiseau & Thomas, 1998; 
Kuras, Cherest, Surdin-Kerjan, & Thomas, 1996). Cbf1 is a bHLH protein and binds as a 
homodimer to E-box sites with a consensus 5′-CACGTG-3′ core (Kuras et al., 1996). 
Therefore, we predict it may be possible that ID3 regulating gene expression by 
interacting with TFs like BCL11A, IRF4, PRDM1, FOXJ3, SMAD4, ZBTB6, STAT2, 
and GATA1. Researchers have already shown that loss of SMAD4 and overexpression of 
IRF4 increases the cell proliferation in Non-small cell lung cancer (NSCLC) (Haeger et 
al., 2016; Qian et al., 2017). In addition, our lab and other researchers have shown ID3 
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involvement in EC proliferation acts as a disease phonotype for NSCLC (Castañon et al., 
2013). The regulation of ID3 through interaction with other TFs proteins enhances the 
cooperation in the modulation of transcription of other genes. Taking into account this 
complete transcriptional scenario, our data describe potential interactions of ID3 with 
both common TFs and core elements, which could cooperate in chromatin remodeling for 
transcriptional regulation in lung endothelial cells. 
Identification of biological processes controlled by overexpressed ID3 in HPMEC has 
been mainly associated to lung EC proliferation and checking at cell cycle phases through 
its transcriptional role in key EC proliferation-related genes (Al-husseini et al., 2015; Das 
& Felty, 2014b; Felty, Yoo, & Kennedy, 2010). At this regard, we observed a 
downregulation of Cell division protein kinase 6 (CDK6), which is an enzyme encoded 
by the CDK6 gene. It is important for the G1 phase progression and G1/S transition of 
the cell cycle (Meyerson et al., 1992). Researchers have shown that deregulation of 
CDK6 has been shown to be important in lymphoid malignancies by increasing 
angiogenesis, a hallmark of cancer (Diaz-Moralli, Tarrado-Castellarnau, Miranda, & 
Cascante, 2013). Interestingly, we observed four fold downregulation of EGR1. EGR1 
acts as a tumor suppressor in NSCLC (Zhang et al., 2013). Our data showed that ID3 
significantly downregulated EGR1 which could result into HPMEC hyper proliferation.  
Intriguingly, ID3 modulates the expression of several genes involved in carcinogenesis 
and lung malignancies in Figures 93 A, B, C and 87 (insulin signaling, mTOR signaling, 
EGFR signaling and MAPK pathways), inflammatory response and angiogenesis 
(VEGFR signaling).  We observed VEGFA overexpression in RNA Seq data, which is 
angiogenesis marker. Moreover, we found upregulation of gene HSPA8 that is a heat 
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shock family protein 70. Its functions contribute to biological processes including signal 
transduction, apoptosis, autophagy, protein homeostasis, and cell growth. It codes for the 
protein HSP72 which is shown to be over expressed in gastric cancers, colon cancers, 
breast cancers, and lung cancers (Wang et al., 2013a) (Mayer & Bukau, 2005; Wang et 
al., 2013b). We also observed EEF2K gene upregulation which codes for 
calcium/calmodulin-dependent eukaryotic elongation factor 2 kinase enzyme (Ryazanov 
et al., 1997). Researchers have shown upregulation EEF2K gene in various cancers 
(Leprivier et al., 2013).  
Moreover, MyCancerGenome has compiled database on molecular profiling of lung 
cancer which is comprised of oncogenes associated with two main histologic subtypes: 
non-small cell lung cancer and small cell lung cancer (SCLC) (Lovly, Horn, 2016). The 
database has identified the total of 23 oncogenes known to be important for lung cancer 
pathogenesis. We compared this list of genes with DE gene list from RNA Seq data that 
resulted into 11 common oncogenes. Similarly, comparison has been done between the 
lists of lung cancer oncogenes with BETA integrative analysis list, we found MAP2K1, 
and MET oncogenes were common. We also used pulmonary arterial hypertension 
knowledgebase (PAHKB), which provides 341 human PH-related genes (293 protein 
coding and 48 non-coding genes) to compare with DE genes and BETA integrative 
analysis data (Zhao, Austin, Hemnes, Loyd, & Zhao, 2014). We found common 69 genes 
and 30 genes in DE genes and BETA integrative analysis data respectively. This evidence 
shows that potential involvement of ID3 in regulation of genes, which are responsible in 
lung endothelial cells proliferation. This endothelial cell hyper proliferation is disease 
phenotype for both PAH and lung cancer (additional file 15). 
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Conclusion 
State-of-the-art cis-regulatory sequencing studies have been combined with RNA 
sequencing to further characterize the functional relevance of TF- interacting DNA 
regions and thus to define their transcriptional output. In our study, we describe ID3 as a 
master regulator of key cellular processes for lung cells biology, including cell cycle 
regulation, DNA repair, replication and metabolism, and cell polarity, and define a large 
set of genes whose expression is modulated by ID3.  
References- 
 
Al-husseini, A. A., Kraskauskas, D., Mezzaroma, E., Nordio, A., Farkas, D., Drake, J. I., 
… Nordio, A. (2015). Vascular endothelial growth factor receptor 3 signaling 
contributes to angioobliterative pulmonary hypertension. Pulmonary Circulation, 
5(1), 101–116. http://doi.org/10.1086/679704.I 
Anders, S., & Huber, W. (2010). Differential expression analysis for sequence count data. 
Genome Biology, 11(10). http://doi.org/10.1186/gb-2010-11-10-r106 
Andrew, S. (2010). Babraham Bioinformatics - FastQC A Quality Control tool for High 
Throughput Sequence Data. Retrieved February 1, 2018, from 
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 
Angelini, C., & Costa, V. (2014). Understanding gene regulatory mechanisms by 
integrating ChIP-Seq and RNA-Seq data: statistical solutions to biological problems. 
Frontiers in Cell and Developmental Biology, 2, 51. 
http://doi.org/10.3389/fcell.2014.00051 
Babb, R., Huang, C. C., Aufiero, D. J., & Herr, W. (2001). DNA Recognition by the 
Herpes Simplex Virus Transactivator VP16: a Novel DNA-Binding Structure. 
Molecular and Cellular Biology, 21(14), 4700–4712. 
http://doi.org/10.1128/MCB.21.14.4700-4712.2001 
Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: a practical 
and powerful approach to multiple testing. Journal of the Royal Statistical Society, 
57(1), 289–300. http://doi.org/10.2307/2346101 
Blaiseau, P.-L., & Thomas, D. (1998). Multiple transcriptional activation complexes 
tether the yeast activator Met4 to DNA. The EMBO Journal, 17(21), 6327–6336. 
http://doi.org/10.1093/emboj/17.21.6327 
 
217 
 
Boer, J. M., Huber, W. K., Sültmann, H., Wilmer, F., Von Heydebreck, A., Haas, S., … 
Poustka, A. (2001). Identification and classification of differentially expressed genes 
in renal cell carcinoma by expression profiling on a global human 31,500-element 
cDNA array. Genome Research, 11(11), 1861–1870. 
http://doi.org/10.1101/gr.184501 
Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: A flexible trimmer for 
Illumina sequence data. Bioinformatics, 30(15), 2114–2120. 
http://doi.org/10.1093/bioinformatics/btu170 
Boyer, L. A., Tong, I. L., Cole, M. F., Johnstone, S. E., Levine, S. S., Zucker, J. P., … 
Young, R. A. (2005). Core transcriptional regulatory circuitry in human embryonic 
stem cells. Cell, 122(6), 947–956. http://doi.org/10.1016/j.cell.2005.08.020 
Breitling, R., Armengaud, P., Amtmann, A., & Herzyk, P. (2004). Rank products: A 
simple, yet powerful, new method to detect differentially regulated genes in 
replicated microarray experiments. FEBS Letters, 573(1–3), 83–92. 
http://doi.org/10.1016/j.febslet.2004.07.055 
Bullard, J. H., Purdom, E., Hansen, K. D., & Dudoit, S. (2009). Evaluation of Statistical 
Methods for Normalization and Differential Expression in mRNA-Seq Experiments 
Evaluation of Statistical Methods for Normalization and Differential Expression in 
mRNA-Seq Experiments. U.C. Berkeley Div. Biostat. Pap. Ser., 11(1), 94. 
http://doi.org/10.1186/1471-2105-11-94 
Castañon, E., Bosch-Barrera, J., López, I., Collado, V., Moreno, M., López-Picazo, J. M., 
… Gil-Bazo, I. (2013). Id1 and Id3 co-expression correlates with clinical outcome in 
stage III-N2 non-small cell lung cancer patients treated with definitive 
chemoradiotherapy. Journal of Translational Medicine, 11, 13. 
http://doi.org/10.1186/1479-5876-11-13 
Chomczynski P, S. N. (1983). Single-step method of RNA isolation by acid guanidinium 
thiocyanate-phenol-chloroform extraction. Anal. Biochem, 162(June 1989), 1993. 
http://doi.org/10.1006/abio.1987.9999 
Conesa, A., Madrigal, P., Tarazona, S., Gomez-Cabrero, D., Cervera, A., McPherson, A., 
… Mortazavi, A. (2016). A survey of best practices for RNA-Seq data analysis. 
Genome Biology. http://doi.org/10.1186/s13059-016-0881-8 
Das, J. K., & Felty, Q. (2014a). Microvascular Lesions by Estrogen-Induced ID3: Its 
Implications in Cerebral and Cardiorenal Vascular Disease. Journal of Molecular 
Neuroscience, 618–631. http://doi.org/10.1007/s12031-014-0401-9 
Das, J. K., & Felty, Q. (2014b). Microvascular Lesions by Estrogen-Induced ID3: Its 
Implications in Cerebral and Cardiorenal Vascular Disease. Journal of Molecular 
Neuroscience, 55(3), 618–631. http://doi.org/10.1007/s12031-014-0401-9 
 
 
218 
 
Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., & Cascante, M. (2013). 
Targeting cell cycle regulation in cancer therapy. Pharmacology & Therapeutics, 
138(2), 255–271. http://doi.org/10.1016/J.PHARMTHERA.2013.01.011 
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., … Gingeras, T. 
R. (2013). STAR: Ultrafast universal RNA-Seq aligner. Bioinformatics, 29(1), 15–
21. http://doi.org/10.1093/bioinformatics/bts635 
Felty, Q. (2006). Estrogen-induced DNA synthesis in vascular endothelial cells is 
mediated by ROS signaling. BMC Cardiovascular Disorders, 6, 16. 
http://doi.org/10.1186/1471-2261-6-16 
Felty, Q., & Porther, N. (2008). Estrogen-induced redox sensitive Id3 signaling controls 
the growth of vascular cells. Atherosclerosis, 198(1), 12–21. 
http://doi.org/10.1016/j.atherosclerosis.2007.12.048 
Felty, Q., Yoo, C., & Kennedy, A. (2010). Gene expression profile of endothelial cells 
exposed to estrogenic environmental compounds: Implications to pulmonary 
vascular lesions. Life Sciences, 86(25–26), 919–927. 
http://doi.org/10.1016/j.lfs.2010.04.007 
Ferrer-Vicens, I., Riffo-Campos, Á. L., Zaragozá, R., García, C., López-Rodas, G., Viña, 
J. R., … García-Trevijano, E. R. (2014). In vivo genome-wide binding of Id2 to 
E2F4 target genes as part of a reversible program in mice liver. Cellular and 
Molecular Life Sciences. http://doi.org/10.1007/s00018-014-1588-1 
Fisher Scientific -, T. (). TRIzol Reagent User Guide  - Pub. no. MAN0001271 - Rev. 
A.0. Retrieved from 
https://tools.thermofisher.com/content/sfs/manuals/trizol_reagent.pdf 
Haeger, S. M., Thompson, J. J., Kalra, S., Cleaver, T. G., Merrick, D., Wang, X. J., & 
Malkoski, S. P. (2016). Smad4 loss promotes lung cancer formation but increases 
sensitivity to DNA topoisomerase inhibitors. Oncogene, 35(5), 577–586. 
http://doi.org/10.1038/onc.2015.112 
Hansen, K. D., Brenner, S. E., & Dudoit, S. (2010). Biases in Illumina transcriptome 
sequencing caused by random hexamer priming. Nucleic Acids Research, 38(12), 
e131–e131. http://doi.org/10.1093/nar/gkq224 
Hua, S., Kallen, C. B., Dhar, R., Baquero, M. T., Mason, C. E., Russell, B. A., … White, 
K. P. (2008). Genomic analysis of estrogen cascade reveals histone variant H2A.Z 
associated with breast cancer progression. Molecular Systems Biology, 4, 188. 
http://doi.org/10.1038/msb.2008.25 
Kim, D., Langmead, B., & Salzberg, S. L. (2015). HISAT: A fast spliced aligner with 
low memory requirements. Nature Methods, 12(4), 357–360. 
http://doi.org/10.1038/nmeth.3317 
 
219 
 
Kuras, L., Cherest, H., Surdin-Kerjan, Y., & Thomas, D. (1996). A heteromeric complex 
containing the centromere binding factor 1 and two basic leucine zipper factors, 
Met4 and Met28, mediates the transcription activation of yeast sulfur metabolism. 
The EMBO Journal, 15(10), 2519–2529. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8665859 
Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. 
Nature Methods, 9(4), 357–359. http://doi.org/10.1038/nmeth.1923 
Leprivier, G., Remke, M., Rotblat, B., Dubuc, A., Mateo, A.-R. F., Kool, M., … 
Sorensen, P. H. (2013). The eEF2 kinase confers resistance to nutrient deprivation 
by blocking translation elongation. Cell, 153(5), 1064–79. 
http://doi.org/10.1016/j.cell.2013.04.055 
Liao, Y., Smyth, G. K., & Shi, W. (2014). FeatureCounts: An efficient general purpose 
program for assigning sequence reads to genomic features. Bioinformatics, 30(7), 
923–930. http://doi.org/10.1093/bioinformatics/btt656 
Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and 
dispersion for RNA-Seq data with DESeq2. Genome Biology, 15(12), 550. 
http://doi.org/10.1186/s13059-014-0550-8 
Lovly, C., L. Horn, W. P. (2016). Molecular Profiling of Lung Cancer - My Cancer 
Genome. Retrieved February 20, 2018, from 
https://www.mycancergenome.org/content/disease/lung-cancer/ 
Mayer, M. P., & Bukau, B. (2005). Hsp70 chaperones: Cellular functions and molecular 
mechanism. Cellular and Molecular Life Sciences, 62(6), 670–684. 
http://doi.org/10.1007/s00018-004-4464-6 
Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., … Tsai, L. H. 
(1992). A family of human cdc2-related protein kinases. The EMBO Journal, 11(8), 
2909–17. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1639063 
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008). Mapping 
and quantifying mammalian transcriptomes by RNA-Seq. Nature Methods, 5(7), 
621–628. http://doi.org/10.1038/nmeth.1226 
Park, P. J. (2009, October 8). ChIP-Seq: Advantages and challenges of a maturing 
technology. Nature Reviews Genetics. http://doi.org/10.1038/nrg2641 
Pathan, M., Keerthikumar, S., Ang, C. S., Gangoda, L., Quek, C. Y. J., Williamson, N. 
A., … Mathivanan, S. (2015). FunRich: An open access standalone functional 
enrichment and interaction network analysis tool. Proteomics, 15(15), 2597–2601. 
http://doi.org/10.1002/pmic.201400515 
Pathan, M., Keerthikumar, S., Chisanga, D., Alessandro, R., Ang, C. S., Askenase, P., … 
Mathivanan, S. (2017). A novel community driven software for functional 
enrichment analysis of extracellular vesicles data. Journal of Extracellular Vesicles, 
6(1). http://doi.org/10.1080/20013078.2017.1321455 
220 
 
Pulmonary Arterial Hypertension KnowledgeBase (PAHKB) Home. (). Retrieved 
February 22, 2018, from https://bioinfo.uth.edu/PAHKB/index.html 
Qian, Y., Du, Z., Xing, Y., Zhou, T., Chen, T., & Shi, M. (2017). Interferon regulatory 
factor 4 (IRF4) is overexpressed in human non-small cell lung cancer (NSCLC) and 
activates the Notch signaling pathway. Molecular Medicine Reports, 16(5), 6034–
6040. http://doi.org/10.3892/mmr.2017.7319 
Ringrose, L. (2017). Epigenetics and Systems Biology. Academic Press. Retrieved from 
https://books.google.com/books 
Ringrose, L., Rehmsmeier, M., Dura, J.-M., & Paro, R. (2003). Genome-wide prediction 
of Polycomb/Trithorax response elements in Drosophila melanogaster. 
Developmental Cell, 5(5), 759–71. http://doi.org/10.1016/S1534-5807(03)00337-X 
Rio, D. C., Ares, M., Hannon, G. J., & Nilsen, T. W. (2010). Purification of RNA Using 
TRIzol (TRI Reagent). Cold Spring Harbor Protocols, 2010(6), pdb.prot5439-
prot5439. http://doi.org/10.1101/pdb.prot5439 
Rougemont, J., & Naef, F. (2012). Computational analysis of protein-DNA interactions 
from ChIP-Seq data. Methods in Molecular Biology, 786, 263–273. 
http://doi.org/10.1007/978-1-61779-292-2_16 
Ryazanov, A. G., Ward, M. D., Mendola, C. E., Pavur, K. S., Dorovkov, M. V, 
Wiedmann, M., … Hait, W. N. (1997). Identification of a new class of protein 
kinases represented by eukaryotic elongation factor-2 kinase. Proceedings of the 
National Academy of Sciences of the United States of America, 94(10), 4884–9. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9144159 
Siggers, T., Duyzend, M. H., Reddy, J., Khan, S., & Bulyk, M. L. (2011). Non-DNA-
binding cofactors enhance DNA-binding specificity of a transcriptional regulatory 
complex. Molecular Systems Biology, 7(1), 555–555. 
http://doi.org/10.1038/msb.2011.89 
Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., … 
Narechania, A. (2003). PANTHER: A library of protein families and subfamilies 
indexed by function. Genome Research, 13(9), 2129–2141. 
http://doi.org/10.1101/gr.772403 
TruSeq, I. (2013). Illumina: TruSeq Stranded mRNA Sample Preparation Guide. Manual, 
(October), 1–4. http://doi.org/# RS-122-9004DOC 
Usadellab. (). Trimmomatic Manual: V0.32. http://doi.org/10.1093/bioinformatics/btu170 
Wang, L. Y., Wang, P., Li, M. J., Qin, J., Wang, X., Zhang, M. Q., & Wang, J. (2011). 
EpiRegNet: Constructing epigenetic regulatory network from high throughput gene 
expression data for humans. Epigenetics, 6(12), 1505–1512. 
http://doi.org/10.4161/epi.6.12.18176 
 
221 
 
Wang, S., Sun, H., Ma, J., Zang, C., Wang, C., Wang, J., … Liu, X. S. (2013). Target 
analysis by integration of transcriptome and ChIP-Seq data with BETA. Nature 
Protocols, 8 VN-re(12), 25022515. http://doi.org/10.1038/nprot.2013.150 
Wang, X., Wang, Q., Lin, H., Li, S., Sun, L., & Yang, Y. (2013a). HSP72 and gp96 in 
gastroenterological cancers. Clinica Chimica Acta, 417, 73–79. 
http://doi.org/10.1016/j.cca.2012.12.017 
Wang, X., Wang, Q., Lin, H., Li, S., Sun, L., & Yang, Y. (2013b). HSP72 and gp96 in 
gastroenterological cancers. Clinica Chimica Acta, 417, 73–79. 
http://doi.org/10.1016/j.cca.2012.12.017 
Wang, Z., Gerstein, M., & Snyder, M. (2009, January 1). RNA-Seq: A revolutionary tool 
for transcriptomics. Nature Reviews Genetics. http://doi.org/10.1038/nrg2484 
Wassermann, M., Wassermann, D., Cucos, S., & Miller, H. J. (1979). World PCBs Map: 
Storage And Effects In Man And His Biologic Environment In The 1970s. Annals of 
the New York Academy of Sciences, 320(1 Health Effect), 69–124. 
http://doi.org/10.1111/j.1749-6632.1979.tb56594.x 
Zhang, H., Chen, X., Wang, J., Guang, W., Han, W., Zhang, H., … Gu, Y. (). EGR1 
decreases the malignancy of human non-small cell lung carcinoma by regulating 
KRT18 expression. http://doi.org/10.1038/srep05416 
Zhao, M., Austin, E. D., Hemnes, A. R., Loyd, J. E., & Zhao, Z. (2014). An evidence-
based knowledgebase of pulmonary arterial hypertension to identify genes and 
pathways relevant to pathogenesis. Mol. BioSyst., 10(4), 732–740. 
http://doi.org/10.1039/C3MB70496C 
 
 
 
 
 
 
 
 
222 
 
 
 
 
 
 
CHAPTER 5 
Determination of ID3 targeted genes resulted from the integrative analysis involved 
in endothelial cell proliferation 
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Abstract 
PAH is an incurable end-stage lung disease that is often fatal and characterized by the 
presence of plexiform vascular lesions in pulmonary arterioles. ECs in plexiform vascular 
lesions (a pathological hallmark of PAH) have been characterized as hyper-proliferative 
and apoptosis-resistant, which is consistent with a neoplastic hypothesis. Epidemiological 
studies have reported that women are up to four times as likely to present with severe 
PAH as men while animal studies have implicated endogenous estrogen as a contributing 
factor for PVL. The impact of exogenous estrogen or estrogenic PCBs is growing as an 
environmental risk factor, particularly exposure to PCBs, in the development of PAH that 
clearly justify the need for further studies to determine the contribution of the 
environment to PVLs. The integrative analysis of ChIP- and RNA-Seq data from our lab 
resulted in ID3 specific targeted genes, which are associated with vascular 
reprogramming. Out of these ID3 target genes, some of the genes have been shown 
involved in vascular reprogramming and EC proliferation. The objective of the research 
is to investigate the interaction of ID3 with these genes and elucidate molecular 
pathogenesis of a highly disordered or neoplastic-like endothelial vascular lesion to more 
accurately address the clinical reality of short survival and no cure for IPAH patients with 
PVLs. Our aim is to generate mechanistic data of this interaction in our cell model with 
ID3 in order to identify target genes involved in promoting the growth of a tumor-like 
vascular lesion. 
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Introduction- 
The integrative ChIP and RNA Seq data of ID3 targeted gene demonstrated that DNAJC2 
and MALAT1 genes were significantly expressed. Therefore, we decided to check the 
DNAJC2 and MALAT1 genes epigenetically regulate ID3 and PCB-induced vascular 
lesions in vitro. DNAJC2 is a gene in Homo sapiens codes for the protein which is an 
officially named as DnaJ heat shock protein family (Hsp40) member C2 (Entrez Gene: 
ZRF1 zuotin related factor 1, ; Matsumoto-Taniura, Pirollet, Monroe, Gerace, & 
Westendorf, 1996). DNAJC2 gene is also known as MPHOSPH11, MPP11, MIDA1, and 
Zuotin-related factor 1, ZRF1 (Gray, Yates, Seal, Wright, & Bruford, 2015). DNAJC2 
gene belongs to the family of the M-phase phosphoprotein (MPP), which encodes a 
phosphoprotein with a J domain and a Myb DNA-binding domain, which localizes to 
both the nucleus and the cytosol. The protein acts as a molecular chaperone for nascent 
polypeptide chains as they exit the ribosome (Matsumoto-Taniura et al., 1996). It has 
been shown that DNAJC2 protein is related to pathways like a cellular response to heat 
stress and cellular Senescence (Gray et al., 2015). Researchers have also shown the 
evidence of involvement of DNAJC2 as leukemia-associated antigen and in primary head 
and neck squamous cell tumors (Demajo et al., 2014; Resto et al., 2000). The DnaJ 
domain of DNAJC2 protein, which is part of the amino-terminal part of the protein is 
conserved ubiquitously from yeast to mammals. This amino part mediates interactions 
with heat shock proteins and is mainly implicated in protein-chaperone functions 
associated with ribosomes (Yan et al., 1998). In addition to this, DNAJC2 can bind to 
nucleic acids through its DnaJ domain (Wilhelm, Reinbolt, Gangloff, Dirheimer, & 
Wilhelm, 1994; Zhang, Lockshin, Herbert, Winter, & Rich, 1992) and has been suggested 
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to have a role in transcriptional regulation (Eisenman & Craig, 2004; Yoshida, Inoue, 
Shoji, Ikawa, & Obinata, 2004). Inou et al. have showed that MIDA1 i.e. DNAJC2 
protein is associated with ID1 protein which regulates cell growth. They have also shown 
that DNAJC2 can directly bind to DNA through amino acid sequence contains 
tryptophan-mediated repeats (Tryp-med repeats) similar to the DNA binding region of 
the c-Myb oncoprotein (Inoue, Shoji, & Obinata, 2000; Shoji, Obinata, 1999).  Recently, 
researchers have shown that DNAJC2 protein is a regulator of the expression of 
polycomb targets - polycomb repressive complexes 1 and 2 (PRC1 and PRC2), which 
play a crucial role in several processes including cell proliferation, and senescence in 
stem cells and cancer (Sauvageau & Sauvageau, 2010).  In humans, the protein structure 
of DNAJC2 contains an additional C-terminal extension with 2 SANT domains. SANT 
domains are similar to the Myb-DNA binding motif, (Boyer, Latek, & Peterson, 2004) 
which is required for Myb proto-oncogene to bind DNA as shown in Figure 95. Indeed, 
the researchers have shown that DNAJC2 can directly bind to DNA. Researchers have 
shown the evidence of binding of DNAJC2 to monoubiquitinated histone H2A (H2Aub1) 
protein through its ubiquitin-binding domain (UBD). In proliferating conditions of cells, 
polycomb proteins occupy H2Aub1 mark. In vitro studies have shown that DNAJC2 
displaces PRC1 from chromatin during differentiation stage by competing for the 
H2Aub1 mark. Once DNAJC2 protein attached to the chromatin by DnaJ binding 
domain, it induces transcriptional activation of differentiation genes (Richly et al., 2010). 
In addition to this, DNAJC2 protein is also responsible for self-renewing, the pluripotent 
state of endothelial stem cells (ESC). Researchers have shown that DNAJC2 protein 
directly interacts with ID1 protein to maintain a self-renewing state of ESCs. Similar to 
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H2Aub1 protein, DNAJC2 protein interacts with ID1 through its UBD domain (Aloia, 
Gutierrez, Caballero, & Di Croce, 2015; Ruzinova & Benezra, 2003). ID1 protein 
regulates the cell differentiation through DNAJC2 protein since ID1 protein belongs to 
the family of ID proteins- ID1, ID2, ID3, and ID4. ID proteins are helix-loop-helix 
(HLH) proteins also known as inhibitors of differentiation function as dominant negative 
regulators of basic HLH (bHLH) transcriptional regulators that drive cell lineage 
commitment and differentiation of cells. Earlier researchers and our lab have shown that 
ID3 regulates cell differentiation, stemness to the cells and angiogenesis (Das et al., 2015; 
Morisaki et al., 2016). With this background information, we checked whether proteins 
ID3 and DNAJC2 also interact with each other.  
 
 
Figure 95- Representative Map Reads from ID3 ChIP-Seq shows 
immunoprecipitated chromatin containing DNA regions corresponding to genes 
DNAJC2-AS1 and MALAT1 
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Experiment – 
Western Blot- 
In order to determine the interaction between ID3 and DNAJC2 protein, we first checked 
the expression of DNAJC2 protein in HPMEC ID3+ cell line with control, E2, PCB153 
and co-treatment E2 +PCB153 treatments. We seeded the HPMEC ID3+ cells in four 
100mm petri dishes each. We added 0.1% DMSO (control), E2 (100 ng/mL), PCB153 
(100 ng/mL) and combination treatment of E2 +PCB153 to separate petri dishes. We 
analyzed that combination treatment of E2 +PCB153 increase 2-3-fold change in 
DNAJC2 protein expression in HPMEC ID3+ cells compared to control. E2 (100 ng/mL), 
PCB153 (100 ng/mL) treatment showed significant (P<0.01) increased than control as 
shown in Figure 96. 
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Immunoprecipitation  
ID3 co-immunoprecipitation of DNAJC2- 
Background- In vivo, the mouse homolog to DNAJC2 known as MIDA1 (mouse Id 
associated 1) has been shown to bind to ID1 and positively regulate cell growth. Hence, 
our aim is to generate mechanistic data of this interaction in our cell model with ID3 in 
order to identify target genes involved in promoting the growth of a tumor-like vascular 
lesion. We postulate that ID3 is a novel co-activator of DNAJC2 and ID3-DNAJC2 
protein-protein interaction is critical in driving the growth of tumor-like vascular lesions. 
Procedure- For immunoblots of immunoprecipitated (IP) lysate the following method was 
used. ID3 protein was pulled down using magnetic beads (Dynabeads protein G). In 
Figure 96- Western Blot analysis of DNAJC2 protein 
Detection of DNAJC2 protein 71 KDa and beta actin as a control 41 KDa in Lung EC 
ID3+ cell line. Gel percentage 7.5%. Dilution of DNAJC2 antibody (1: 2000) i.e. 5 µL 
in 10 mL of blocking buffer- Primary antibody is rabbit Ab (polyclonal). Incubation 
time overnight at 4 oC for Primary antibody. Secondary Ab is anti-rabbit Ab. 
Dilution of Secondary antibody (1: 50000). E2 & PCB153 = 100ng/mL  
229 
 
Brief, the lysate was incubated with 10 mg of antibody and 50 mL (1.5 mg) of Dynabeads 
(Invitrogen) in microcentrifuge tubes with rotation for 10 minutes at room temperature. 
Samples were then placed on a magnetic particle concentrator (DynaMagTM-2, 
Invitrogen) and the supernatant was discarded. Dynabeads–Ab–Ag complex was washed 
3 times with washing buffer and tubes were placed on magnetic particle concentrator to 
remove the supernatant. The magnetic Dynabeads–Ab–Ag complex was suspended with 
20 mL of Elution Buffer and boiled in SDS sample buffer for 5 min. Samples were 
placed on the magnetic particle concentrator and the supernatant containing protein were 
separated by SDS-PAGE and immunoblotted as described above as shown in Figure 97. 
Experimental Design: ID3 and DNAJC2 cross-linked to DNA (chromatin) will be 
measured by Western blot using lung EC ID3+ and/or lung EC WT. 
Using approved ChIP protocol: 
Step 1: Fix cells to cross-link DNA to protein. 
Step 2: Sonicate to lyse cells and shear chromatin. Note: run a DNA gel to determine 
optimum conditions for shearing DNA. 
Step 3: Immunoprecipitated DNA bound by ID3 and/or DNAJC2. 
Experiment 1 (ID3 bound DNA) 
Sample 1: IP chromatin cross-linked proteins with polyclonal ID3 Ab. 
Sample 2: IP chromatin cross-linked proteins with IgG Ab (negative control). 
Sample 3: Whole cell lysate (Lung EC ID3+ positive control) 
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We loaded the immunoprecipitated lysate in SDS-PAGE and detected ID3 using 
antibody. We ran three samples: (i) ID3 IP lysate; (ii) IgG IP lysate (negative control); 
and (iii) whole cell lysate 100 µg (positive control). 
Experiment 2 (DNAJC2 bound DNA) 
Sample 1: IP chromatin cross-linked proteins with polyclonal DNAJC2 Ab 
Sample 2: IP chromatin cross-linked proteins with IgG Ab (negative control). 
Sample 3: Whole cell lysate (Lung EC ID3+ positive control) 
We loaded the immunoprecipitated lysate in SDS-PAGE and detected DNAJC2 using 
antibody. We ran three samples: (i) DNAJC2 IP lysate (ii) IgG IP lysate (negative 
control) and (iii) whole cell lysate 100 µg (positive control). 
Procedure- 
Experiment-1 - Dilution of ID3 antibody (1: 1000) i.e 10 µL in 10 mL of blocking buffer- 
BSA (0.5g +10 mL TBST). Primary antibody is rabbit Ab (polyclonal). Incubation time 
overnight at 4 degrees Celsius for Primary antibody. Secondary Ab is anti-rabbit Ab. 
Dilution of Secondary antibody (1: 5000) i.e. 2 µL in 10 mL of blocking buffer.  
Molecular weight of ID3 is 17 KDa. Separating Gel percentage- 15% DNAJC2 (abcam) 
ab134572 Rabbit polyclonal used for IP. ID3 (CalBioReagent) monoclonal used for 
western blot. 
Experiment-2 - Dilution of DNAJC2 antibody (1: 2000) i.e 5 µL in 10 mL of blocking 
buffer. Primary antibody is rabbit Ab (polyclonal). Incubation time overnight at 4 oC for 
Primary antibody. Secondary Ab is anti-rabbit Ab. Dilution of Secondary antibody (1: 
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50000). Molecular weight of DNAJC2 is 71 KDa. Separating Gel percentage- 7.5%. 
DNAJC2 (abcam) ab134572 Rabbit polyclonal used for western blot. ID3 (Santacruz 
Biotechnology sc- 490) monoclonal antibody. 
Results- 
 
 
 
 
Figure 97- Immunoprecipitation of ID3 and DNAJC2 
ID3 protein was isolated by immunoprecipitation (IP) technique using magnetic beads 
and detected by immunoblot. ID3 protein of immunoprecipitated DNAJC2 protein was 
determined with anti-ID3 antibody. ID3 bands detected from immunoprecipitated cell 
lysate corresponded with the molecular weight of 17 KDa for ID3. 
Electrochemiluminescence (ECL) band intensity for phosphorylated ID3 was imaged 
with a Bio-Rad Versa Doc instrument. Similarly, DNAJC2 protein detected from 
immunoprecipitated ID3 protein lysate at 71 KDa.  
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Immunofluorescence and immunoprecipitation experiments showed that ID3 and 
DNAJC2 interact with each other as shown in Figure 97 and 98. 
Figure 98- Co-localization of ID3 and DNAJC2 
 Confocal microscopy of the co-localization of ID3 (blue) with DNAJC2 (Red) in 
lung EC ID3+ cells. Cells were treated with DMSO (Left) or PCB153 (0.3 µM) 
(Right) for 24h. ID3 was determined by immunofluorescent labelling with rabbit anti-
ID3 polyclonal antibody (Alexa Fluor 566-conjugated secondary antibody). DNAJC2 
was determined by immunofluorescent labelling with mouse monoclonal IgG (Alexa 
Fluor 633-conjugated secondary antibody). 
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CRISPR/Cas9 experiment 
 
Hypothesis: The CRISPRCas9 MALAT1/DNAJC2 (ZRF1) epigenetically regulate 
the phenotypic expression like spheroid size and numbers in lung EC ID3+. 
Background: Our aim is to generate mechanistic data of this interaction in our cell 
model with ID3 in order to identify target genes involved in promoting the growth of a 
tumor-like vascular lesion. We postulated that ID3 is a novel co-activator of DNAJC2 
and ID3-DNAJC2 protein-protein interaction is critical in driving the growth of tumor-
like vascular lesions. In order to determine the interaction between ID3 and DNAJC2 
proteins, we did a co-immunoprecipitation experiment in two ways. In the first 
experiment, we used an ID3 polyclonal antibody to pull own ID3 bound proteins from 
Lung EC ID3+ protein sample and then immunoblotted with the monoclonal DNAJC2 
antibody. We found the expression of DNAJC2 protein at 71 KDa, which is confirmed by 
using standard protein ladder for molecular weight determination on western blots. In 
another similar experiment, we used the DNAJC2 antibody for immunoprecipitation from 
the sample and then immunoblotted with the monoclonal ID3 antibody. We found the 
expression of ID3 protein at 17 KDa, which is confirmed by using standard protein ladder 
for molecular weight determination on western blots. Moreover, we did mRNA 
sequencing experiment with lung EC ID3+ cells and analyzed the data. We found out that 
Metastasis Associated Lung Adenocarcinoma Transcript1 (MALAT1) mRNA was 
expressed higher folds in lung EC ID3+ cells compared to the control wild type HPMEC 
cells.  
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Therefore, to check whether MALAT1 and DNAJC2 proteins co-regulate with ID3 
protein, we decided to silence the expression of MALAT1 and DNAJC2 proteins and 
study the effect of silencing on the stem like property of lung EC ID3+ cells.  
MALAT1 gene is non-protein coding gene which is also known as Nuclear Paraspeckle 
Assembly Transcript 2 (Ji, Diederichs, Wang, Böing, et al., 2003; Kryger, Fan, Wilce, & 
Jaquet, 2012; Zhang et al., 2017). Noncoding RNAs (ncRNAs) are defined as 
untranslated regulatory RNA molecules. In humans, at least 98% of the total genome 
does not get translated into protein. Only 2% of total DNA sequences responsible for 
non-protein coding regions (Yin, Hamblin, & Chen, 2014). So, the non-protein coding 
part of genome consists of Noncoding RNAs which include microRNAs, and long 
noncoding RNAs (Bartel & Chen, 2004). MALAT1 gene produces non-long coding RNA. 
In addition to this, More than 8000bp sequence present in MALAT1 gene is highly 
conserved in 33 mammalian species and the highest expression of MALAT1 mRNA is 
found to be in pancreas and lung (Chen, Li, Lodish, & Bartel, 2004; Ji, Diederichs, 
Wang, Boïng, et al., 2003). MALAT1 gene transcribes into a precursor transcript. This 
transcript resides in the nucleus, which is thought to form molecular scaffolds for 
ribonucleoprotein complexes. Then, RNase P cleaves of a tRNA-like small ncRNA 
(known as mascRNA) from the 3' end of transcript and extract a long non-coding RNA ( 
Ma et al., 2015; Rinn & Chang, 2012). Primarily, MALAT1 gene is identified by 
subtractive hybridization in stage I NSCLC (non-small cell lung cancer) tumors 
(Hutchinson et al., 2007; Ji, Diederichs, Wang, Boïng, et al., 2003).  
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At the beginning, many researchers have been originally identified lncRNA MALAT1 as 
a prognostic marker for non-small cell lung cancer, in the cerebrovascular pathogenesis 
of ischemic stroke. Researchers have done several experiments to prove the elevated 
level of lncRNA MALAT1 responsible for NSCLC. In one of the experiments, scientist 
tested increasing levels of MALAT1 expression in cultured NSCLC cell lines (A549 and 
HTB58) via qPCR analysis (Ma et al., 2015). Gutschner et al. 2013 showed in vivo and in 
vitro experiments that NSCLC cell lines transfected with MALAT1- shRNA proliferate 
(Gutschner et al., 2013). Moreover, another group of researchers in the literature showed 
that inhibition of MALAT1 forces cells to switch its gears from anti-proliferative to 
impaired endothelial cell proliferation in vitro and in vivo and reduced retinal vessel 
growth. They have also showed that when siRNA transfected for MALAT1 treated with 
HUVECs reduces the expression of MALAT1 induces angiogenic sprouting and 
migration but represses proliferation. These researchers have also found out that when 
HUVECs exposed to hypoxia environment, the expression MALAT1 increased 
substantially (Michalik et al., 2014). Similarly, when we treated with lung EC ID3+ cells 
to SU5416 which is a selective synthetic inhibitor of the Flk-1/KDR vascular endothelial 
growth factor (VEGF) receptor tyrosine kinase in presence of hypoxia environment in our 
lab, we found the expression of stem cell markers Oct-4, Sox-2, and Nanog by cell 
cytometry and immunohistochemistry analysis. At the same time, surprisingly we found 
the elevated expression of VEGFR3 markers on lung EC ID3+ cells (Doke & Felty, 
2016). We proposed these stem likes cells, which are pluripotent cell that gives rise to a 
clonal pulmonary vascular lesion that supports the aggressive growth of NSCLC.  
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Looking at the close relation of lncRNA MALAT1 and ID3 protein to metastatic growth 
of NSCLC, therefore, we studied the effect of lncRNA MALAT1 on the lung EC ID3+. 
Experiments- 
Spheroid Assays- 
Question: Does the long noncoding RNA (lncRNA) MALAT1 and DNAJC2 regulate the 
growth of ID3 expressing lung endothelial spheroids (lung EC ID3+)? 
Purpose: Small noncoding RNAs (i.e. microRNAs), >200-nucleotide long transcripts, 
namely lncRNAs, can interfere with gene expressions and signaling pathways at various 
stages. ID3 may be epigenetically regulated by the long-noncoding RNA MALAT1 based 
on the following evidence: MALAT1 expression is augmented by hypoxia in endothelial 
cells (a contributing factor in the rodent model of PAH) and MALAT1 supports the 
proliferative response of endothelial cells both phenomena are correlated with ID3. Thus, 
the purpose of this experiment is to determine whether lncRNA MALAT1 regulates the 
formation of ID3 expressing endothelial spheroids. It is unclear whether endothelial- or 
smooth muscle-based lesions have a similar impact on the course of PAH.  
Experimental Design: 
We followed the protocol for endothelial spheroid and 3-D cell culture as described in 
Das JK et al. Microvascular Research (2015). In brief, cells were suspended in serum-free 
stem cell medium containing DMEM/F12 (1:1) supplemented with B27®. For EC 
spheroid generation, approximately 100-150 cells per well were seeded in an ultra-low 
attachment 96-well plate (Corning Inc, Lowell, MA). 
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2. Experiment 2 Design: 
 Transfect (i) Lung EC ID3+ and (ii) Lung EC vector with MALAT1 sgRNA 
CRISPR/Cas9 All-in-One Lentivector set (Human) Applied Biological Materials 
(ABM) K1258505.  
 Transfect (i) Lung EC ID3+ and (ii) Lung EC vector with DNAJC2 sgRNA 
CRISPR/Cas9 All-in-One Lentivector set (Human) Applied Biological Materials 
(ABM) K0614705. 
 
 Transfect (i) Lung EC ID3+ and (ii) Lung EC vector with Scrambled sgRNA 
CRISPR/Cas9. 
After 24-48 h transfection, seed cells in triplicate (100-150 cells per well) in ultra-low 
attachment 96-well plates as described previously and recorded phenotype changes. 
Results: We found that knockdown of lncRNA MALAT1 resulted in the following 
phenotype changes- decreased endothelial spheroid number, decreased endothelial 
spheroid size when compared to the control endothelial spheroids transfected with 
Scrambled sgRNA CRISPR/Cas9. The nuclear transcript MALAT1 has been functionally 
associated with gene regulation and alternative splicing and its regulation has been shown 
to impact proliferation, apoptosis, migration and invasion. Therefore, these results 
showed ID3 may be epigenetically regulated by the long-noncoding RNA MALAT1 
(metastasis-associated lung adenocarcinoma transcript 1) as shown in Figure 99, 100 and 
101.  
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Figure 99- It shows pictures of spheroids with CRISPR/CAS9 MALAT1 /ZRF1 
treatment. 
 CRISPR/CAS9 MALAT1 /ZRF1 treatment decreases spheroid size and number in the 
PCB153 treated wells. The decrese in  the size and number of spheroid in 
CRISPR/CAS9 MALAT1 /ZRF1 treated wells are significantly lower compared to 
scrambled sgRNA  control. Scale bar= 10µm. 
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Figure 100- CRISPR/CAS9 MALAT1 /ZRF1 knockdown reduced spheroid number 
CRISPR/CAS9 MALAT1 /ZRF1 knockdown ID3 expression in lung EC ID3+ and result 
in a decrease in spheroid number compared to spheroid with scrambled sgRNA 
CRISPR/Cas9. (*)PCB153 treatment in CRISPR/CAS9 MALAT1 /ZRF1 significantly 
different from PCB153 treatment in scrambled sgRNA (P<0.01) at day 10. Data were 
analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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Figure 101- CRISPR/CAS9 MALAT1 /ZRF1 knockdown reduced spheroid size 
CRISPR/CAS9 MALAT1 /ZRF1 knockdown ID3 expression in lung EC ID3+ and result 
in a decrease in spheroid diameter compared to spheroid with scrambled sgRNA 
CRISPR/Cas9. (*)PCB153 treatment in CRISPR/CAS9 MALAT1 /ZRF1 significantly 
different from PCB153 treatment in scrambled sgRNA (P<0.01) at day 10 Data were 
analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
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PCR experiment 
Purpose: To investigate how non-coding RNAs regulate ID3 when exposed to PCBs. 
RNA Isolation and Quantitative real-time PCR (qRT-PCR) 
Total RNA was isolated and purified using the RNeasy Mini Kit from Qiagen (Valencia, 
CA). RNA sample quality was verified by electrophoresis on a denaturing agarose gel 
and then reverse transcribed into cDNA using the RT² First Strand Kit from SuperArray 
Bioscience Corporation (Frederick, MD) according to the manufacturer's protocol. The 
PCR reactions using cDNA were performed in an Applied Biosystems 7300 Real-Time 
PCR System using RT2 SYBR Green/ROX qPCR Master Mix and the manufacturer's 
thermal cycler protocol (95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s, 60 °C 
for 1 min). The threshold cycle (CT) from each well was determined using ABI 7300 
SDS software. 
MALAT1-set siRNA/shRNA/RNAi Lentivector (Human) 
The siRNA specifically targeting MALAT1 was constructed by abm Company (USA), 
HPMEC and HPMEC ID3+ cells were transfected with siRNA targeting MALAT1 using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Cells 
transfected with Scramble was used as the negative control, the Scramble siRNA 
sequence was as follows: sense, AACAUCUCUUGGGCUUUUAUU, antisense, 
GAGAAUUAAGUAAAUGCCCUU. Cells were collected after transfection for RNA 
extraction 
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Target Sequence 1762: GACCTTGAAATCCATGACG 
5374: TCAGAAGAGTTGCTTCATTTCATCTGGGA 
5427: ACAGATAAGTTTAACTTGCATCTGCAGTA 
5605: TGGGCTTCAGTGATGGGATAGTACACTTC 
Sequencing Primers TACGTCCAAGGTCGGGCAGGAAGA 
Mammalian Selection - Puromycin. Direct non-viral plasmid transfection for immediate 
expression. Package into Lentiviral particles for high efficiency transduction and stably 
integrated expression. RNA interference lentiviral vectors contain siRNAs. We employed 
a dual convergent promoter system where the sense and antisense strands of the siRNA 
are expressed by two different promoters rather than in a hairpin loop to avoid any 
possible recombination events that can occur. 
LncRNA MALAT1 polymerase chain reaction (PCR) array  
PCR analysis of cDNA from RNA isolated from HPMEC ID3+ treated with vehicle 
control (0.1% DMSO), PCB153, or 17β-estradiol for 24h was performed in triplicate 
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using RT2.  RT² lncRNA qPCR Assay for Human MALAT1 (LPH18065A) and RT² 
lncRNA qPCR Assay for Human HIF1A-AS2 (LPH00171A) from Qiagen Inc. were used 
to compare the relative expression of genes. Relative changes in gene expression between 
the treated and untreated HPMEC ID3+  RNA were calculated by the ΔΔCT method as 
previously described (Livak & Schmittgen, 2001). First, target genes in were normalized 
to the endogenous control or housekeeping genes: RPL13A, GAPDH, or ACTB. Next, 
each treatment group was normalized to the untreated group (vehicle control, 0.1% 
DMSO). Using the SA Biosciences PCR Array Data Analysis Web Portal, fold changes 
in gene expression were analyzed between groups using the equation- 
ΔΔCT= [CT target gene−Avg.CT housekeeping genes] treated group−CT target gene− 
Avg. CT housekeeping genes] control group. Each value is a repeat of three independent 
experiments. ANOVA and Fisher's least significant difference test were used for multi-
group comparisons, with a P value of less than 0.05 considered significant. 
 
Results and Conclusion- 
To validate our results from RNA Seq studies, we did RT-qPCR analysis. We validated 
the expression of lncRNA MALAT1 in HPMEC ID3+ cells. When we treated the cells 
with E2 and PCB153, the MALAT1 showed 4-5 fold higher expression compared to 
control as shown in Figure 102. These results signify the interaction between ID3 
overexpression and MALAT1 is significant. Researchers have already shown a critical 
role for MALAT1 in NSCLC cancer metastasis, which is the major cause of cancer 
recurrence and tumor-related death. Therefore, we hypothesized that MALAT1 and ID3 
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might be a potential therapeutic target to inhibit endothelial cell proliferation due to 
exposure to PCB.   
 
 
 
 
 
 
 
 
 
 
Figure 102- MALAT1 expression in HPMEC ID3+ cells. 
Upregulation of lncRNA MALAT1 mRNA expression when treated with E2 and 
PCB153. HPMEC ID3+ cells were treated with either vehicle or E2 or PCB153 for 24 h, 
and the mRNA expression of MALAT1 was validated by using RT-qPCR. Data are 
represented as mean ± SE. * p<0.01.  
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Figure 103- Knockdown of MALAT1 in HPMEC ID3+ cells measured by qRT-PCR  
HPMEC and HPMEC ID3+ cells were transfected with siRNA targeting MALAT1, QRT-
PCR assay was employed to detect the endogenous expression of MALAT1 to confirm 
the knockdown efficiency. The HPMEC cells transfected with Scramble was used as the 
negative control.*P < 0.01 vs. the control. 
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CHAPTER 6 
The ID3 Protein: A Novel, Potential Target for Therapy to Inhibit the Proliferative 
Plexiform Lesion in PAH and NSCLC. 
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Introduction 
The proliferative vascular lesion is a major cause of high morbidity and mortality in 
severe end stage IPAH patients because the pulmonary vascular lesion progressively 
obliterate pulmonary arterioles and impinge upon the unobstructed vessels resulting in 
heart failure. The prognosis of these patients remains poor because the current treatment 
modalities rely on vasodilators, which are not designed to control the growth of PVL, 
which has become a major clinical barrier for the treatment of end stage PAH. We have 
earlier shown that PCB-induced ROS upregulated ID3 levels and this re-programmed 
adult human ECs into iPSCs. Furthermore, we have demonstrated that ID3 signals 
VEGFR3 expression in vitro (Das et al., 2015). Hence, our findings support the idea that 
ID3 re-programs the adult ECs through inducing VEGFR3 to induce pluripotent 
endothelial stem cells. This is consistent with the fact that VEGFR3 knockout mice are 
embryonically lethal and display defects in remodeling the primary vascular plexus. 
Recently, the expression of VEGFR3 has been shown in non-malignant orbital vascular 
lesions (Atchison et al., 2016). Based on these evidences, we hypothesize that ID3-
VEGFR3 signaling act to drive stemness by enhancing proliferation and inhibiting 
differentiation. Therefore, we propose that blocking this signaling pathway will suppress 
stem cell–related cell proliferation. We postulate the following signaling pathway: 
PCBs → ID3 → VEGFR3 and/or PCB → ROS → ID3→ VEGFR3 
Our preliminary data have shown that PCB-induced ROS contribute to cell proliferation 
and endothelial spheroid growth. Using the previously published data, we decided to use 
BNC420 drug to check whether epigenetic regulation of ID3 is affected in the presence 
and absence of PCBs. 
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Materials and Methods 
Cell culture and treatment conditions  
Primary cells, Human pulmonary microvascular endothelial cells or Human lung 
endothelial cells (HPMEC-ST1.6R.).  HPMEC cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM-F12) supplemented with 5% (v/v) fetal bovine serum 
(FBS). Cells were cultured at 37 ºC in a humidified atmosphere with 5% CO2.  
 
Estrogenic chemical treatments  
Stock solutions of PCB153 was prepared in DMSO. The same amount of DMSO as in 
PCB and estradiol-treated cells were added to control cultures. The level of DMSO in 
experimental media was less than 0.1%. PCB blood levels have been reported to reach 
approximately 1000 ng/mL (∼3 μM) in occupationally exposed individuals (Wassermann 
et al., 1979). Our unpublished data showed a significant increase in PCB- induced 
vascularization with PCB153 concentrations of 10–100 ng/mL. Based on known PCB 
blood levels from occupational exposure and our preliminary results; we chose a PCB 
dose of 100 ng/mL (∼0.3 µM) to expose endothelial cells. Our previous studies also 
showed endothelial cell proliferation and vascular tube formation at physiological doses 
of 17β-estradiol (Das & Felty, 2014a; Felty, 2006; Felty & Porther, 2008b) therefore, 
HPMEC and HPMEC ID3+ were exposed to estradiol at 100 ng/mL (∼3.6 nM). PCB 
congeners 2,2′,4,4′,5,5′-hexachlorobiphenyl (PCB153) were purchased from 
AccuStandard (NewHaven, CT) and dissolved in dimethyl sulfoxide (DMSO). All other 
chemicals and reagents were purchased from Sigma (St. Louis, MO). 
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BNC420 Treatment 
Stock solutions of BNC420 was prepared in dimethyl sulfoxide (DMSO). The same 
amount of DMSO as in PCB and estradiol-treated cells were added to control cultures. 
The level of DMSO in experimental media was less than 0.1%. BNC420 is a novel 
VEGFR3 selective inhibitor provided by Bionomics Limited via approved Material 
Transfer Agreement (Leske et al., 2015). The single oral dose of BNC420 used in mice is 
at 75 mg/kg, which is well below the IC50 value. This dose is equivalent to 0.15 mM 
(Mol. Wt. = 501.55). We treated the cells with lower dose than 0.15 mM. Therefore, 
BNC420 is dissolved in DMSO at a stock conc. of 10 mM and further to achieve working 
concentration of 0.1 mM stock solution was diluted in culture medium for in vitro use as 
per Bionomics suggestions. 
ID3 overexpression 
The HPMEC cells were stably transfected with either Precision LentiORF for ID3 
(Thermo Scientific Open Biosystems) or empty vector lentiviral pLEX-JRED/TurboGFP 
by the trans-lentiviral packaging kit with Express-in transfection reagent according to the 
manufacturer’s instructions. We used the MOI (multiplicity of infection) of 25 and 
selected cells that overexpressed ID3 with blasticidin S (5 mg/ml) as per manufacturer’s 
instructions. Cells expressing TurboGFP were identified by fluorescence microscopy. 
Western blot 
Whole cell lysates were prepared with lysis buffer containing 25 mM Tris-HCl buffer 
(pH 8.0), 150 mM NaCl, 0.2% NP-40, 10% glycerol, 8 mM b-glycerophosphate, 2.5 mM 
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sodium pyro- phosphate, 10 mM NaF, 0.2 mM Na3VO4, 1 mM DTT and 10 ml/ml 
protease inhibitor cocktail (Sigma-Aldrich) followed the published protocol of our 
laboratory (Das & Felty, 2014a). Proteins were quantified using the Bradford Assay 
Reagent (Bio-Rad) according to the manufacturer’s instructions. Proteins (35–75 mg) 
were separated by 15% SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) 
membranes (Millipore). Membranes were blocked with 5% nonfat milk and incubated 
with the following antibodies: ID3 (Cal BioReagent) and b-actin (Cell Signaling). Anti- 
body dilutions used were according to manufacturer’s recommendations for detection by 
immunoblot. Gel percentage 15%. Primary antibody ID3 monoclonal Ab- 1:2500 and 
Secondary Ab- 1:10000. Membranes were then incubated with horseradish peroxidase-
conjugated secondary IgG antibodies and visualized with ECL Plus Western blot reagents 
(GE Healthcare, Amersham). The membranes were re-probed for b-actin as a loading 
control. Electrochemiluminescence (ECL) intensity of detected target proteins was 
imaged and quantified with a Bio-Rad Versa Doc instrument. All immunoblots have 
completed a minimum of three times for each experiment. 
Immunofluorescence 
The cells will be fixed with methanol and incubated at −20 °C for 15 min.  
Immunofluorescence staining was performed according to standard procedures.  Briefly, 
the cells were blocked with 3% normal goat serum at 4 °C for 1 h and then incubated 
with antibodies: anti-ID3 overnight at 4 °C. After washing with 1× phosphate buffered 
saline (PBS), cells were incubated with anti-mouse-IgG Alexa Fluor® 633 for ID3 (Santa 
Cruz Biotechnology Inc.). Cells were washed with PBS mounted with Fluoromount-
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GTM re- agent. The spheroids with GFP or RFP were photographed and analyzed using a 
Nikon C1 laser SCANNING confocal microscope. 
Endothelial spheroid assay 
HPMEC ID3+ cells were suspended in serum-free DMEM/F12 (1:1) culture medium 
supplemented with B27. For EC spheroid formation, approximately 100–150 HPMEC 
ID3+ cells were seeded separate well in an ultra-low attachment 96-well plate (Corning 
Inc. Lowell, MA) followed the published protocol of our laboratory (Das & Felty, 
2014a). The effect of estrogenic chemical PCB153 was determined by pre-treating the 
cells with 100 ng/mL E2 2h prior to exposure with 100 ng/mL (∼0.3 µM) PCB153 on the 
day of seeding cells. Endothelial spheroids were grown for 10 days in liquid culture in the 
absence or presence of PCB153. A total of 15 endothelial spheroids with a minimum 
diameter of 50 µm were counted in each experimental group. Pictures were taken on 10d 
after seeding. We counted number and size of spheroids on 10d. Data were analyzed by 
ANOVA; Tukey HSD test for multiple comparisons 
MTT assay 
To determine the effect of extra estrogen environmental pollutant PCB153 on the 
metabolic activity of lung endothelial cells, we performed some cell viability and cell 
proliferation assays. For cell viability measurement, we performed MTT assay which is 
colorimetric assay and measures the metabolic activity of cells. Actually, MTT is a 
tetrazolium dye known as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. 
NAD(P)H-dependent oxidoreductase enzymes present in mitochondria of metabolically 
active and dividing cells. This enzyme catalyses tetrazolium dye and converts into 
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insoluble formazan, which gives a purple colour (Berridge & Tan, 1993; M. V. Berridge 
et al., 2005). The intensity of the purple colour which can be measured at an optical 
density (OD) of 590 nm and its proportional to a number of metabolic active cells. We 
seeded HPMEC and HPMEC ID3+ cells with 50% confluence in 96 well clear-walled 
plate. We allowed the cells to grow for 24h in 5% FBS culture medium. After 24 hours, 
we gave treatments, 0.1% DMSO (control), PCB153 (100 ng/mL) to make total volume 
100 µL in each well. We measured the metabolic activity of cells after 48h with the 
addition of MTT dye and evaluating the purple colour intensity at 590nm.  
SRB assay 
The sulforhodamine B (SRB) assay is used for measurement of the total cellular protein 
content of adherent cells in a 96-well format. This assay is useful in the determination of 
cellular proliferation and growth. We seeded HPMEC and HPMEC ID3+ cells with 50% 
confluence in 96 well clear-walled plate. We allowed the cells to grow for 24h in 5% 
FBS culture medium. After 24 hours, we gave treatments, 0.1% DMSO (control), 
PCB153 (100 ng/mL) to make total volume 100 µL in each well. After an incubation of 
48h, cell monolayers were fixed with 10% (wt/vol) trichloroacetic acid and stained for 30 
min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol) 
acetic acid. The protein-bound dye is dissolved in 10 mM Tris base solution for OD 
determination at 590 nm using a microplate reader (Vichai & Kirtikara, 2006). 
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BrdU assay 
BrdU assay is a direct method for evaluation of cell proliferation. In this rapid method, 
Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) is a synthetic nucleoside and 
analogue of thymidine gets incorporated into DNA synthesis of proliferating cells. It is a 
suitable method for detection and quantification of the stimulatory effect of 
environmental chemicals (Russo et al., 1984). For BrdU assay, we used Roche’s kit and 
followed the manual instructions. 
We seeded HPMEC and HPMEC ID3+ cells in 5% FBS DMEM F-12 media with 50% 
confluence and cultured with addition of BrdU in 96 well clear-walled plate. After 24 
hours, we gave treatments, 0.1% DMSO (control), PCB153 (100 ng/mL) to make total 
volume 100 µL in each well. After an incubation of 48h, cell monolayers fixed with 
FixDenat. Followed by fixation we added anti- BrdU-POD, which binds to BrdU in 
newly synthesized DNA. This immune complex detected by a plate reader at 450 nm. 
STATISTICAL ANALYSIS 
All experiments were performed at least three times and data are expressed as mean ± 
standard deviation Graphpad prism version 5.01 was used to perform graphics and the 
two-tailed student’s t-test was used to compare statistical significance. P<0.05 was set as 
a statistical significance. Data were analyzed by ANOVA; Tukey HSD test for multiple 
comparisons.  
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Results- 
Selection of optimum BNC420 Treatment dose  
BNC420 is a novel VEGFR3 selective inhibitor made by company Biogenomics. It has 
been shown in mouse model that angiogenesis specially inhibited by BNC420. In every 
protein targeted molecular drug treatment research revolved around ensuring cellular 
protein homeostasis. The efficacy of drug treatment is based on assessment of how it 
affects cellular viability, that is, their cytotoxic effect. Investigations of cytotoxicity often 
require testing several different concentrations and drug exposure times using cells in 
culture. Therefore, we used colorimetric tetrazolium salt assay to test putative cytotoxic 
effects associated with exposure to a BNC420. MTT assay monitors metabolic activity of 
cultured cells, was adapted to analyze the viability of cells exposed to BNC420. It was 
found that 24h exposure to increasing concentration of BNC420 reduced the viability of 
lung EC ID3+ cells, with the most severe effect observed at 10 µM dose of 24 h exposure 
with MTT reductions approaching 30% of non-exposed cells as shown in Figure 104. For 
a series of incubations for 24 h, it was found that concentration 0.1 µM did not affect the 
viability, and BNC420 concentrations of 0.5 µM reduced the MTT reduction rate to 
approximately 20% the level displayed by cells receiving vehicle alone. Generally, less 
than 10 µM concentration of a drug in plasma is accepted because higher than 10 µM of a 
drug inhibit necessary enzymes. The most of the drugs on the market have less than 10 
µM therapeutic plasma concentrations. In most cases, the IC50 of the best candidate 
compound should be lower to 10 µM, which is acceptable for NIH to screen the NCI60 
program. Therefore, lower dose the IC50 of candidate drug was, the higher potentially it 
become the new drug for any diseases. (Hansen & Bross, 2010; Hughes, Rees, 
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Kalindjian, & Philpott, 2011; Wang, Newton, Liu, Atkins, & Lu, 2000; Williams et al., 
2002). We decided to use the dose of 0.1 µM to treat the lung cell and measure the 
changes at molecular level in the expression level of ID3 protein as well as phenotypic 
changes. The single oral dose of BNC420 used in mice is at 75 mg/kg by Biogenomics 
Company, which is well below the IC50 value. This dose is equivalent to 0.15 mM (Mol. 
Wt. = 501.55). We tried to mimic similar drug concentration in Lung EC ID3+ cells with 
lower dose than LC50 value. We treated the cells with lower dose than 0.15 mM. 
BNC420 inhibited Lung EC ID3+ cells with 50% survival  at 15 µM. 
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Figure 104- Graph of cell cytotoxity assay for BNC420 drug 
Graph of cell survival was determined 24 h after exposure to BNC420. LC50∼15 µM by 
using MTT assay. Results shown are averages of triplicates ± SD (<10%). 
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BNC420 inhibits PCB153-induced lung endothelial cell proliferation 
We have earlier tested the lung endothelial cell proliferation in presence of estrogenic 
chemicals by MTT, SRB and BrdU assay. In this experiment, we tested the effect of 
BNC420 drug on the cell proliferation of HPMEC ID3+ cells in presence or absence of 
PCB153. The PCB153 induced cell proliferation measured by MTT, SRB and BrdU 
assay. We tested range of BNC420 concentration starting from 10 µM to 0.1 µM (Figure 
105 A,B,C). Our data revealed that in presence of treatment PCB153 (100 ng/mL) with 
addition of different concentration of BNC420 drug ranges from 10 µM to 0.1 µM 
showed a significant gradual inhibition in cell proliferation. We measured the growth in a 
number of cells in terms increase in OD value. Our MTT assay results were corroborated 
by SRB and BrdU assay. The data from SRB and BrdU assays reported that treatment 
PCB153 (100 ng/mL) showed a significant gradual inhibition in cell proliferation. In 
terms of SRB assay, the total protein content of treated cells was inhibited. The BrdU 
assay data results showed the synthesis of new DNA in proliferating cells was 
significantly inhibited in treatments than control. These results prove that PCB153 (100 
ng/mL) is an estrogenic chemical drives the endothelial cells proliferation. These data 
shows that BNC420 with dose of 0.1 µM and 1 µM effectively inhibits PCBindcued 
cellulr proliferation without having any cellular toxicity effects.  
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BNC420 inhibits PCB153-induced lung EC spheroid formation 
The endothelial cells lines the innermost layer of artery maintains the balance between 
vasoconstriction and vasodilation of pulmonary artery. When endothelial dysfucntion 
happens, the cells undergo proliferation and form plexiform lesions, which grow in the 
three-dimension structure resembles spheroid. These cells do not follow characteristics of 
the cells, which grow in a monolayer. The cells derived from tumour tissue alter their 
both genotype and phenotype characteristics once they cultured in monolayer (Lee et al., 
2006). Therefore, we tried to imitate the conditions of tumour in vitro. In addition to this, 
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Figure 105 A, B, C- BNC420 inhibits the PCB153 induced cell proliferation 
A, B, C- BNC420 inhibits the PCB153 induced cell proliferation measured using 
MTT, SRB and BrdU assay 24 h after exposure to BNC420. Results shown are 
averages of triplicates ± SD (<10%). 
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recent data from our laboratory showed that ID3 induced a molecular stem cell-like 
signature—CD133+ VEGFR3+ CD34+ in microvascular ECs. These spheroid also form 
angiogenic sprouting network. We grew the cells in no FBS DMEM F-12 medium 
supplemented with B-27 reduced growth supplement. We used a stem cell sphere-
forming assay to determine the effect of BNC420 drug on HPMEC ID3+ cells spheres. 
We treated spheroid-containing wells with 0.1 µM BNC420 in presence or absence of 
estrogenic chemicals like E2 and PCB153 as shown in Figure 106. We checked whether 
BNC420 inhibits spheroid growth of HPMEC ID3+ cells. We found that BNC420 
significantly inhibited the growth of spheroids in terms of spheroid number and spheroid 
size compare to E2 and PCB153 treated spheroid-containing wells as shown in Figures 
107 and 108. 
 
 
Figure 106- shows pictures of spheroids with BNC420 treatment. 
 BNC420 treatment decreases Spheroid size and number in the PCB153 and E2 treated 
wells. The decrease in  the size and number of spheroid in BNC420 treated wells are 
significantly lower compared to respective  control. Scale bar= 10µm. 
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 Figure 107- BNC420 treatments decreased the size of spheroids compared to control. 
Graph shows quantification of spheroid diameter. Error bars represent the mean sphere 
size ± SD in 5 spheres. E2 & PCB153= 100 ng/ mL. Representative microphotographs of 
treatment groups are shown inset. E2 & PCB153= 100 ng/mL. BNC420= 0.1 μM 
Measurements were performed from a representative experiment repeated three times in 
triplicate. (*a) BNC420 treatment significantly different from vehicle control at (P<0.01).  
(**) PCB & E2 treatment significantly different from vehicle control at (P<0.01). (*) 
BNC420 treatment significantly different from PCB153 + BNC420 & E2 + BNC420 
(P<0.05) at day 10 Data; Tukey HSD test for multiple comparisons. Magnification X200. 
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BNC420 inhibits PCB153-induced ID3 expression 
We performed immunoblot and fluorescent microscopy experiment after detecting 
change in spheroid and cell viability assay due to the treatment of BNC420. The 
immunoblot and fluorescent microscopy results revealed that BNC420 significantly down 
regulated ID3 protein expression in lung EC ID3+ cells compared to control as shown in 
Figure 109, 110 and 111.  
 
Figure 108- BNC420 treatments decreased the number of spheroids compared to 
control. 
Graph shows quantification of spheroid number. Error bars represent the mean sphere 
number ± SD in 5 wells. E2 & PCB153= 100 ng/mL. BNC420= 0.1 μM Measurements 
were performed from a representative experiment repeated three times in triplicate. (*a) 
BNC420 treatment significantly different from vehicle control at (P<0.01).  (**) PCB & 
E2 treatment significantly different from vehicle control at (P<0.01). (*) BNC420 
treatment significantly different from PCB153 + BNC420 & E2 + BNC420 (P<0.05) at 
day 10 Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons. 
Magnification X200. 
 
265 
 
 
 
 
 
 
 
 
 
 
 
Figure 110- Western blot analysis of inhibition of PCB-induced ID3 expression 
by BNC420 
The experiment shows inhibition of ID3 protein by 0.1 µM BNC420 dose with or 
without exposure to PCB153. BNC420= 0.1 μM, PCB153 = 100 ng/ mL    (∼0.3 µM). 
  
 
Control PCB153 BNC420 BNC420 +PCB153 
Figure 109- Representative images of fluorescent microscopy to study the effect of 
BNC420 drug on ID3 expression 
Fluorescent microscopy experiment was used to compare the effect of BNC420 0.1 µM 
on PCB153 treated lung EC ID3+ cells. The experiment showed that BNC420 treatment 
decreased the expression of ID3. BNC420= 0.1 μM, PCB153 = 100 ng/mL    (∼0.3 µM). 
Scale bar= 50 μm 
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Conclusion  
Using a novel VEGFR3 selective inhibitor BNC420 (provided by Bionomics Limited via 
approved Material Transfer Agreement), we determined BNC420 treatment of hiPSCs 
controls the epigenetic regulation of ID3 and regression of PCB-induced vascular lesions 
in vitro. These results are very promising can give impetus for further development of 
BNC420 drug and can used as a molecular target against ID3 protein. Molecular targeting 
overexpreesed ID3 expression can regress angiogenesis and lung EC cell proliferation 
which are markers of NSCLC and PAH.  
Figure 111- The relative expression level of ID3 protein in BNC420 drug treated 
lung EC ID3+ cells 
Shows the relative expression level of ID3 protein in lung EC ID3+ cell line when 
treated with PCB153, BNC 0.1 μM and PCB153 + BNC 0.1 μM. PCB153 = 100 ng/ 
mL    (∼0.3 µM). (*) PCB513 treatment significantly different from PCB153 + 
BNC420 (P<0.05) at day 10 Data were analyzed by ANOVA; Tukey HSD test for 
multiple comparisons. 
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Overall summary 
 
Stable ectopic expression of ID3 in lung endothelial cells contributed to endothelial-
mesenchymal transition (EndMT) and cell proliferation. ID3 overexpressing cells showed 
the loss of VE-cadherin and gain of N-Cadherin and vimentin, which are markers of 
EndMT. Using an endothelial spheroid assay, an established method to measure aberrant 
hyper-proliferation of endothelial cells in PAH patients, we show that stable ectopic 
expression of ID3 increased the number and size of vascular spheres. 
We investigated ID3 transcriptional reprogramming using ChIP-seq and RNA-seq 
technology. We show here for the first time that ID3 is part of a more general mechanism 
of transcriptional regulation. Our ChIP-Seq data show that ID3 binds to a subset of 
approximately 1200 target genes. Comprehensive motif analysis of ChIP-seq data using 
the MEME Suite software toolkit revealed that ID3 bound to the GAGAGAGAGA motif 
sequence on genomic DNA. We also show a significant preference of ID3 binding to 
motifs associated with transcription factors IRF1, ZRF1, BC11A, IRF4, PRDM1, FOXJ3, 
SMAD4, ZBTB6, GATA1, and STAT2.  Using an integrative approach of ChIP-Seq and 
RNA-Seq data, we identified 27 genes was bound by ID3 and RNA was differentially 
expressed in ID3 overexpressing cells. 
Our data demonstrated that PCB153 and/or ID3 induces proliferation of lung endothelial 
cells via transcriptional reprogramming. Discoveries from these findings will lay the 
necessary groundbreaking work for testing the efficacy of ID3 antagonists for the 
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prevention and treatment of pathological vascular remodeling as well as provide a new 
paradigm by which PCBs may contribute to lung vascular toxicity. 
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